The epidemiology of herpes simplex virus type 2 in sub-Saharan

Africa: systematic review, meta-analyses, and meta-regressions

Manale Harfouche MPH,^{a,b*} Farah M. Abu-Hijleh MD,^{c*} Charlotte James PhD,^d

Katharine J. Looker PhD,^d and Laith J. Abu-Raddad PhD^{a,b,e}

^a Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar

^b World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine–Qatar, Cornell University, Qatar Foundation – Education City, Doha, Qatar

^c Department of Public Health, College of Health Sciences, Academic Quality Affairs Office, QU Health, Qatar University, Doha, Qatar

^d Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom

^e Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA

* These authors contributed equally to the work.

Word count: Abstract: 252 words, Text: 3,433 words Number of tables: 5 Number of figures: 1 Running head: HSV-2 epidemiology in Africa Keywords: Seroprevalence; Genital ulcer disease; Genital herpes; Synthesis; Region.

Reprints or correspondence: Professor Laith J. Abu-Raddad, Infectious Disease Epidemiology Group, World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine - Qatar, Qatar Foundation - Education City, P.O. Box 24144, Doha, Qatar. Telephone: +(974) 4492-8321. Fax: +(974) 4492-8333. E-mail: <u>lja2002@qatar-med.cornell.edu</u>.

Abstract

Background: Herpes simplex virus type 2 (HSV-2) infection is a prevalent sexually transmitted infection with a sizable disease burden that is highest in sub-Saharan Africa. This study aimed to characterize HSV-2 epidemiology in this region.

Methods: Cochrane and PRISMA guidelines were followed to systematically review, synthesize, and report HSV-2 related findings. Meta-analyses and meta-regressions were conducted.

Findings: From 218 relevant publications, 451 overall outcome measures and 869 stratified measures were extracted. Pooled incidence rates ranged between 2.4-19.4 per 100 person-years across populations. Pooled seroprevalence was lowest at 37.3% (95% confidence interval (CI): 34.9-39.7%) in general populations and high in female sex workers and HIV positive individuals at 62.5% (95% CI: 54.8-70.0%) and 71.3% (95% CI: 66.5-75.9%), respectively. In general populations, pooled seroprevalence increased steadily with age. Compared to women, men had a lower seroprevalence with an adjusted risk ratio (ARR) of 0.61 (95% CI: 0.56-0.67). Seroprevalence decreased in recent decades with an ARR of 0.98 (95% CI: 0.97-0.99) per year. Seroprevalence was highest in Eastern and Southern Africa. Pooled HSV-2 proportion in genital ulcer disease was 50.7% (95% CI: 44.7-56.8%) and in genital herpes it was 97.3% (95% CI: 84.4-100%).

Interpretation: Seroprevalence is declining by 2% per year, but a third of the population is infected. Age and geography play profound roles in HSV-2 epidemiology. Temporal declines and geographic distribution of HSV-2 seroprevalence mirror that of HIV prevalence, suggesting sexual risk behavior has been declining for three decades. HSV-2 is the etiological cause of half of GUD and nearly all genital herpes cases.

Funding: This work was supported by pilot funding from the Biomedical Research Program at

Weill Cornell Medicine in Qatar and by the Qatar National Research Fund [NPRP 9-040-3-008].

Introduction

Herpes simplex virus type 2 (HSV-2) infection is a highly prevalent sexually transmitted infection (STI) worldwide.(1) It is a leading cause of genital ulcer disease (GUD) and genital herpes, manifesting in the form of painful, recurrent, and frequent genital lesions.(2-8) Its vertical transmission from mother-to-child can lead to neonatal herpes, a severe and sometimes fatal outcome in newborns.(3, 9) HSV-2 is linked to a 3-fold increase in sexual transmission and acquisition of HIV,(10-12) implying a potential epidemiological synergy between the two viruses.(11, 13, 14)

HSV-2 is typically asymptomatic in most of those who acquire it.(3) This trait coupled with HSV-2's chronic and reactivating nature, as well as its subclinical shedding,(15, 16) increases its rate of transmission and leads to high antibody prevalence (seroprevalence) among general and higher-risk populations alike.(11, 17, 18) Since HSV-2 is more transmissible than HIV and produces long-lasting antibodies, it has been used as an objective biological marker of sexual risk behavior and risk of HIV infection.(19-23) Analyses using empirical data and mathematical modeling supported the utility of using HSV-2 seroprevalence to predict HIV epidemic potential.(19, 20, 24)

Inadequate understating of HSV-2 epidemiology and its considerable consequences on sexual and reproductive health and the HIV epidemic,(11, 13) calls for urgent preventive and control measures to tackle it. The World Health Organization (WHO) outlined a "Global Health Sector Strategy on STIs"(25) that sets goals to eliminate STIs as a main public health concern by 2030 through integration of preventive and control measures. Consequently, WHO, along with their global partners, are spearheading efforts to develop an HSV vaccine as an urgent priority.(26,

4

To inform these efforts, we conducted a systematic review to characterize HSV-2 infection levels and trends in sub-Saharan Africa (SSA), the hub of the HIV epidemic.(28, 29) We estimated pooled means for each outcome measure (incidence rate, seroprevalence, proportion of HSV-2 in GUD, and proportion of HSV-2 in genital herpes) across populations and subpopulations. We also conducted meta-regression analyses to assess temporal trends and identify predictors of high seroprevalence and between-study heterogeneity.

Methodology

Data sources and search strategy

This systematic review was guided by the Cochrane Collaboration Handbook(30) and was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines(31) which can be found in Table S1. The review was informed by the methodology applied recently in a series of systematic reviews for HSV-1 infection.(32-36) All available publications were systematically reviewed up to August 23, 2020. The search was conducted in PubMed and Embase databases, using search strategies with exploded MeSH/Emtree terms, broad search criteria, and no language or year restrictions to widen the scope and include all subheadings (Table S2). The definition of Africa included 45 countries, as defined by the WHO for the African Region,(37) covering countries of sub-Saharan Africa. The list of countries and their subregional stratification is in Box S1.

Study selection and eligibility criteria

Search results were imported into the reference manager Endnote (Thomson Reuters, USA), whereby duplicate publications were identified and removed. The remaining records were screened for relevance based on titles and abstracts, followed by full text screening of relevant and potentially relevant records. Additional bibliography screening was performed on both reviews and the relevant articles to identify any missing publications.

Inclusion criteria were met if publications reported primary data on any of the following four outcomes: 1) HSV-2 incidence rate, 2) HSV-2 seroprevalence, 3) proportion of HSV-2 detection in GUD, and 4) proportion of HSV-2 detection in genital herpes. A sample size of ≥ 10 was required for inclusion for all outcome measures. Exclusion criteria encompassed case reports, series, commentaries, reviews, and qualitative studies. In this review, "publication" refers to a document reporting any outcome measure, whilst a "study" refers to details of a specific outcome measure. Special care was given to ensure that overlapping studies were only included once and not in duplicate.

Data extraction and synthesis

Data extraction and double extraction were performed by MH and FA independently. A list of extracted variables is in Box S2.

Overall outcome measures and their stratified measures were extracted, provided the stratification agreed with a pre-set stratification hierarchy and the subsample in each stratum was ≥10. The pre-set stratification hierarchy sequence for incidence and seroprevalence measures was as follows: population type (see Box S3 for definition), sex, and age. As for proportion of HSV-2 detection in GUD and genital herpes, the sequence was: genital herpes episode status (primary *versus* recurrent episode), sex, age, and study site (hospital *versus* outpatient clinic). Measures reporting any HSV-2 outcome among children <15 years old were only reported, and not included in the analyses.

Quality assessment

Relevant studies were subjected to a pre-quality assessment to evaluate the validity of the assays used, given their limitations.(38, 39) This assessment was done with the help of an expert from the University of Washington, Professor Rhoda Ashley-Morrow. Only studies with valid, sensitive, and specific assays were included in the review. These studies were then evaluated using the Cochrane approach for risk of bias (ROB) assessment.(30) Study's precision was classified into low *versus* high based on the study sample size (<100 *versus* \geq 100).(40) Studies were classified into low *versus* high ROB using two quality domains: sampling method (probability *versus* non-probability based sampling) and response rate (\geq 80% *versus* <80% or unclear). Effect of ROB on study outcome was investigated through meta-regression as noted below.

Meta-analyses

Pooled mean estimates for all four outcomes were calculated across all strata using metaanalyses, provided each stratum had ≥ 3 measures.

Only studies reporting incidence rate by person-time were included in the meta-analyses. Log transformed incidence rates were used to calculate pooled estimates using the inverse variance method in the metarate function.(41, 42)

HSV-2 seroprevalence measures and proportion of HSV-2 detection in GUD and in genital herpes were each pooled using the DerSimonian-Laird random-effects model,(41) applying the Freeman-Tukey double arcsine transformation to stabilize the variance,(43) and factoring knowledge of the applicability of this transformation.(44) Existence of heterogeneity in effect size was assessed using Cochran's Q statistic.(41, 45) Magnitude of between-study variation attributed to *true* difference in effect size, as opposed to *chance*, was measured using I².(41, 45) Distribution of *true* measures around the pooled mean was described using the prediction interval.

Meta-analyses were conducted in R version 3.4.1(46) using the meta package.(42)

Meta-regressions

Univariable and multivariable random-effects meta-regression analyses were conducted using log transformed seroprevalence measures to examine factors and predictors potentially associated with increased HSV-2 seroprevalence, as well as sources of between-study heterogeneity. Pre-set variables included in these analyses are listed in Box S4.

Factors included in the multivariable models had to have a p-value<0.1 in the univariable model. Strength of evidence for an association was deemed significant for factors with a p-value<0.05 in the multivariable models.

Meta-regressions were conducted in Stata/SE version 13(47) using the metareg package.(48)

Role of the funding source

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the article. The corresponding author had full access to all the data in the study and had the final responsibility for the decision to submit for publication.

Results

Search results and scope of evidence

Figure 1 depicts the PRISMA flow chart describing the study selection process.(31) A total of 14,830 citations were captured in the initial search (2,039 from PubMed and 12,791 from Embase). After deduplication, title and abstract screening, and full text screening, relevant publications were identified. Thirteen additional publications, including country level reports, were identified through bibliography screening.(49-61)

In total, 218 publications met the inclusion criteria. Extracted measures encompassed 47 seroconversion rates, 48 overall (65 stratified) incidence rates, 322 overall (773 stratified) seroprevalence measures, 25 overall (31 stratified) proportions of HSV-2 detection in GUD, and 9 overall (11 stratified) proportions of HSV-2 detection in genital herpes.

Incidence overview and pooled mean estimates for HSV-2 incidence rate

Table S3 summarizes extracted seroconversion and incidence rates. Studies were either longitudinal cohorts (number of measures (n)=35; 49.2%) or randomized controlled trials (n=36; 50.7%), with a follow-up duration ranging between 6 weeks to 6 years. HSV-2 seroconversion rates (n=47) ranged between 0.0-58.0% across studies, reflecting in part the widely variable duration of follow-up.

In general populations, HSV-2 incidence rates among women (n=20) ranged between 3.6-21.7 per 100 person-years with a median of 7.5 and a pooled mean of 7.2 (95% confidence interval (CI): 5.5-9.4) per 100 person-years (Table 1). Among men (n=20), incidence rate ranged between 1.5-10.5 per 100 person-years with a median of 5.5 and a pooled mean of 4.1 (95% CI: 3.1-5.3) per 100 person-years. Higher incidence rates were found in higher risk populations. A summary of pooled mean incidence rate by population type and associated forest plots are in Table 1 and Figure S1, respectively.

Prevalence overview

Tables S4, S5, S6, S7, and S8 summarize (the overall) seroprevalence measures (n=322) across the subregions of SSA. Half the studies were published after the year 2010 (n=176; 55.5%), and most were based on cross-sectional study design (n=202; 62.7%) and convenience sampling (n=233; 72.4%).

For the stratified seroprevalence measures, HSV-2 seroprevalence among general population women (n=290) ranged between 0.1-97.4% with a median of 43.1%, and among general population men (n=186) between 0.0-84.2% with a median of 27.5% (Table 2).

In higher-risk populations (n=40), almost all studies were conducted among female sex workers (FSWs; n=39) with seroprevalence ranging between 4.3-99.0% with a median of 65.0% (Table 2). High seroprevalence was observed in HIV positive individuals and in individuals in HIV discordant couples, ranging between 42.0-95.2% with a median of 79.7% among women (n=20), and between 44.0-94.2% with a median of 61.4% among men (n=15).

Tables 2, 3, and S9 summarize HSV-2 seroprevalence measures for further populations and subpopulations, including by population type, country, subregion, age, sex, and year of publication.

Pooled mean estimates for HSV-2 seroprevalence

Tables 2, 3, and S9 show results of seroprevalence meta-analyses across populations and subpopulations. Pooled mean seroprevalence was lowest at 37.3% (95% CI: 34.9-39.7%) in general populations (n=507), followed by 47.4% (95% CI: 43.2-51.5%) in HIV negative populations (n=51), 57.1% (95% CI: 50.1-63.9%) in intermediate-risk populations (n=45), 61.2% (95% CI: 56.5-65.9%) in STI clinic attendees and symptomatic populations (n=72),

61.4% (95% CI: 53.4-69.1%) in higher-risk populations (n=40; mainly FSWs), and 71.3% (95% CI: 66.5-75.9%) in HIV positive individuals and in individuals in HIV discordant couples (n=42; Table 2).

Among general populations, the pooled mean seroprevalence varied across African subregions (Table 3), with the lowest being 25.0% (95% CI: 20.9-29.4%) in Western Africa (n=68), followed by 35.8% (95% CI: 31.6-40.0%) in Southern Africa (n=226), 41.9% (95% CI: 38.4-45.3%) in Eastern Africa (n=188), and 52.4% (95% CI: 40.4-64.3%) in Central Africa (n=25). Similar hierarchy was observed across subregions for women and men, with women having consistently higher pooled mean seroprevalence compared to men (Table S9).

Across age groups (Table 3), pooled mean seroprevalence increased gradually from 12.4% (95% CI: 10.6-14.3%) in those <20 years-old (n=88), followed by 34.2% (95% CI: 30.7-37.8%) in those 20-30 years-old (n=112), 57.1% (95% CI: 54.8-63.3%) in those 30-40 years-old (n=69), 64.6% (95% CI: 59.5-69.5%) in those 40-50 years-old (n=48), to then decrease slightly to 58.2% (95% CI: 50.3-65.9%) in those >50 years-old. A similar trend was observed across age groups for each of women and men, but seroprevalence grow faster with age for young women (Table S9).

Heterogeneity was evident in almost all meta-analyses (p-value<0.001), and was confirmed by the wide prediction intervals (Tables 2, 3, and S9). Most heterogeneity was attributed to true variation in seroprevalence rather than chance (I²>50%). Forest plots for meta-analyses across African subregions stratified by population type are in Figure S2.

Predictors of HSV-2 seroprevalence

Table 4 shows results of the meta-regression analyses for HSV-2 seroprevalence. Nine variables were eligible for inclusion in the multivariable model (p-value<0.1 in univariable analysis). Two multivariable models were conducted, one including year of publication as a categorical variable and one including it as a linear term.

The model including year of publication as a categorical variable explained 57.5% of seroprevalence variation and included population type, age group, sex, African subregion, country's income, assay type, sampling method, response rate, and year of publication category (Table 4). Compared to general populations who had the lowest seroprevalence, seroprevalence was highest in HIV positive individuals and in individuals in HIV discordant couples [adjusted risk ratio (ARR) of 2.17 (95% CI: 1.78-2.65)], followed by STI clinic attendees and symptomatic populations, higher-risk populations, intermediate-risk populations, and HIV negative populations.

Compared to women, men had a 0.61-fold (95% CI: 0.56-0.67) lower seroprevalence. Seroprevalence increased rapidly with age at young age, but the increase plateaued by age 40-50 years. Seroprevalence was highest in Eastern Africa, followed by Southern Africa, Central Africa, and lowest in Western Africa. Country's income was not associated with seroprevalence. Studies that had a lower or unknown response rate had a higher seroprevalence. Meanwhile, assay type, study sample size, and study sampling method were not associated with seroprevalence.

Compared to those published before the year 2005, studies published in 2006-2015 [ARR of 0.85 (95% CI: 0.76-0.96)] and after 2015 [ARR of 0.80 (95% CI: 0.69-0.93)] had lower seroprevalence.

12

The model including year of publication as a linear term (Table 4) showed similar results and indicated declining seroprevalence with time [ARR of 0.98 (95% CI: 0.97-0.99)]. The model explained 57.5% of seroprevalence variation

Sensitivity analyses including year of data collection as a categorical variable or as a linear term (in replacement of year of publication) arrived at similar results (Table S10).

Overview and meta-analyses of HSV-2 isolation in genital ulcer disease and in genital herpes

Table S11 summarizes extracted proportions of HSV-2 detection in GUD and in genital herpes. In GUD cases (n=31), proportion of HSV-2 detection ranged between 8.3-100% with a median of 49.1% and a pooled mean proportion of 50.7% (95% CI: 44.7-56.8%) (Table 5). Among women (n=8), it ranged between 35.0-100% with a median of 49.5% and a pooled proportion of 59.0% (95% CI: 44.7-72.6%), and among men (n=13), it ranged between 8.3-72.2% with a median of 49.1% and a pooled proportion of 47.3% (95% CI: 37.2-57.5%).

In genital herpes cases (n=11), proportion of HSV-2 detection ranged between 53.0-100% with a median of 100% and a pooled mean proportion of 97.3% (95% CI: 84.4-100%) (Table 5). No study distinguished between primary and recurrent genital herpes episodes.

These meta-analyses showed evidence of heterogeneity (p-value<0.001, I²>50%, and wide prediction intervals). Forest plots are in Figure S3.

Quality assessment

Quality assessment of diagnostic methods excluded 51 publications due to potential issues in the implemented diagnostic assays. Quality assessment of included seroprevalence measures is summarized in Table S12. Briefly, 288 studies (89.4%) had high precision, 88 studies (27.3%)

and 85 studies (26.4%) had low ROB in the sampling method and in the response rate domains, respectively. Twenty-three studies (7.1%) had high ROB in both quality domains.

Discussion

This systematic review presented a detailed assessment of HSV-2 epidemiology in sub-Saharan Africa. Strikingly, the results demonstrate that HSV-2 seroprevalence has been declining by about 2% per year over the last three decades (Table 4). This decline is in line with the observed declines in HIV epidemics in SSA during the same timeframe.(62) Drivers of the decline in HIV prevalence have been subject to debate, with various mechanisms posited including natural epidemic dynamics,(63) increased HIV-associated mortality,(64, 65) impact of interventions,(65) heterogeneity in host susceptibility to HIV infection,(66, 67) and reductions in sexual risk behavior.(65, 68-71) Considering that HSV-2 seroprevalence has been shown to provide an *objective proxy biomarker* of population-level sexual risk behavior,(19-24) our finding of rapidly declining HSV-2 seroprevalence suggests that sexual risk behavior has been declining, and that this decline has reduced the transmission of both HIV and HSV-2 infections. With evidence of HSV-2 infection increasing risk of HIV acquisition and transmission,(10-13) it remains to be seen whether the declining HSV-2 incidence may have also contributed to the declines seen in HIV incidence in SSA.

Despite declining HSV-2 transmission in SSA, incidence rate is still high (Table 1), and much higher than that found elsewhere in the world.(1) For instance, the incidence rate in the United States (<1 per 100 person-years)(72) is an order of magnitude lower than that in SSA. The results further demonstrate that age plays a profound effect in HSV-2 epidemiology—age alone accounted for 30% of the seroprevalence variation (Table 4). HSV-2 infection in SSA is

typically acquired at a young age not long after sexual debut, especially so for women, manifesting in a rapidly increasing seroprevalence with age before plateauing at high levels by ages 40-50 (Tables 1, 3, 4, and S9).

Population risk classification was also found to play an important role in HSV-2 epidemiology, accounting for 13% of seroprevalence variation (Table 4). Both incidence rate and seroprevalence were found at much higher levels in specific at-risk populations, such as female sex workers (Tables 2 and 4), with both measures displaying the "classical hierarchy" of STI exposure by sexual risk behavior, also seen with other STIs.(73, 74) Despite its prominence amongst higher risk populations, HSV-2 infection is also widely disseminated in SSA with high levels of infection even in the lower risk general population where over a quarter of men and nearly half of women are infected (Tables 2 and 4).

Although HSV-2 seroprevalence is high everywhere in SSA, there are still considerable variations by subregion. Infection levels were highest in Eastern Africa followed by Southern Africa, Central Africa, and lowest in Western Africa (Table 4). Incidentally, this pattern is also seen for HIV infection with Eastern Africa and Southern Africa being most affected and Western Africa least affected.(75, 76) This further suggests a strong link between HSV-2 and HIV epidemiologies,(24) reflecting a similar mode of transmission and hinting at a biological/epidemiological synergy.(10-14) The results further demonstrate that women are almost twice as likely to be infected as men (Table 4), reflecting a higher bio-anatomical susceptibility to the infection.(77, 78)

Another finding of this study is that HSV-2 infection is the cause of half of GUD cases in SSA (Table 5), confirming that this infection is the main cause of this disease in this part of the world where nearly 60 million individuals are estimated to be affected with HSV-related GUD.(79)

15

Although HSV-2 seroprevalence is declining (Table 4), it will likely remain the main cause of GUD in SSA, as other causes such as syphilis have also been declining.(80, 81) HSV-2 infection (as opposed to HSV-1 infection) was also found to account for nearly all cases of genital herpes (>97%; Table 5). This finding is presumably due to the nature of HSV-1 being widely acquired in childhood in SSA through oral transmission,(33) and distinguishes this region from other global regions where there is an increasing role for HSV-1 in genital herpes,(33-36) with some countries already observing HSV-1 as the cause of a large proportion of cases of genital herpes.(33-36)

This study had limitations, principally the unavailability of data for 15 of 45 African countries. There was also less data for Central and Western Africa than for Eastern and Southern Africa, in addition to data for seroprevalence eclipsing those of GUD and genital herpes. Despite these limitations, a large volume of data was available to sufficiently power an array of analyses. Included studies exhibited heterogeneity (Tables 2, 3, and S9); however, more than half of this heterogeneity (57%) was subsequently explained through meta-regressions (Table 4). Studies differed by assay type, sample size, sampling method, and response rate, yet none of these study characteristics appeared to affect seroprevalence with the exception of response rate where studies with lower or unknown response rate had a higher seroprevalence (Table 4). Overall, these limitations should not pose a barrier to the critical interpretation of this study's results, or its findings.

Conclusions

In conclusion, HSV-2 seroprevalence is declining rapidly in SSA. Yet, HSV-2 incidence and seroprevalence remain at high levels, with over a third of the population being infected. Age and subregion within SSA play a critical role in HSV-2 epidemiology and explain much of the

16

observed variation in seroprevalence. The geographical distribution of this infection was also found to be similar to that of HIV infection, and the declines in HSV-2 seroprevalence mirrored those for HIV prevalence. These findings suggest that the declines in both infections were driven by reductions in sexual risk behavior following the massive expansion of the HIV epidemic in this continent, and may suggest that some of the declines in HIV incidence could have been attributed to the declines in HSV-2 incidence. HSV-2 infection was found to be the etiological cause of half of GUD cases in this region, and virtually all cases of genital herpes. These findings demonstrate the urgent need for both prophylactic and therapeutic HSV-2 vaccines to tackle the disease burden of this infection,(82) and argue for further acceleration of ongoing efforts for vaccine development.(26, 27, 83)

Contributors

MH and FAH conducted the systematic search, data extraction, and data analysis. MH wrote the first draft of the paper. CJ and KJL contributed to the systematic search, data extraction, and interpretation of the results. LJA conceived the study and led the data extraction and analysis and interpretation of the results. All authors contributed towards drafting and revising the manuscript.

Declaration of interests

MH, FAH, CJ, and LJA declare no competing interests. KL is currently funded by GlaxoSmithKline (GSK) for a gonorrhea vaccine modeling project.

Acknowledgements

The authors gratefully acknowledge Professor Emeritus Rhoda Ashley Morrow from the University of Washington, for her support in assessing the quality of study diagnostic methods. The authors are also grateful for Ms. Adona Canlas for administrative support. The authors are grateful for pilot funding by the Biomedical Research Program and infrastructure support provided by the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar. This publication was made also possible by NPRP grant number 9-040-3-008 from the Qatar National Research Fund (a member of Qatar Foundation). The findings achieved herein are solely the responsibility of the authors. KL thanks the National Institute for Health Research, Health Protection Research Unit in Evaluation of Interventions at the University of Bristol, in partnership with Public Health England, for research support. The authors alone are responsible for the views expressed in this article and they do not necessarily represent the views, decisions or policies of the institutions with which they are affiliated, the NHS, the NIHR, the Department of Health and Social Care or Public Health England.

Figure 1. Flow chart of article selection for the systematic review of HSV-2 infection in sub-Saharan Africa, per the PRISMA guidelines.(31)

ation	14,830 citations identified through international database searching (PubMed=2,039 and Embase=12,791)								
Identific	1,563 duplicates removed								
	13,267 unique citations identified and titles/abstracts screened								
eening	11,993 citations removed after title/abstract screening								
Scr	1,274 unique publications retrieved for full text screening								
	1,069 publications excluded for the following								
Eligibility	13 additional publications identified through screening bibliographies of publications and reviews • Full-text did not include data on relevant indicators (n=651) • Studies not taking place in Africa (n=129) • Abstract and full-text could not be retrieved (n=19) • Potential issues were identified in the diagnostic method (n=51) • Duplicate data (n=219)								
	218 publications met inclusion criteria								
\square	Measures included in the systematic review and meta-analyses/meta-regressions:								
Included	 Measures included in the systematic review and meta-analyses/meta-regressions: 47 overall HSV-2 seroconversion rates. 48 overall HSV-2 incidence rates that yielded 65 stratified incidence rates. 322 overall HSV-2 seroprevalence measures that yielded 773 stratified seroprevalence measures. 25 overall proportion measures of HSV-2 detection in clinically-diagnosed genital ulcer disease that yielded 31 stratified proportions. 9 overall proportion measures of HSV-2 detection in clinically-diagnosed genital herpes that yielded 11 stratified proportions. 								

Abbreviations: HSV-2 = Herpes simplex virus type 2.

	Outcome	Samples	HSV-2 incid	dence rate	Pooled mean HSV-2 incidence	Heterogeneity	measures
Dopulation type	measures		(per 100 per	son-years)	rate		
r opulation type	Total N	Total	Range	Median	Mean (per 100 person-years)	\mathbf{Q}^*	$\mathrm{I}^{2^{\dagger}}\left(\% ight)$
		person-years			(95% CI)	(p-value)	(95% CI)
General populations							
Women	20	21,607.4	3.6-21.7	7.5	7.2 (5.5-9.4)	321.1 (p<0.001)	94.1 (92.1-95.6)
<25 years old	6	6,914.5	4.0-21.7	9.1	6.7 (4.6-9.7)	51.5 (p<0.001)	90.3 (81.6-94.9)
≥ 25 years old	3	154.0	9.0-15.4	9.3	11.4 (7.1-18.3)	1.1 (p=0.582)	0.0 (0.0-80.8)
Mixed ages	11	14,538.9	3.6-21.0	7.0	6.9 (4.7-10.1)	257.5 (p<0.001)	96.1 (94.5-97.3)
Men	20	29,287.3	1.5-10.5	5.5	4.1 (3.1-5.3)	250.9 (p<0.001)	92.4 (89.7-94.4)
<25 years old	6	3,841.1	1.5-10.4	6.5	4.0 (2.3-7.0)	49.9 (p<0.001)	90.0 (80.9-94.7)
≥ 25 years old	8	1,835.2	4.0-10.5	6.5	6.5 (5.3-7.9)	7.7 (p=0.364)	8.6 (0.0-70.4)
Mixed age	6	23,611.1	1.4-4.9	5.0	2.4 (1.6-3.6)	120.0 (p<0.001)	95.8 (93.1-97.5)
Mixed sexes	5	15,603.7	2.3-3.6	3.5	3.2 (2.5-3.7)	17.9 (p=0.001)	77.7 (46.2-90.7)
Intermediate-risk populat	ions						
Women	3	774.8	14.2-28.6	17.3	19.4 (11.8-32.1)	16.8 (p<0.001)	88.1 (66.9-95.7)
Higher-risk populations							
Female sex workers	3	1,458.0	8.7-23.0	21.0	18.0 (13.1-24.9)	11.2 (p=0.004)	82.2 (45.2-94.2)
HIV negative populations	5						
Mixed sexes	5	5,203.0	5.2-11.0	6.1	7.9 (6.0-10.5)	31.7 (p<0.001)	87.4 (73.0-94.1)
HIV positive individuals and in individuals in HIV disc		als in HIV discord	ant couples				
Mixed sexes	3	2,606.8	5.5-14.8	7.7	8.6 (4.7-15.7)	38.2 (p<0.001)	94.8 (88.1-97.7)
Other populations							
Mixed sexes	6	767.3	3.4-35.1	17.1	14.2 (8.6-23.6)	27.7 (p<0.001)	82.0 (61.6-91.5)

Table 1. Pooled mean estimates for herpes simplex virus type 2 incidence rate among different populations in sub-Saharan Africa.

*Q: the Cochran's Q statistic is a measure assessing the existence of heterogeneity in incidence rates. *I²: a measure that assesses the magnitude of between-study variation that is due to actual differences in incidence rates across studies rather than chance.

Abbreviations: CI = Confidence interval, HIV = human immunodeficiency virus, HSV-2 = Herpes simplex virus type 2.

Demulation toma	Outcome measures	Sample size	Sample HSV-2 seron size (%		Pooled mean HSV-2 seroprevalence	Heterogeneity measures			
	Total N	Total n	Range	Median	Mean (%) (95% CI)	Q* (p-value)	I ^{2†} (%) (95% CI)	Prediction interval [‡] (%)	
General populations	507	230,541	0.0-97.4	39.5	37.3 (34.9-39.7)	73,247.9 (p<0.001)	99.3 (99.3-99.3)	0.7-88.0	
Women	290	134,034	0.1-97.4	43.1	43.1 (39.8-46.5)	44,291.3 (p<0.001)	99.3 (99.3-99.4)	1.8-92.4	
Men	186	83,898	0.0-84.2	27.5	29.1 (25.7-32.6)	21,577.1 (p<0.001)	99.1 (99.1-99.2)	0.1-77.7	
Mixed	31	12,609	1.3-90.9	33.9	32.5 (27.3-37.8)	975.5 (p<0.001)	96.9 (96.3-97.4)	8.4-62.9	
Intermediate-risk populations	45	9,259	0.0-92.2	58.0	57.1 (50.1-63.9)	1,906.5 (p<0.001)	97.7 (97.3-98.0)	13.7-94.6	
Women	29	8,267	20.5-92.2	70.6	66.4 (59.1-73.3)	1,283.4 (p<0.001)	97.8 (97.4-98.2)	25.4-96.4	
Men	13	849	9.1-88.5	43.0	43.6 (31.4-56.2)	150.1 (p<0.001)	92.0 (88.1-94.6)	4.3-88.7	
Mixed	3	143	0.0-45.0	21.0	18.2 (0.5-43.4)	29.1 (p<0.001)	93.1 (83.3-97.2)	0.0-100	
Higher-risk populations	40	13,476	4.3-99.0	63.7	61.4 (53.4-69.1)	3,264.9 (p<0.001)	98.8 (98.7-98.9)	13.4-98.2	
FSWs	39	13,036	4.3-99.0	65.0	62.5 (54.8-70.0)	2,898.0 (p<0.001)	98.7 (98.5-98.8)	15.7-97.9	
MSM	1 [§]	440	-	-	22.3 (18.5-26.3) [§]	-	-	-	
HIV negative populations	51	38,533	6.0-89.0	44.0	47.4 (43.2-51.5)	3,198.9 (p<0.001)	98.4 (98.2-98.6)	19.7-75.9	
Women	34	33,699	17.0-89.0	46.5	52.1 (47.5-56.7)	2,283.9 (p<0.001)	98.6 (98.3-98.7)	25.6-78.0	
Men	13	3,119	11.0-80.4	31.6	37.9 (30.2-46.0)	227.1 (p<0.001)	94.7 (92.5-96.3)	10.9-69.8	
Mixed	4	1,715	6.0-57.9	35.6	35.8 (23.0-49.8)	84.4 (p<0.001)	96.4 (93.5-98.1)	0.0-93.1	
HIV positive individuals and in									
individuals in HIV discordant	42	15,521	17.5-95.2	70.2	71.3 (66.5-75.9)	1,514.7 (p<0.001)	97.3 (96.8-97.7)	38.9-94.9	
couples									
Women	20	6,183	42.0-95.2	79.7	76.7 (70.1-82.7)	587.4 (p<0.001)	96.8 (95.9-97.5)	43.2-97.9	
Men	15	4,306	44.0-94.2	61.4	72.0 (63.7-79.6)	311.0 (p<0.001)	95.5 (93.9-96.7)	36.2-96.8	
Mixed	7	5,032	17.5-70.2	62.3	54.6 (47.4-61.8)	108.9 (p<0.001)	94.5 (91.0-96.6)	31.0-77.1	
STI clinic attendees and symptomatic populations [¶]	72	11,996	14.7-93.3	60.7	61.2 (56.5-65.9)	1,826.8 (p<0.001)	96.1 (95.6-96.6)	22.9-93.0	
Women	26	4,038	38.0-93.3	75.3	69.2 (62.7-75.4)	393.3 (p<0.001)	93.6 (91.8-95.1)	35.2-94.7	
Men	38	6,585	14.7-86.4	56.6	52.9 (46.9-58.8)	791.4 (p<0.001)	95.3 (94.3-96.1)	18.8-85.6	
Mixed	8	1,373	85.0-85.0	79.4	75.8 (68.5-82.5)	35.9 (p<0.001)	80.5 (62.3-89.9)	51.8-93.7	
Other populations	16	6,506	11.2-89.4	48.1	50.3 (41.9-58.7)	546.4 (p<0.001)	97.3 (96.5-97.9)	17.4-58.7	
Women	9	5,642	27.8-89.4	48.7	53.8 (45.6-61.9)	260.2 (p<0.001)	96.9 (95.6-97.9)	24.8-81.5	
Men	3	803	11.2-38.6	23.7	23.4 (10.5-39.4)	48.2 (p<0.001)	95.9 (91.0-98.1)	0.0-100	
Mixed	4	61	46.7-83.3	75.7	71.1 (54.4-85.5)	5.1 (p=0.164)	41.2 (0.0-80.2)	13.7-100	

Table 2. Pooled mean estimates for herpes simplex virus type 2 seroprevalence among the different at risk populations in sub-Saharan Africa b	by sex.
---	---------

Mixed40140.7-05.575.771.1 (34.4-05.5)5.1 (p=0.104)41.2 (0.0-00.2)15.7-10*Q: the Cochran's Q statistic is a measure assessing the existence of heterogeneity in seroprevalence.*12: a measure that assesses the magnitude of between-study variation that is due to actual differences in seroprevalence across studies rather than chance.*Prediction interval: a measure that estimates the distribution (95% interval) of true seroprevalence around the estimated mean.*No meta-analysis was done due to the small number of studies (n < 3).</td>*Symptomatic populations include patients with clinical manifestations related to an STI.Abbreviations: CI = Confidence interval, FSWs = Female sex workers, HIV = Human immunodeficiency virus, HSV-2 = Herpes simplex virus type 2, MSM = Men who have sex with men, STI = Sexually transmitted disease.

	Outcome measures	Sample size	HSV-2 seroj	prevalence	Pooled mean HSV-2 seroprevalence	Hete	rogeneity measures	
Population classification	Total n	Total N	Range	Median	Mean (%) (95% CI)	Q* (p-value)	I ^{2†} (%) (95% CI)	Prediction interval [‡] (%)
African countries								
Benin	16	3,991	1.0-57.0	28.0	24.6 (17.1-32.9)	447.1 (p<0.001)	96.6 (95.6-74.4)	1.1-63.5
Burkina Faso	14	5,932	4.1-40.5	20.3	19.5 (14.7-24.8)	297.3 (p<0.001)	95.6 (94.0-96.8)	3.5-43.8
Cameroon	23	2,309	3.0-90.9	59.0	53.6 (40.9-66.2)	804.9 (p<0.001)	97.3 (96.6-97.8)	2.4-99.6
Ethiopia	10	2,444	7.9-59.5	28.5	27.3 (16.8-39.3)	277.4 (p<0.001)	96.8 (95.4-97.7)	0.2-73.7
Kenya	71	34,605	1.9-91.3	42.4	39.9 (34.3-45.9)	8,018.6 (p<0.001)	99.1 (99.1-99.2)	3.0-86.2
Malawi	55	9,571	0.0-87.5	50.0	45.1 (38.2-52.0)	2,192.8 (p<0.001)	97.5 (97.2-97.8)	4.5-90.2
Nigeria	14	2,205	8.7-61.3	29.3	28.5 (16.1-42.7)	486.9 (p<0.001)	97.3 (96.5-98.0)	0.0-85.6
South Africa	79	44,449	1.5-92.5	31.0	34.1 (27.3-41.9)	19,846.8 (p<0.001)	99.6 (99.6-99.6)	0.0-93.4
Tanzania	41	18,731	7.0-68.0	36.8	37.4 (33.7-41.1)	1,008.2 (p<0.001)	96.0 (95.3-96.7)	16.1-61.6
Uganda	59	52,216	9.9-90.7	53.4	50.5 (44.2-56.8)	12,120.9 (p<0.001)	99.5 (99.5-99.6)	8.5-92.1
Zambia	42	25,973	1.0-80.0	41.5	36.3 (28.2-44.8)	7,909.4 (p<0.001)	99.5 (99.4-99.5)	0.3-88.7
Zimbabwe	42	20,530	0.1-71.0	30.6	26.0 (17.5-35.5)	8,678.9 (p<0.001)	99.5 (99.5-99.6)	0.0-88.6
Other countries [§]	41	7,585	2.6-97.4	22.2	31.1 (24.5-38.1)	1,564.8 (p<0.001)	97.4 (97.0-97.8)	0.1-77.3
African subregions								
Eastern Africa	188	110,399	1.9-91.3	42.4	41.9 (38.4-45.3)	25,111.0 (p<0.001)	99.3 (99.2-99.3)	4.9-85.6
Southern Africa	226	100,925	0.0-92.5	40.3	35.8 (31.6-40.0)	43,422.5 (p<0.001)	99.5 (99.5-99.5)	0.0-92.9
Western Africa	68	16,005	1.0-97.4	21.9	25.0 (20.9-29.4)	2,442.9 (p<0.001)	97.3 (96.9-97.6)	1.2-63.7
Central Africa	25	3,212	3.0-90.9	59.0	52.4 (40.4-64.3)	1,065.0 (p<0.001)	97.7 (97.3-98.1)	2.6-98.9
Age group								
<20 years	88	40,217	0.0-46.0	11.0	12.4 (10.6-14.3)	2,419.1 (p<0.001)	96.4 (96.0-96.8)	1.0-32.6
20-30 years	112	49,099	2.9-91.3	36.8	34.2 (30.7-37.8)	7,583.3 (p<0.001)	98.5 (98.4-98.6)	5.0-72.7
30-40 years	69	26,412	16.4-90.4	60.6	57.1 (54.8-63.3)	3,210.2 (p<0.001)	97.9 (97.6-98.1)	24.6-89.2
40-50 years	48	12,470	20.0-92.5	61.7	64.6 (59.5-69.5)	1,445.1 (p<0.001)	96.7 (96.2-97.2)	29.8-92.5
>50 years	15	4,054	39.6-80.9	60.6	58.2 (50.3-65.9)	321.3 (p<0.001)	95.6 (94.1-96.8)	26.3-86.8
Mixed	175	98,289	0.1-97.4	35.0	36.2 (32.1-40.3)	31,073.2 (p<0.001)	99.4 (99.4-99.5)	0.4-87.7
Year of publication category								
≤2005	124	27,633	1.0-90.9	45.5	42.1 (38.1-46.2)	5,477.8 (p<0.001)	97.8 (97.6-97.9)	6.2-83.8
2005-2015	283	142,060	0.0-97.4	38.4	35.7 (32.6-38.9)	42,499.0 (p<0.001)	99.3 (99.3-99.3)	0.6-86.0
>2015	100	60,848	1.5-92.5	35.8	35.9 (30.1-41.8)	23,039.3 (p<0.001)	99.6 (99.5-99.6)	0.0-90.9
All studies	507	230,541	0.0-97.4	39.5	37.3 (34.9-39.7)	73,247.9 (p<0.001)	99.3 (99.3-99.3)	0.7-88.0

Table 3. Pooled mean estimates for herpes simplex virus type 2 seroprevalence among general populations in sub-Saharan Africa.

*Q: the Cochran's Q statistic is a measure assessing the existence of heterogeneity in seroprevalence.

[†] I²: a measure that assesses the magnitude of between-study variation that is due to actual differences in seroprevalence across studies rather than chance.

*Prediction interval: a measure that estimates the distribution (95% interval) of true seroprevalence around the estimated mean.

[§]Other countries: Chad, Cote D'Ivoire, Eritrea, Gabon, Gambia, Ghana, Mali, Namibia, Rwanda, Senegal.

Abbreviations: CI = Confidence interval, HSV-2 = Herpes simplex virus type 2.

Table 4. Univariable and multivariable meta-regression analyses for herpes simplex virus type 2 seroprevalence in sub-Saharan Africa.

			Outcome measures	Sample size	Univariable analysis				Multivariable analysis			
			Total n	Total N	RR (95%CI)	p-value	LR test	Adjusted	Model 1	*	Model 2	n volue
		Convertence	507	220 5 4 1	1.00		p-value	12.0	AKK (95% CI)	p-value	AKK (95% CI)	p-value
		Seneral populations	307	230,341	1.00	-0.001	<0.001	12.9	1.00	-0.001	1.00	-0.001
		Higher rick populations	43	9,239	1.75(1.55-2.21) 1.70(1.21,2.20)	< 0.001			1.30(1.24-1.61) 1.58(1.28,1.04)	< 0.001	1.49(1.25-1.01) 1.50(1.20, 1.06)	<0.001
	Donulation	Higher-fisk populations	40	15,470	1.70(1.51-2.20) 1.41(1.12,1.78)	< 0.001			1.36(1.26-1.94) 1.21(1.07, 1.50)	< 0.001	1.39(1.29-1.90) 1.20(1.07, 1.50)	< 0.001
	Population	HIV negative populations	51	38,333	1.41 (1.12-1.78)	0.005			1.31 (1.07-1.39)	0.008	1.50 (1.07-1.59)	0.008
	type	discondent counter	42	15,521	2.18 (1.70-2.80)	< 0.001			2.17 (1.78-2.65)	< 0.001	2.18 (1.78-2.66)	< 0.001
		CTL slinis offen deep and compared and the second	70	11.000	1.00 (1.54.2.20)	-0.001			1.76 (1.40.2.09)	-0.001	1 79 (1 51 2 10)	-0.001
		Still chinic attendees and symptomatic populations	12	11,996	1.88 (1.54-2.28)	< 0.001			1.76 (1.49-2.08)	< 0.001	1.78 (1.51-2.10)	< 0.001
		Other populations	10	0,500	1.55 (1.05-2.27)	0.035	-0.001	22.6	1.22 (0.90-1.05)	0.179	1.24 (0.92-1.08)	0.150
ц.		<20 years	108	42,984	1.00	-	<0.001	32.0	1.00	-	1.00	-
ris		20-30 years	144	55,344	2.49 (2.07-3.00)	< 0.001			2.51 (2.15-2.93)	< 0.001	2.53 (2.17-2.94)	<0.001
cte	Age group	30-40 years	84	27,875	4.26 (3.46-5.24)	< 0.001			4.44 (3.74-5.28)	< 0.001	4.46 (3.75-5.30)	<0.001
rae	001	40-50 years	52	12,650	4.62 (3.64-5.86)	< 0.001			5.27 (4.32-6.44)	< 0.001	5.27 (4.31-6.43)	<0.001
iha		>50 years	16	4,127	4.30 (2.96-6.24)	< 0.001			4.80 (3.52-6.56)	< 0.001	4.64 (3.40-6.33)	<0.001
nc		Mixed ages	369	182,852	3.10 (2.64-3.64)	< 0.001			2.37 (2.05-2.73)	< 0.001	2.38 (2.07-2.75)	< 0.001
tio		Women	447	204,899	1.00	-	< 0.001	4.7	1.00	-		
ula	Sex	Men	269	100,000	0.68 (0.60-0.78)	< 0.001			0.61 (0.56-0.67)	< 0.001	0.61 (0.56-0.67)	< 0.001
Ido		Mixed sexes	57	20,933	0.89 (0.70-1.12)	0.337			0.78 (0.65-0.94)	0.011	0.80 (0.66-0.96)	0.018
<u>A</u>		Eastern Africa	298	144,196	1.00	-	< 0.001	3.3	1.00	-	1.00	-
	African subregion	Southern Africa	319	128,395	0.82 (0.72-0.94)	0.006			0.85 (0.76-0.96)	0.014	0.86 (0.76-0.97)	0.015
		Western Africa	94	21,301	0.63 (0.52-0.77)	< 0.001			0.60 (0.52-0.70)	< 0.001	0.61 (0.53-0.71)	< 0.001
	Subregion	Central Africa	48	5,832	1.01 (0.78-1.31)	0.909			0.75 (0.61-0.93)	0.009	0.75 (0.61-0.93)	0.009
		Mixed regions	14	26,225	1.23 (0.79-1.91)	0.347			1.01 (0.47-2.17)	0.965	1.02 (0.47-2.18)	0.955
		LIC	326	123,156	1.00	-	0.027	0.7	1.00	-	1.00	-
	Country's	LMIC	285	107,905	0.86 (0.75-0.98)	0.030			0.95 (0.86-1.05)	0.385	0.96 (0.87-1.07)	0.540
	income	UMIC	145	63,908	0.89 (0.75-1.05)	0.195			1.12 (0.96-1.31)	0.131	1.14 (0.97-1.33)	0.093
		Mixed	17	30,863	1.35 (0.90-2.03)	0.141			0.84 (0.42-1.67)	0.622	0.86 (0.43-1.71)	0.670
		Western Blot	82	19,787	1.00	-	0.089	0.5	1.00	-	1.00	-
~	Assay type	ELISA	681	304,639	0.86 (0.71-1.05)	0.157			1.02 (0.87-1.20)	0.730	1.03 (0.88-1.21)	0.663
S log		Rapid test	10	1,406	0.55 (0.31-0.97)	0.041			0.71 (0.46-1.08)	0.111	0.74 (0.48-1.12)	0.162
dol	a 1 * *	≥100	740	324,163	1.00	-	0.634	0.0	-	-	-	-
eri eri	Sample size*		33	1,669	1.07 (0.79-1.45)	0.654			-	-	-	-
act	Sampling	Probability based	311	165,963	1.00	-	< 0.001	3.6	1.00	-	1.00	-
y I ar:	method	Non-probability based	462	159,869	1.35 (1.20-1.53)	< 0.001			1.06 (0.94-1.19)	0.289	1.06 (0.94-1.18)	0.303
ch ud		>80%	255	142.489	1.00	-	< 0.001	4.0	1.00	-	1.00	-
St	Response rate	<80%	153	57.722	0.95 (0.80-1.12)	0.564			1.18 (1.04-1.34)	0.007	1.19 (1.05-1.35)	0.007
	P	Unclear	365	125.621	1.34 (1.17-1.53)	< 0.001			1.30 (1.16-1.45)	< 0.001	1.29 (1.15-1.44)	< 0.001
7 %	Vear of	~2005	218	38,609	1.00		<0.001	3.1	1.00			-
ora	nublication	2006-2015	422	208 948	0.86 (0.74-0.98)	0.032	<0.001	5.1	0.85 (0.76-0.96)	0.009	-	-
iai I	category	>2015	133	200,940	0.67 (0.56-0.98)	<0.052			0.80 (0.69-0.90)	0.009	-	-
rer var	Vear of nublicat	tion	773	325 832	0.07 (0.07 0.00)	<0.001	<0.001	2.0	0.00 (0.09-0.93)	0.005	0.08 (0.07 0.00)	0.006
	I CAL OI DUDIICA	11011	115	545.054	0.2/10.2/-0.201	<u>\0.001</u>	<0.001	4.7	-	-	0.20(0.2/-0.22)	0.000

^{*} Variance explained by multivariable model 1 (adjusted R^2) = 57.47%.

[†]Variance explained by multivariable model 2 (adjusted R^2) = 57.50%.

^{*}Sample size denotes the sample size of each study population found in the original publication.

Abbreviations: ARR = Adjusted risk ratio, CI = Confidence interval, ELISA = Enzyme-linked immunosorbent type-specific assay, HIV = Human immunodeficiency virus, HSV-2 = Herpes simplex virus type 2, LIC = Low-income country, LMIC = Lowermiddle-income country, LR = Likelihood ratio, RR = Risk ratio, STI = Sexually transmitted infection, UMIC = Upper-middle-income country.

Domulation trace	Outcome measures	OutcomeSampleProportionmeasuressizeisolation		on of HSV-2Pooled proportion of HSV-2 isolation (%)		Heterogeneity measures				
Population type	Total n	Total N	Range	Median	Mean (95% CI)	Q* (p-value)	I ^{2†} (%) (95% CI)	Prediction Interval [‡] (%)		
Patients with GUD	31	4,296	8.3-100	49.1	50.7 (44.7-56.8)	423.6 (p<0.001)	92.9 (91.0-94.4)	19.7-81.5		
Women	8	816	35.0-100	49.5	59.0 (44.7-72.6)	88.1 (p<0.001)	92.1 (86.7-95.2)	13.0-100		
Men	13	1,915	8.3-72.2	49.1	47.3 (37.2-57.5)	225.1 (p<0.001)	94.7 (92.4-96.2)	11.4-84.8		
Mixed sexes	10	1,565	22.4-73.0	50.0	49.1 (39.0-59.2)	110.3 (p<0.001)	91.8 (87.1-94.8)	15.5-83.2		
Patients with genital herpes	11	1,380	53.0-100	100	97.3 (84.4-100)	586.5 (p<0.001)	98.3 (97.8-98.7)	22.8-100		
Men	6	715	53.0-100	100	97.3 (73.4-100)	318.8 (p<0.001)	98.4 (97.7-98.9)	0.0-100		
Mixed sexes	5	665	91.4-100	85.4	97.8 (91.9-100)	23.9 (p<0.001)	83.3 (62.0-92.6)	66.2-100		

Table 5. Pooled proportions of herpes virus type 2 (HSV-2) virus isolation in clinically-diagnosed GUD and in clinically-diagnosed genital herpes in Africa.

*Q: The Cochran's Q statistic is a measure assessing the existence of heterogeneity in pooled outcome measures, here proportions of HSV-2 virus isolation.

[†] I²: A measure assessing the magnitude of between-study variation that is due to true differences in proportions of HSV-2 virus isolation across studies rather than sampling variation.

[‡] Prediction interval: A measure quantifying the distribution 95% interval of true proportions of HSV-2 virus isolation around the estimated pooled mean.

Abbreviations: CI = Confidence interval, GUD = Genital ulcer disease, HSV-2 = Herpes simplex virus type 2.

References

1. James C, Harfouche M, Welton NJ, Turner KME, Abu-Raddad LJ, Gottlieb SL, et al. Herpes simplex virus: global infection prevalence and incidence estimates, 2016. Bulletin of the World Health Organization. 2020;98(5):315-29.

2. Ahmed HJ, Mbwana J, Gunnarsson E, Ahlman K, Guerino C, Svensson LA, et al. Etiology of genital ulcer disease and association with human immunodeficiency virus infection in two tanzanian cities. Sex Transm Dis. 2003;30(2):114-9.

3. Gupta R, Warren T, Wald A. Genital herpes. Lancet. 2007;370(9605):2127-37.

4. Halioua B, Malkin JE. Epidemiology of genital herpes - recent advances. Eur J Dermatol. 1999;9(3):177-84.

5. Mertz KJ, Trees D, Levine WC, Lewis JS, Litchfield B, Pettus KS, et al. Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The Genital Ulcer Disease Surveillance Group. J Infect Dis. 1998;178(6):1795-8.

6. Morse SA. Etiology of genital ulcer disease and its relationship to HIV infection. Sex Transm Dis. 1999;26(1):63-5.

7. O'Farrell N. Increasing prevalence of genital herpes in developing countries: implications for heterosexual HIV transmission and STI control programmes. Sex Transm Infect. 1999;75(6):377-84.

8. Weiss HA, Buve A, Robinson NJ, Van Dyck E, Kahindo M, Anagonou S, et al. The epidemiology of HSV-2 infection and its association with HIV infection in four urban African populations. AIDS. 2001;15 Suppl 4:S97-108.

9. Looker KJ, Magaret AS, May MT, Turner KME, Vickerman P, Newman LM, et al. First estimates of the global and regional incidence of neonatal herpes infection. Lancet Glob Health. 2017;5(3):e300-e9.

10. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS. 2006;20(1):73-83.

11. Abu-Raddad LJ, Magaret AS, Celum C, Wald A, Longini Jr IM, Self SG, et al. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PloS one. 2008;3(5).

12. Looker KJ, Elmes JAR, Gottlieb SL, Schiffer JT, Vickerman P, Turner KME, et al. Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis. Lancet Infect Dis. 2017;17(12):1303-16.

13. Looker KJ, Welton NJ, Sabin KM, Dalal S, Vickerman P, Turner KM, et al. Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: a population attributable fraction analysis using published epidemiological data. The Lancet Infectious Diseases. 2020;20(2):240-9.

14. Omori R, Nagelkerke N, Abu-Raddad LJ. HIV and herpes simplex virus type 2 epidemiological synergy: misguided observational evidence? A modelling study. Sexually transmitted infections. 2018;94(5):372-6.

15. Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Annals of internal medicine. 1994;121(11):847-54.

16. Wald A, Zeh J, Selke S, Warren T, Ryncarz AJ, Ashley R, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. New England Journal of Medicine. 2000;342(12):844-50.

17. Wald A, Krantz E, Selke S, Lairson E, Morrow RA, Zeh J. Knowledge of partners' genital herpes protects against herpes simplex virus type 2 acquisition. The Journal of infectious diseases. 2006;194(1):42-52.

18. Wald A, Langenberg AG, Link K, Izu AE, Ashley R, Warren T, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. Jama. 2001;285(24):3100-6.

19. Abu-Raddad LJ, Schiffer JT, Ashley R, Mumtaz G, Alsallaq RA, Akala FA, et al. HSV-2 serology can be predictive of HIV epidemic potential and hidden sexual risk behavior in the Middle East and North Africa. Epidemics. 2010;2(4):173-82.

20. Omori R, Abu-Raddad LJ. Sexual network drivers of HIV and herpes simplex virus type 2 transmission. AIDS. 2017;31(12):1721-32.

21. van de Laar MJ, Termorshuizen F, Slomka MJ, van Doornum GJ, Ossewaarde JM, Brown DW, et al. Prevalence and correlates of herpes simplex virus type 2 infection: evaluation of behavioural risk factors. Int J Epidemiol. 1998;27(1):127-34.

22. Cowan FM, Johnson AM, Ashley R, Corey L, Mindel A. Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations. BMJ. 1994;309(6965):1325-9.

23. Obasi A, Mosha F, Quigley M, Sekirassa Z, Gibbs T, Munguti K, et al. Antibody to herpes simplex virus type 2 as a marker of sexual risk behavior in rural Tanzania. J Infect Dis. 1999;179(1):16-24.

24. Kouyoumjian SP, Heijnen M, Chaabna K, Mumtaz GR, Omori R, Vickerman P, et al. Global population-level association between herpes simplex virus 2 prevalence and HIV prevalence. Aids. 2018;32(10):1343-52.

25. World Health Organization. Global health sector strategy on sexually transmitted infections 2016-2021: toward ending STIs. World Health Organization; 2016.

26. Gottlieb SL, Deal CD, Giersing B, Rees H, Bolan G, Johnston C, et al. The global roadmap for advancing development of vaccines against sexually transmitted infections: Update and next steps. Vaccine. 2016;34(26):2939-47.

27. Gottlieb SL, Giersing B, Boily MC, Chesson H, Looker KJ, Schiffer J, et al. Modelling efforts needed to advance herpes simplex virus (HSV) vaccine development: Key findings from the World Health Organization Consultation on HSV Vaccine Impact Modelling. Vaccine. 2017.

28. UNAIDS. Global HIV/AIDS response:UNAIDS report on the global AIDS epidemic 2013 (available at:

http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UN AIDS_Global_Report_2013_en.pdf, accessed April 2014). 2013.

29. UNAIDS. AIDS by the numbers (available at

http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2013/JC2571 AIDS_by_the_numbers_en.pdf, accessed April 2014)

2013.

30. Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions: John Wiley & Sons; 2011.

31. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS med. 2009;6(7):e1000097.

32. Chaabane S, Harfouche M, Chemaitelly H, Schwarzer G, Abu-Raddad LJ. Herpes simplex virus type 1 epidemiology in the Middle East and North Africa: systematic review, meta-analyses, and meta-regressions. Scientific reports. 2019;9(1):1-11.

33. Harfouche M, Chemaitelly H, Abu-Raddad LJ. Herpes simplex virus type 1 epidemiology in Africa: Systematic review, meta-analyses, and meta-regressions. J Infect. 2019;79(4):289-99.

34. Khadr L, Harfouche M, Omori R, Schwarzer G, Chemaitelly H, Abu-Raddad LJ. The epidemiology of herpes simplex virus type 1 in Asia: systematic review, meta-analyses, and meta-regressions. Clinical Infectious Diseases. 2018;68(5):757-72.

35. Sukik L, Alyafei M, Harfouche M, Abu-Raddad LJ. Herpes simplex virus type 1 epidemiology in Latin America and the Caribbean: Systematic review and meta-analytics. PloS one. 2019;14(4):e0215487.

36. Yousuf W, Ibrahim H, Harfouche M, Abu Hijleh F, Abu-Raddad L. Herpes simplex virus type 1 in Europe: systematic review, meta-analyses and meta-regressions. BMJ Glob Health. 2020;5(7).

37. World Health Organization. WHO regional offices, (Available at:

http://www.who.int/about/regions/en/, Accessed in May, 2017) 2017 [

38. Ashley-Morrow R, Nollkamper J, Robinson NJ, Bishop N, Smith J. Performance of focus ELISA tests for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies among women in ten diverse geographical locations. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2004;10(6):530-6.

39. Ashley RL. Performance and use of HSV type-specific serology test kits. Herpes. 2002;9(2):38-45.

40. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26(4):404-13.

41. Borenstein M H, L. V., Higgins, J. P. T. and Rothstein, H.R. Introduction to Meta-Analysis Chichester, UK: John Wiley & Sons, Ltd; 2009.

42. Schwarzer G. meta: An R package for meta-analysis. R news. 2007;7(3):40-5.

43. Freeman MF, Tukey JW. Transformations related to the angular and the square root. The Annals of Mathematical Statistics. 1950:607-11.

44. Schwarzer G, Chemaitelly H, Abu-Raddad LJ, Rücker G. Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions. Research synthesis methods. 2019;10(3):476-83.

45. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in metaanalyses. BMJ: British Medical Journal. 2003;327(7414):557.

46. RStudio Team. RStudio: Integrated Development for R. RStudio, Inc., Boston, MA URL <u>http://www.rstudio.com/</u>. 2015.

47. StataCorp. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP. 2015.

48. Harbord RM, Higgins JPT. Meta-regression in Stata. Stata Journal. 2008;8(4):493-519.

49. Aryee EA, Bailey RL, Natividad-Sancho A, Kaye S, Holland MJ. Detection,

quantification and genotyping of Herpes Simplex Virus in cervicovaginal secretions by real-time PCR: a cross sectional survey. Virol J. 2005;2(1):61.

50. Austrian K, Hewett PC, Soler-Hampejsek E, Bozzani F, Behrman JR, Digitale J. Adolescent Girls Empowerment Programme: research and evaluation mid-term technical report. 2016.

51. Cisse BC, Zaba F, Meite S, Mlan A, Inwoley K, Kouassi M'Bengue A, et al. Seroprevalence of herpes simplex virus 2 infection among pregnant women in urban health training Yopougon-Attie (Cote D'ivoire). Academic Journals. 2015;6(3):17-21.

52. Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infectious Diseases. 2012;12(1):19-26.

53. Jespers V, Crucitti T, Menten J, Verhelst R, Mwaura M, Mandaliya K, et al. Prevalence and correlates of bacterial vaginosis in different sub-populations of women in sub-Saharan Africa: a cross-sectional study. PLoS One. 2014;9(10):e109670.

54. Low AJ, Clayton T, Konate I, Nagot N, Ouedraogo A, Huet C, et al. Genital warts and infection with human immunodeficiency virus in high-risk women in Burkina Faso: a longitudinal study. BMC Infect Dis. 2011;11(1):20.

55. Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovirbased preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine. 2015;372(6):509-18.

56. McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet. 2010;376(9749):1329-37.

57. MOH Uganda, ORC Macro. Uganda HIV/AIDS sero-behavioural survey: 2004-2005. Calverton, Maryland, USA: Ministry of Health and ORC Macro.; 2006.

58. NASCOP (National AIDS/STI Control Program). 2007 Kenya AIDS Indicator Survey: Final Report. Nairobe, Kenya; September 2009.

59. Odebisi-Omokanye M, Udeze A, Akanbi K, Jimoh N, Imam M. Serosurvey of Herpes Simplex Virus type-2 infection among HIV Infected Individuals Accessing a Secondary Health Care Facility in Kwara State, North Central Nigeria. Nig J Pure & Appl Sci. 2017;30(2).

60. Priddy FH, Wakasiaka S, Hoang TD, Smith DJ, Farah B, del Rio C, et al. Anal sex, vaginal practices, and HIV incidence in female sex workers in urban Kenya: implications for the development of intravaginal HIV prevention methods. AIDS Res Hum Retroviruses. 2011;27(10):1067-72.

61. Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. Lancet. 2019;394(10195):303-13.

62. UNAIDS/WHO. Global HIV/AIDS response:Epidemic update and health sector progress towards Universal Access (available at:

http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/201111 30_UA_Report_en.pdf). 2011.

63. Garnett GP, Gregson S, Stanecki KA. Criteria for detecting and understanding changes in the risk of HIV infection at a national level in generalised epidemics. Sex Transm Infect. 2006;82 Suppl 1:i48-51.

64. Walker PT, Hallett TB, White PJ, Garnett GP. Interpreting declines in HIV prevalence: impact of spatial aggregation and migration on expected declines in prevalence. Sex Transm Infect. 2008;84 Suppl 2:ii42-8.

65. UNAIDS. Trends in HIV incidence and prevalence: natural course of the epidemic or results of behavioural change? ; 1999.

66. Nagelkerke N, de Vlas SJ, Jha P, Luo M, Plummer FA, Kaul R. Heterogeneity in host HIV susceptibility as a potential contributor to recent HIV prevalence declines in Africa. Aids. 2009;23(1):125-30.

67. Nagelkerke NJ, Arora P, Jha P, Williams B, McKinnon L, de Vlas SJ. The rise and fall of HIV in high-prevalence countries: a challenge for mathematical modeling. PLoS computational biology. 2014;10(3):e1003459.

68. Hallett TB, Gregson S, Mugurungi O, Gonese E, Garnett GP. Assessing evidence for behaviour change affecting the course of HIV epidemics: a new mathematical modelling approach and application to data from Zimbabwe. Epidemics. 2009;1(2):108-17.

69. Hallett TB, Aberle-Grasse J, Bello G, Boulos LM, Cayemittes MP, Cheluget B, et al. Declines in HIV prevalence can be associated with changing sexual behaviour in Uganda, urban Kenya, Zimbabwe, and urban Haiti. Sex Transm Infect. 2006;82 Suppl 1:i1-8.

70. Kilian AH, Gregson S, Ndyanabangi B, Walusaga K, Kipp W, Sahlmuller G, et al. Reductions in risk behaviour provide the most consistent explanation for declining HIV-1 prevalence in Uganda. Aids. 1999;13(3):391-8.

71. Awad SF, Abu-Raddad LJ. Could there have been substantial declines in sexual risk behavior across sub-Saharan Africa in the mid-1990s? Epidemics. 2014;8:9-17.

72. Ayoub HH, Amara I, Awad SF, Chemaitelly H, Abu-Raddad LJ. Analytic characterization of the herpes simplex virus type 2 epidemic in the United States, 1950-2050. Under Review.

73. Low N, Broutet N, Adu-Sarkodie Y, Barton P, Hossain M, Hawkes S. Global control of sexually transmitted infections. The Lancet. 2006;368(9551):2001-16.

74. Smolak A, Chemaitelly H, Hermez JG, Low N, Abu-Raddad LJ. Epidemiology of chlamydia trachomatis in the Middle East and North Africa: a systematic review, meta-analysis, and meta-regression. The Lancet Global Health. 2019;7(9):e1197-e225.

75. UNAIDS. Global HIV & AIDS statistics — 2019 fact sheet 2019 [Available from: <u>https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf</u>, Accessed in March, 2020.

76. Cuadros DF, Awad SF, Abu-Raddad LJ. Mapping HIV clustering: a strategy for identifying populations at high risk of HIV infection in sub-Saharan Africa. International journal of health geographics. 2013;12(1):28.

77. McQuillan GM, Kruszon-Moran D, Flagg EW, Paulose-Ram R. Prevalence of herpes simplex virus type 1 and type 2 in persons aged 14-49: United States, 2015-2016. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; 2018.

78. Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med. 1992;116(3):197-202.

79. Looker KJ, Johnston C, Welton NJ, James C, Vickerman P, Turner KM, et al. The global and regional burden of genital ulcer disease due to herpes simplex virus: a natural history modelling study. BMJ global health. 2020;5(3):e001875.

80. Korenromp EL, Mahiané SG, Nagelkerke N, Taylor MM, Williams R, Chico RM, et al. Syphilis prevalence trends in adult women in 132 countries–estimations using the Spectrum Sexually Transmitted Infections model. Scientific reports. 2018;8(1):1-10.

81. Smolak A, Rowley J, Nagelkerke N, Kassebaum NJ, Chico RM, Korenromp EL, et al. Trends and predictors of syphilis prevalence in the general population: global pooled analyses of 1103 prevalence measures including 136 million syphilis tests. Clinical Infectious Diseases. 2018;66(8):1184-91.

82. Ayoub HH, Chemaitelly H, Abu-Raddad LJ. Epidemiological Impact of Novel Preventive and Therapeutic HSV-2 Vaccination in the United States: Mathematical Modeling Analyses. Vaccines. 2020;8(3):366.

83. World Health Organization. World Health Organization preferred product characteristics for herpes 2 simplex virus vaccines. <u>https://www.who.int/immunization/research/ppc-tpp/HSV_Vaccine_PPCs_for_Public_Comment.pdf</u>. 2019.

Web extra material

The epidemiology of herpes simplex virus type 2 in sub-Saharan Africa:

systematic review, meta-analyses, and meta-regressions

Manale Harfouche MPH,^{a,b*} Farah M. Abu-Hijleh MD,^{c*} Charlotte James PhD,^d Katharine J.

Looker PhD,^d and Laith J. Abu-Raddad PhD^{a,b,e}

^a Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar

^b World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine–Qatar, Cornell University, Qatar Foundation – Education City, Doha, Qatar

^c Department of Public Health, College of Health Sciences, Academic Quality Affairs Office, QU Health, Qatar University, Doha, Qatar

^d Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom

^e Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA

Table of Contents

Table S	1. Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) checklist. ¹	4
Table San Africa.	2. Data sources and search criteria for systematically reviewing HSV-2 epidemiology in sub-Saharan	6
Box S1.	List of the 45 countries included in our definition for sub-Saharan Africa by subregion. ²	7
Box S2.	List of variables extracted from the relevant publications meeting the inclusion criteria.	8
Box S3.	Definitions of population type classifications	9
Box S4.	Variables included in the univariable and multivariable meta-regression analyses	0
Table S	3. Studies reporting HSV-2 seroconversion rate or incidence rate in sub-Saharan Africa	1
Figure S incidenc	S1. Forest plot presenting the outcome of the pooled mean herpes simplex virus type 2 (HSV-2) e rate by population type in sub-Saharan Africa	3
Table Setstratified	4. Studies reporting HSV-2 seroprevalence in Eastern Africa. This table includes only overall and not 1 seroprevalence measures	4
Table Samestratified	5. Studies reporting HSV-2 seroprevalence in Southern Africa. This table includes only overall and not a seroprevalence measures,	8
Table Sstratified	6. Studies reporting HSV-2 seroprevalence in Western Africa. This table includes only overall and not a seroprevalence measures	1
Table S'stratified	7. Studies reporting HSV-2 seroprevalence in Central Africa. This table includes only overall and not a seroprevalence measures	3
Table Sincludes	8. Studies reporting HSV-2 seroprevalence across several regions in sub-Saharan Africa. This table only overall and not stratified seroprevalence measures.	4
Table Sex strat	9. Pooled mean estimates for herpes simplex virus type 2 seroprevalence among general populations by ification in sub-Saharan Africa.	5
Figure S seroprev	S2. Forest plots presenting the outcomes of the pooled mean herpes simplex virus type 2 (HSV-2) valence among the different at risk populations across the sub-Saharan Africa subregions	6
A)	Eastern Africa	6
B)	Southern Africa	0
C)	Western Africa	5
D)	Central Africa	7
E)	Mixed regions in sub-Saharan Africa	8
Table Sseropreva catego	10. Univariable and multivariable meta-regression analyses for herpes simplex virus type 2 valence among the different at risk populations in sub-Saharan Africa using the year of data collection a rical variable or as a linear term (in replacement of year of publication)	s 9
Table Sand in cl	11. Studies reporting proportions of HSV-2 virus isolation in clinically-diagnosed genital ulcer disease linically-diagnosed genital herpes in sub-Saharan Africa	0
Figure S	S3. Forest plots presenting the outcomes of the pooled mean proportions of HSV-2 virus isolation in y-diagnosed genital ulcer disease (GUD) and in clinically-diagnosed genital herpes in sub-Saharan	4
Africa		1
A)	Patients with GUD	1

B)	Patients with genital herpes	2
Table S	512. Summary of the precision assessment and risk of bias assessment for the studies reporting HSV-2	
seroprev	valence in sub-Saharan Africa	3
Refere	nces	4

Section/topic	#	Checklist item	Reported in main text on
Title			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	p.1
Abstract	1		
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	p.2-3
Introduction			
Rationale	3	Describe the rationale for the review in the context of what is already known.	p. 3
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	p. 3
Methods			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	NA
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	p. 4
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	p. 3-4
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Supplementary Table 2
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	p. 4
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	p. 5; Supplementary Box 2
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	p. 5; Supplementary Box 2
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	р. 5-6
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	p. 6
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I ²) for each meta-analysis.	р. б
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	р. 5-б
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating	p. 7

Table S1. Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) checklist.(1)

		which were pre-specified.	
Results			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	p. 8; Figure 2
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	p. 8 and 9; Tables 1 and 4
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	p. 10-11; Supplementary Table 3
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	p. 8-10; Tables 2 and 5; Supplementary Figures 1 and 2
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	P. 8 and 10; Tables 2 and 5
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	p. 10-11; Supplementary Table 3
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	p. 9-10; Table 3
Discussion			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	p. 11
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	p. 13
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	p. 11-13
funding			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	p. 14

Abbreviations: NA = Not applicable, p = page.

Table S2. Data sources and search criteria for systematically reviewing HSV-2 epidemiology in sub-Saharan Africa.

PubMed (last searched: August 23rd, 2020)

(Simplexvirus[MeSH] OR Herpes Simplex[MeSH] OR Herpes Genitalis[MeSH] OR Herpes Hominis[Text] OR HSV type-2[Text] OR HSV type 2[Text] OR HSV2[Text] OR HSV-2[Text] OR HSV [Text] OR Human herpes virus[Text] OR Herpes simplex virus type 2[Text] OR Herpes simplex virus type-2[Text] OR herpes simplex virus 2[Text] OR herpes simplex virus-2[Text] OR herpes simplex type 2[Text] OR herpes simplex type-2[Text] OR herpes simplex 2[Text] OR herpes simplex-2[Text] OR Herpesvirus type 2[Text] OR Herpesvirus type-2[Text] OR Herpesvirus 2[Text] OR Herpesvirus-2[Text] OR Herpes virus type-2[Text] OR Herpesvirus type-[Text] OR Herpes virus [Text] OR Herpes virus-2[Text] OR genital herpes[Text] OR Herpes Genitalis[Text] OR Stomatitis Herpetic[Text] OR Herpes Labialis[Text]) AND (Africa South of the Sahara [MeSH] OR Comoros [MeSH] OR Ethiopia[MeSH] OR Madagascar[MeSH] OR Mauritius[MeSH] OR Sao Tome and Principe [MeSH] OR "Seychelles" [MeSH] OR Angola* [Text] OR Benin* [Text] OR Botswan* [Text] OR Batswana[Text] OR Burkina fas*[Text] OR Burkina*[Text] OR Burundi*[Text] OR Cameroon*[Text] OR Cabo Verde*[Text] OR cape verd*[Text] OR Central Africa Republic[Text] Central Africa*[Text] OR Chad*[Text] OR Comor*[Text] OR Congo*[Text] OR Cote d'Ivoire[Text] OR Ivorian*[Text] OR Democratic Republic of Congo[Text] OR Equatorial Guinea*[Text] OR Equatoguinean*[Text] OR Eritr*[Text] OR Ethiop*[Text] OR Gabon*[Text] OR Gambia*[Text] OR Ghana*[Text] OR Ghinea*[Text] OR Guinea-Bissau[Text] OR Kenya*[Text] OR Lesotho*[Text] OR Basotho*[Text] OR Liberia*[Text] OR Madagascar*[Text] OR Malagasy*[Text] OR Malawi*[Text] OR Mali*[Text] OR Maurit*[Text] OR Mozambi*[Text] OR Namibia*[Text] OR Niger*[Text] OR Nigeria*[Text] OR Rwanda*[Text] OR Sao Tome and Principe*[Text] OR Sao Tome*[Text] OR Senegal*[Text] OR Seychell*[Text] OR Sierra Leone*[Text] OR South Africa*[Text] OR Swazi*[Text] OR Togo*[Text] OR Uganda*[Text] OR United Republic of Tanzania[Text] OR Tanzan*[Text] OR Zambia*[Text] OR Zimbabwe*[Text] OR Mauritania*[Text])

Embase (last searched: August 23rd, 2020)

(exp Herpes simplex/ or exp Herpesviridae/) OR (Herpes simplex or Herpes simplex virus or HSV type-2 or HSV type 2 or HSV2 or HSV-2 or HSV 2 or human herpes virus or Herpes simplex virus type 2 or Herpes simplex virus type-2 or herpes simplex virus 2 or herpes simplex virus-2 or herpes simplex type 2 or herpes simplex type-2 or herpes simplex 2 or herpes simplex-2 or Herpesvirus type 2 or Herpesvirus type-2 or Herpesvirus 2 or Herpesvirus-2 or Herpes virus type 2 or Herpes virus type-2 or Herpes virus 2 or Herpes virus-2 or genital herpes or Herpes Genitalis or herpes labialis or herpetic stomatitis).mp.) AND (exp "Africa south of the Sahara" or exp Southern African/ or African/ or exp Central African/ or exp West African/ or exp South African/ or exp Central African Republic/ or exp East African/ or exp Mauritius/ or exp Mauritania/ or exp "Sao Tome and Principe"/ or exp Seychelles/) or (angola* or Benin* or Botswan* or Batswana* or Burkina Fas* or Burkina* or Burundi* or Cameroon* or Cabo verde* or Cape Verd* or Central Africa* or "Central African Republic*" or Chad* or Comor* or Congo* or Cote D'ivoire* or Ivorian* or "Democratic Republic of Congo*" or Equatorial Guinea* or Equatoguinean* or Ethiop* or Eritr* or Gabon* or Gambia* or Ghana* or Ghinea* or Guinea-Bissau* or Kenya* or Lesotho* or Basotho* or Liberia* or Madagascar* or Malagasy* or Malawi* or Mali* or Maurit* or Mozambi* or Namibia* or Niger* or Nigeria* or Rwanda* or "Sao Tome and Principe*" or Sao Tome* or Senegal* or Seychell* or Sierra Leone* or South Africa* or Swazi* or Togo* or Uganda* or United republic of Tanzania* or Tanza* or Zambia* or Zimbabwe* or Mauritania*).mp.)

Abbreviations: HSV-2 = Herpes simplex virus type 2.
Box S1. List of the 45 countries included in our definition for sub-Saharan Africa by subregion.(2)

Eastern Africa: Comoros, Ethiopia, Eritrea, Kenya, Madagascar, Mauritius, Rwanda, Seychelles, Tanzania, and Uganda.

Southern Africa: Angola, Botswana, Lesotho, Malawi, Mozambique, Namibia, South Africa, Eswatini (formerly known as Swaziland), Zambia, and Zimbabwe.

Western Africa: Benin, Burkina Faso, Cabo Verde, Cote d'Ivoire, Gambia, Ghana, Guinea-Bissau, Guinea, Liberia, Mali, Niger, Nigeria, Senegal, Sierra Leone, and Togo.

Central Africa: Burundi, Cameroon, Central African Republic, Chad, Congo, Democratic Republic of Congo, Equatorial Guinea, Gabon, and Sao Tome-and Principe.

Northern Africa: Mauritania.

Box S2. List of variables extracted from the relevant publications meeting the inclusion criteria.

- 1. Author(s)
- 2. Publication title
- 3. Publication year
- 4. Year(s) of data collection
- 5. Country of origin
- 6. Country of survey
- 7. City
- 8. Study site
- 9. Study design
- 10. Study sampling procedure
- 11. Study population
- 12. Population demographic characteristics (e.g., sex and age)
- 13. Diagnostic assay
- 14. Sample size
- 15. HSV-2 outcome measures

Abbreviations: HSV-2 = Herpes simplex virus type 2

Box S3. Definitions of population type classifications.

- 1. **General populations** (populations at low risk): these include populations at lower risk of exposure to HSV-2, such as antenatal clinic attendees, blood donors, and pregnant women, among others.
- 2. **Intermediate-risk populations**: these include populations who presumably have frequent sexual contacts with populations engaging in high sexual risk behavior, and have therefore a higher risk of exposure to HSV-2 than the general population. These comprise prisoners, people who inject drugs, and truck drivers, among others.
- 3. **Higher-risk populations**: these include populations at high risk of exposure to HSV-2 as a consequence of specific sexual risk behaviors such as female sex workers, men who have sex with men, male sex workers, and transgender populations, among others.
- 4. **HIV negative populations**: these include populations with confirmed HIV negative status as part of the study's inclusion criteria.
- 5. **HIV positive individuals and individuals in HIV discordant couples**: these include populations who are HIV positive or are in a spousal relationship with an HIV positive individual.
- 6. **STI clinic attendees and symptomatic populations**: these include patients attending STI clinics, or have clinical manifestations related to an STI.
- 7. **Other populations**: these include populations not satisfying above definitions, or populations with an undetermined risk of acquiring HSV-2 infection.

Abbreviations: HSV-2 Herpes simplex virus type 2, STI = Sexually transmitted infection, HIV = Human immunodeficiency virus.

Box S4. Variables included in the univariable and multivariable meta-regression analyses.

- 1- Population type as defined in Box S3
- 2- Sex
- 3- Age groups classified to best fit reported data as:
 - \circ <20 years-old
 - o 20-30 years-old
 - \circ 30-40 years-old
 - 040-50 years-old
 - \circ >50 years-old
 - Mixed age bands
- 4- African subregion as defined in Box S1
- 5- Country's income as classified by the World Bank(3)
- 6- Assay type:
 - o Western Blot
 - o ELISA
 - o Rapid test
- 7- Sample size:
 - $\circ \ge 100$
 - $\circ < 100$
- 8- Sampling method;
 - Probability-based sampling
 - o Non-probability based sampling
- 9- Response rate:
 - ∘≥80%
 - ○<80%
 - o Unclear
- 10-Year of publication category:
 - o≤2005

o 2006-2015

- o>2015
- 11-Year of publication as a linear term
- 12- Year of data collection category*
 - ○<2000
 - o 2000-2010
 - o>2010
- 13- Year of data collection as a linear term

^{*} The categories were set based on the observed median time between the year of publication and year of data collection of 5 years. Abbreviations: ELISA = Enzyme-linked immunosorbent assay

	Table S3. S	Studies re	porting HS	SV-2 sero	conversion	rate or in	ncidence	rate in sul	o-Saharan	Africa.
--	-------------	------------	------------	-----------	------------	------------	----------	-------------	-----------	---------

	Year(s) of		Original		HSV-2	<i>a</i> .		Person-	HSV-2	HSV-2 incidence
Author, year	data	Country	study	Population characteristics	serological	Sample	Follow-up	years of	seroconversion	rate (per 100
	collection	-	design	-	assay	size	duration	follow-up	rate (%)	person-years)
General populations										
Abdool Karim,	2007-10	South Africa	RCT	Women enrolled in a clinical trial	ELISA	422	18 months	561.3	20.6	15.5
2015(4)										
Akinyi, 2017(5)	2007-10	Kenya	Cohort	Participants in the "Incidence Cohort" study	ELISA	673	1 year	-	-	7.3
Biraro, 2013(6)	1990-94	Uganda	Cohort	Male samples collected between 1990-1994	ELISA	-	18 months	3,404.0	-	2.3
Biraro, 2013(6)	1995-99	Uganda	Cohort	Male samples collected between 1995-1999	ELISA	-	18 months	4,662.0	-	2.0
Biraro, 2013(6)	2000-04	Uganda	Cohort	Male samples collected between 2000-2004	ELISA	-	18 months	4,933.0	-	2.2
Biraro, 2013(6)	2005-07	Uganda	Cohort	Male samples collected between 2005-2007	ELISA	-	18 months	2,107.0	-	2.8
Biraro, 2013(6)	1990-94	Uganda	Cohort	Female samples collected between 1990-1994	ELISA	-	18 months	2,420.0	-	4.3
Biraro, 2013(6)	1995-99	Uganda	Cohort	Female samples collected between 1995-1999	ELISA	-	18 months	3,385.0	-	3.9
Biraro, 2013(6)	2000-04	Uganda	Cohort	Female samples collected between 2000-2004	ELISA	-	18 months	4,103.0	-	3.6
Biraro, 2013(6)	2005-07	Uganda	Cohort	Female samples collected between 2005-2007	ELISA	-	18 months	1,878.0	-	3.7
De Baetselier, 2015(7)	2009-10	South Africa	Cohort	Females enrolled in an RCT	ELISA	407	56 weeks	229.5	13.4	18.3
del Mar Pujades,	1991-94	Tanzania	RCT	Males enrolled in an RCT	ELISA	221	2 years	-	11.3	-
2002(8)										
del Mar Pujades,	1991-94	Tanzania	RCT	Females enrolled in an RCT	ELISA	206	2 years	-	17.5	-
2002(8)										
Hallfors, 2017(9)	2011-14	Kenya	RCT	Orphans in grades 7 and 8	ELISA	357	3 years	-	30.8	-
Heffron, 2011(10)	2006-07	Zambia	Cohort	Non-migrant male farmers	ELISA	484	16 months	-	6.8	-
Jewkes, 2008(11)	2003-04	South Africa	RCT	Individuals in the intervention arm	ELISA	-	2 years	1,759.2	-	3.2
Jewkes, 2008(11)	2003-04	South Africa	RCT	Individuals in the control arm	ELISA	-	3 years	1,623.3	-	4.6
Kamali, 1999(12)	1990-93	Uganda	Cohort	15-24 years old males and females	WB	373	4 years	-	20.9	-
Kamali, 2003(13)	1994-00	Uganda	RCT	Individuals in intervention arm A	EIA	-	6 years	4,381.6	-	2.3
Kamali, 2003(13)	1994-00	Uganda	RCT	Individuals in intervention arm B	EIA	-	6 years	4,595.5	-	3.6
Kamali, 2003(13)	1994-00	Uganda	RCT	Individuals in control arm C	EIA	-	6 years	4,628.6	-	3.5
Kebede, 2004(14)	1997-02	Ethiopia	Cohort	HSV-2 seronegative males and females	ELISA	953	5 years	3,225.5	58.0	1.8
McFarland, 1999(15)	1993-97	Zimbabwe	Cohort	Male factory workers	WB	1,444	4 years	3,316.0	14.1	6.2
Mensche, 2020(16)	2007-13	Malawi	Cohort	School students	ELISA	2,072	6 years	-	8.5	-
Munjoma, 2010(17)	2002-04	Zimbabwe	Cohort	Pregnant women	ELISA	173	10 months	144.2	11.9	13.9
Nakubulwa, 2016(18)	2013-14	Uganda	Cohort	Pregnant women	ELISA	191	-	-	7.8	-
Pettifor, 2016(19)	2011-12	South Africa	RCT	Individuals in the control arm	ELISA	1,114	3 years	2,525.0	9.1	4.0
Pettifor, 2016(19)	2011-12	South Africa	RCT	Individuals in the intervention arm	ELISA	1,214	3 years	2,675.0	8.8	4.0
Radebe, 2011(20)	2008-10	South Africa	RCT	Male students	ELISA	-	54 months	-	-	2.9
Radebe, 2011(20)	2008-10	South Africa	RCT	Female students	ELISA	-	54 months	-	-	6.4
Rosenberg, 2018(21)	2013-15	South Africa	Cohort	18-25 years old women	ELISA	645	2 years	-	6.8	-
Sobngwi, 2009(22)	2002-04	South Africa	RCT	Individuals in the control arm	ELISA	-	21 months	1,003.0	-	3.5
Sobngwi, 2009(22)	2002-04	South Africa	RCT	Individuals in the intervention arm	ELISA	-	21 months	995.0	-	2.3
Stoner, 2018(23)	2011-15	South Africa	Cohort	<20 years old young women	ELISA	1,963	4 years	-	5.9	-
Tobian, 2009(24)	2002-06	Uganda	RCT	15-49 years old men	ELISA	-	2 years	5,793.7	-	4.9
Tobian, 2012(25)	2002-07	Uganda	RCT	Spouses of circumcised men	WB	359	3 years	656.5	11.1	6.1
Tobian, 2012(25)	2002-07	Uganda	RCT	Spouses of uncircumcised men	WB	363	4 years	648.5	11.3	6.3
van de Wijgert,	1999-04	Zimbabwe	Cohort	Zimbabwean women	ELISA	-	5 years	-	-	8.6
2009(26)										
Wagner, 1994(27)	-	Uganda	Cohort	Seronegative adults	WB	36	1 year	-	16.7	-
Intermediate-risk popu	lations									
Kapiga, 2013(28)	2008-10	Tanzania	Cohort	Women working in food facilities and bars	ELISA	450	1 year	339.0	21.5	28.6
Meque, 2014(29)	2009-12	Mozambique	Cohort	Women working in service facilities	ELISA	151	1 year	-	20.5	-
Ondondo, 2014(30)	2005-06	Kenya	Cohort	Fishermen	ELISA	-	1 year	-	23.6	-
Riedner, 2006(31)	2000-02	Tanzania	Cohort	Women working in a bar	EIA	-	27 months	98.0	-	17.3

Tassiopoulos, 2007(32)	2002-03	Tanzania	Cohort	Individuals working in a hotel and bar	ELISA	360	1 year	337.8	13.3	14.2
Higher-risk populations										
Braunstein, 2011b(33) Chohan, 2009(34) Kaul, 2007(35) Masese, 2014(36) Ramjee, 2005(37) Traore, 2013(38)	2007-09 1993-06 1998-02 1993-11 1996-97 2009-11	Rwanda Kenya Kenya Kenya South Africa Burkina Faso	Cohort Cohort RCT Cohort RCT RCT	FSWs in Rwanda FSWs in Kenya FSWs in Kenya FSWs in Kenya FSWs in South Africa FSWs in Burkina Faso	ELISA ELISA ELISA ELISA ELISA ELISA	182 297 121 406 44	2 years 28 months 4.4 years 5 years 3.6 years 1 year	150.0 499.0 - 809.0 -	1.9 38.7 22.3 40.4 54.9	8.7 23.0 21.0 11.0
HIV negative population	S									
De Bruyn, 2011(39) De Bruyn, 2011(39) De Bruyn, 2011(39) McCormack, 2010(40)	2002-05 2002-05 2002-05 2005-08	South Africa South Africa Zimbabwe 4 African countries*	RCT RCT RCT RCT	Women in Durban Women in Johannesburg Women in Harare Females in the intervention arm receiving 2% gel	ELISA ELISA ELISA ELISA	495 328 1,193 297	2 years 3 years 4 years 1 year	689.0 443.0 949.0	15.4 10.4 8.4 11.5	11.0 7.7 5.2
McCormack, 2010(40)	2005-09	4 African countries*	RCT	Females in the intervention arm receiving 0.5% gel	ELISA	919	1 year	-	11.9	-
McCormack, 2010(40)	2005-09	4 African countries*	RCT	Females in the control arm	ELISA	888	1 year	-	13.0	-
Mehta, 2012(41) Mehta, 2012(41) Mehta, 2013(42) Mlisana, 2012(43)	2002-05 2002-05 2002-07 2004-05	Kenya Kenya Kenya South Africa	RCT RCT RCT Cohort	Circumcised men Uncircumcised men Men enrolled in an RCT HIV Negative women	ELISA ELISA ELISA ELISA	986 1,035 2,044	2 years 2 years 6 years 2 years	1,493.5 1,628.5 -	8.7 9.7 33.5	5.8 6.1 - 26.0
Perti, 2014(44)	-	South Africa	Cohort	HIV negative pregnant women	WB	91	6 weeks	-	0.0	-
HIV positive individuals	and individu	als in HIV discor	dant couples							
Celum, 2014(45)	2008-11	Kenya and Uganda	RCT	Partners of HIV positive persons in an RCT	WB	1,041	2 years	1,422.2	7.6	5.6
Celum, 2014(45)	2008-11	Kenya and Uganda	RCT	Partners of HIV positive persons in an RCT	WB	481	2 years	672.0	10.8	7.7
Cowan, 2008a(46)	1997-00	Zimbabwe	RCT	HIV positive mothers with HIV positive infants	WB	50	6 weeks	-	22.0	-
Cowan, 2008a(46)	1997-00	Zimbabwe	RCT	HIV positive mothers with HIV negative infants	WB	106	6 weeks	-	15.1	-
del Mar Pujades, 2002(8)	1991-94	Tanzania	RCT	HIV positive females enrolled in a large RCT	ELISA	32	2 years	-	38.7	-
del Mar Pujades, 2002(8)	1991-94	Tanzania	RCT	HIV positive Males enrolled in a large RCT	ELISA	22	2 years	-	31.8	-
Muiru, 2013(47)	2007-09	Kenya	Cohort	Participants from HIV discordant couples	ELISA	382	2 years	512.6	19.8	14.8
Other populations		-					5			
Okuku, 2011(48) Okuku, 2011(48) van de Wijgert, 2000(26)	2005-08 2005-08 1999-04	Kenya Kenya Uganda	Cohort Cohort Cohort	Women from different risk populations Men from different risk populations Women from different risk populations	ELISA ELISA ELISA	164 443 -	4 years 4 years 4 years	- - -	23.8 11.9	22.1 9.0 10.6

* The four African countries were: South Africa, Tanzania, Uganda, and Zambia. Abbreviations: EIA = Enzyme immunosorbent assay, ELISA = Enzyme-linked immunosorbent assay, FSWs = Female sex workers, HIV = Human immunodeficiency virus, HSV-2 = Herpes simplex virus type 2, RCT = Randomized controlled trial, WB = Western blot.

Figure S1. Forest plot presenting the outcome of the pooled mean herpes simplex virus type 2 (HSV-2) incidence rate by population type in sub-Saharan Africa.

Author, Year H	SV-2 seroconverters	100 person-years	Events per 100 person-years	W(Random) IR	95%CI
				,	
General populations	20	004.0		4 60/ 40.0	174.4471
Abdool Karim, 2015	29	204.0		1.6% 10.2	[7.1; 14.7]
Biraro, 2013	104	2420.0	-	1.6% 4.3	[3.5: 5.2]
Biraro, 2013	132	3385.0	-	1.6% 3.9	[3.3; 4.6]
Biraro, 2013	146	4103.0	-	1.6% 3.6	[3.0; 4.2]
Biraro, 2013	70	1878.0	*	1.6% 3.7	[2.9; 4.7]
De Baetselier, 2015	42	229.5		1.6% 18.3	[13.5; 24.8]
Jewkes, 2008	43	803.7		1.6% 5.3	[4.0; 7.2]
Kamali 1999	11	116.3		1.4% 9.5	[5.2, 17.1]
Kamali, 1999	12	55.2		1.5% 21.7	[12.3: 38.3]
Kamali, 1999	7	75.2		1.3% 9.3	[4.4; 19.5]
Kamali, 1999	3	33.3		1.0% 9.0	[2.9; 27.9]
Kamali, 1999	7	45.5		1.3% 15.4	[7.3; 32.3]
Munjoma, 2010 Rettifor, 2016	20	144.2	-	1.5% 13.9	[8.9; 21.5]
Pettifor, 2016	101	2525.0	-	1.6% 4.0	[3.3; 4.9]
Tobian, 2012	40	656.5		1.6% 6.1	[4.5: 8.3]
Tobian, 2012	41	648.5	<u></u>	1.6% 6.3	[4.7; 8.6]
Kebede, 2004	19	514.2		1.5% 3.7	[2.4; 5.8]
Biraro, 2013	78	3404.0	-	1.6% 2.3	[1.8; 2.9]
Biraro, 2013	94	4662.0		1.6% 2.0	[1.6; 2.5]
Biraro, 2013 Biraro, 2012	109	4933.0		1.6% 2.2	[1.8; 2.7]
Jewkes 2008	14	958.9	+	1.5% 1.5	[0.9: 2.5]
Jewkes, 2008	18	882.4	-	1.5% 2.0	[1.3; 3.2]
Kamali, 1999	5	163.0		1.2% 3.1	[1.3; 7.4]
Kamali, 1999	12	115.8	•	1.5% 10.4	[5.9; 18.2]
Kamali, 1999	8	105.1		1.4% 7.6	[3.8; 15.2]
Kamali, 1999 Kamali, 1999	6	68.7		1.3% 8.7	[3.9; 19.4]
McFarland, 1999	/ 26	422.0		1.6% 62	[4.2: 9.0]
McFarland, 1999	84	1299.0		1.6% 6.5	[5.2; 8.0]
McFarland, 1999	30	580.0		1.6% 5.2	[3.6; 7.4]
McFarland, 1999	28	349.0		1.6% 8.0	[5.5; 11.6]
McFarland, 1999	19	291.0	<u> </u>	1.5% 6.5	[4.2; 10.2]
McFarland, 1999	8	147.0		1.4% 5.4	[2.7; 10.9]
Tobian 2009	284	228.0		1.4% 3.9	[2.1; 7.6]
Kebede, 2004	39	2711.3		1.6% 1.4	[1,1; 2,0]
Sobngwi-Tambekou, 2009	35	1003.0	-	1.6% 3.5	[2.5; 4.9]
Sobngwi-Tambekou, 2009	23	995.0	-	1.5% 2.3	[1.5; 3.5]
Kamali, 2003	100	4381.6		1.6% 2.3	[1.9; 2.8]
Kamali, 2003	167	4595.5		1.7% 3.6	[3.1; 4.2]
Fixed effect model	101	4628.6		1.7% 3.5	[3.0; 4.1]
Random effects model			0	68.8% 5.1	[4.3: 6.0]
Heterogeneity: $I^2 = 94\%$, $\chi^2_{eff} = 1$	717.66				,
High risk populations		100.0			
Chohan, 2009 Brounstein, 2011b	115	499.0		1.6% 23.0	[19.2; 27.7]
Masese 2014	13	150.0		1.5% 8.7	[5.0; 14.9] [17.4: 23.6]
Fixed effect model	104	000.0	\diamond	20.5	[18.3: 23.0]
Random effects model				4.8% 18.0	[13.1; 24.9]
Heterogeneity: $I^2 = 82\%$, $\chi^2_{df} = 1$	11.23				
LIN/ accestive accessed					
Hiv negative populations	76	690.0		1.6% 11.0	10 0-12 01
De Bruyn, 2011	34	443.0		1.6% 7.7	[5.5: 10.7]
De Bruyn, 2011	100	949.0		1.6% 10.5	[8.7; 12.8]
Mehta, 2012	86	1493.5	-+	1.6% 5.8	[4.7; 7.1]
Mehta, 2012	100	1628.5	÷.	1.6% 6.1	[5.0; 7.5]
Fixed effect model			\$	7.9	[7.2; 8.7]
Haterogeneity: $l^2 = 87\% x^2 = 1$	31 74			8.1% 7.9	[6.0; 10.5]
rieterogeneity. 7 = 0770, Xdf = 5	51.74				
HIV positive populations a	nd HIV discordant co	ples			
Celum, 2014	79	1422.2		1.6% 5.6	[4.5; 6.9]
Celum, 2014	52	672.0		1.6% 7.7	[5.9; 10.2]
Fixed effect model	76	512.6		1.6% 14.8	[11.8; 18.6]
Random effects model				4.9% 8.6	[4.7: 15.7]
Heterogeneity: $I^2 = 95\%$, $\chi^2_{df} = 3$	38.21				
Intermediate risk populatio	ons	000 0		1.00/ 00 0	[00 E. 04 0]
Riedner 2006	97	339.0		1.0% 28.0	[23.5, 34.9]
Tassiopoulos, 2007	48	337.8		1.6% 14.2	[10.7; 18.9]
Fixed effect model		001.0	\sim	- 22.1	[18.9; 25.7]
Random effects model				4.8% 19.4	[11.8; 32.1]
Heterogeneity: $I^2 = 88\%$, $\chi^2_{df} = 1$	16.83				
Other populations					
Okuku, 2011	15	82 9	→	1.5% 18.1	[10.9: 30.0]
Okuku, 2011	19	79.4		1.5% 23.9	[15.3; 37.5]
Okuku, 2011	5	14.3	→	1.2% 35.0	[14.6; 84.0]
Okuku, 2011	7	204.7		1.3% 3.4	[1.6; 7.2]
Okuku, 2011	27	267.4		1.6% 10.1	[6.9; 14.7]
Fixed effect model	19	118.6	$ \stackrel{\longrightarrow}{\leq} $	1.5% 16.0	[10.2; 25.1]
Random effects model				8.7% 14.3	[8.6: 23.6]
Heterogeneity: $I^2 = 82\%$, $\chi^2_{eff} = 32\%$	27.7				, 10.01
Fixed effect model	3622		1	5.9	[5.7; 6.1]
Heterogeneity: 12 = 07%2 =	1996 41	1		100.0% 6.7	[5.6; 8.1]
Residual heterogeneity: $I^2 = 93$	$3\%, \chi^2_{59} = 843.37$	(5 10 15 20 25	5	

Author, year	Year(s) of data collection	Country	Study site	Original study design [*]	Sampling method	Population	HSV-2 serological assay	Sample size	HSV-2 seroprevalence (%)
General populations									
Akinyi, 2017(5)	2007-10	Kenya	Community	Cohort	Conv	16-17 years old adolescents	ELISA	243	10.7
Amornkul, 2009(49)	2003-04	Kenya	Community	CS	RS	<34 years old women	ELISA	930	53.0
Amornkul, 2009(49)	2003-04	Kenya	Community	CS	RS	<34 years old men	ELISA	832	25.8
Anjulo, 2016(50)	2013-14	Ethiopia	Outpatient clinic	CS	RS	Antenatal clinic attendees	ELISA	252	32.1
Behling, 2015(51)	2003-06	Kenya	Community	RCT	RS	School students in a large trial	ELISA	139	14.4
Biraro, 2013(6)	1990-94	Uganda	Community	CS	Conv	Male samples collected between 1990-1994	ELISA	1,083	41.0
Biraro, 2013(6)	1995-99	Uganda	Community	CS	Conv	Male samples collected between 1995-1999	ELISA	1,067	38.9
Biraro, 2013(6)	2000-04	Uganda	Community	CS	Conv	Male samples collected between 2000-2004	ELISA	1,485	28.5
Biraro, 2013(6)	2005-07	Uganda	Community	CS	Conv	Male samples collected between 2005-2007	ELISA	1,539	30.8
Biraro, 2013(6)	1990-94	Uganda	Community	CS	Conv	Female samples collected between 1990-1994	ELISA	1,118	62.4
Biraro, 2013(6)	1995-99	Uganda	Community	CS	Conv	Female samples collected between 1995-1999	ELISA	1.303	55.3
Biraro, 2013(6)	2000-04	Uganda	Community	ČŠ	Conv	Female samples collected between 2000-2004	ELISA	1,799	48.0
Biraro 2013(6)	2005-07	Uganda	Community	CS	Conv	Female samples collected between 2005-2007	ELISA	2,060	50.5
Braunstein 2011a(52)	2005-07	Rwanda	Community	CS	Conv	VCT clients	FLISA	1,250	43.2
De Walque $2012(53)$	2009-10	Tanzania	Community	RCT	RS	Controls in a RCT	FLISA	1,230	33.9
De Walque, $2012(53)$	2009 10	Tanzania	Community	PCT	PS	Intervention group A	FLISA	615	36.8
De Walque, $2012(53)$	2009-10	Tanzania	Community	RCT	DS NS	Intervention group B	FLISA	660	34.2
De walque, $2012(33)$	2009-10	I alizailia Duranda	Outratiant alinia	CS	Conv	Eastile women	ELISA	281	34.2
Dhomt, 2010(54)	2007-09	Rwanda	Outpatient clinic	CS CS	Conv	Fertile women	ELISA	201	41.0
D10111, 2010(54)	2007-09	Kwanua		CS CS	Conv		ELISA	304	39.0
Dhont, $2010(54)$	2007-09	Rwanda	Outpatient clinic	CS	Conv	Male partners of fertile women	ELISA	170	35.0
Dhont, 2010(54)	2007-09	Rwanda	Outpatient clinic	CS	Conv	Male partners of infertile women	ELISA	251	51.0
Joyle, 2010(55)	2007-08	Tanzania	Community	CS	Conv	Females in the control arm of an RCT	ELISA	3,238	42.5
Joyle, 2010(55)	2007-08	Tanzania	Community	CS	Conv	Males in the control arm of an RCT	ELISA	3,493	26.7
Duflo, 2015(56)	2009-10	Kenya	Community	Cohort	RS	<21 years old women	ELISA	5,509	11.8
Duflo, 2015(56)	2009-10	Kenya	Community	Cohort	RS	<21 years old men	ELISA	6,302	7.4
Ghebrekidan, 1999(57)	1995	Eritrea	Hospital	CS	Conv	Rashaida tribe members	WB	45	5.0
Ghebrekidan, 1999(57)	1995	Eritrea	Outpatient clinic	CS	Conv	Pregnant women	WB	102	23.0
Ghebrekidan, 1999(57)	1995	Eritrea	Community	CS	Conv	1-5 years old children	WB	54	11.0
Ghebrekidan, 1999(57)	1995	Eritrea	Community	CS	Conv	>5 years old children	WB	70	1.0
Ghebremichael, 2011(58)	2002-03	Tanzania	Community	CS	Conv	>20 years old men	EIA	567	39.2
Ghebremichael, 2012(59)	2002-03	Tanzania	Community	CS	RS	>20 years old women	EIA	1,418	42.9
Gorander, 2006(60)	-	Tanzania	Hospital	CS	Conv	Blood donors	WB	196	41.3
Guwatudde, 2009(61)	2006	Uganda	Community	Cohort	Conv	15-49 years old males and females	ELISA	2.025	57.0
Hallfors $2015(62)$	2011-12	Kenva	Community	RCT	CRS	Students	ELISA	837	3 3
Hokororo 2015(62)	2011 12	Tanzania	Outpatient clinic	CS	Conv	Pregnant women	FLISA	403	34.7
Holt $2003(64)$	1992	Ethionia	Outpatient clinic	CS CS	Conv	Antenatal clinic attendees	WB	85	26.0
I_{000} I_{0	2010 11	Konyo	Outpatient clinic	CS CS	Conv	Kanyan woman		110	20.0
2014(05)	2010-11	Kellya	Outpatient chine	CS CS	Conv		ELISA	20	20.0
Jespers, 2014(65)	2010-11	Kenya	Outpatient clinic	CS CS	Conv	Kenyan pregnant women	ELISA	30	17.0
Jespers, 2014(65)	2010-11	Kenya	Outpatient clinic	CS	Conv	Adolescents	ELISA	30	37.0
Kamali, 1999(12)	1990-93	Uganda	Community	CS	Conv	15-54 years old males	WB	367	36.0
Kamali, 1999(12)	1990-93	Uganda	Community	CS	Conv	15-54 years old females	WB	541	71.5
Kamali, 2002(66)	1994-00	Uganda	Community	RCT	Conv	Participants in trial Arm A - information only	EIA	2,396	28.4
Kamali, 2002(66)	1994-00	Uganda	Community	RCT	Conv	Participants in trial Arm B - STI awareness	EIA	2,417	27.9
Kamali, 2002(66)	1994-00	Uganda	Community	RCT	Conv	Participants in trail Arm C - routine health services	EIA	2,262	28.1
Kapiga, 2006(67)	2002-03	Tanzania	Community	CS	CRS	20-44 years old women	EIA	1,418	43.8
Kapiga, 2006(67)	2002-03	Tanzania	Community	CS	CRS	20-44 years old men	EIA	566	39.1

'	Table S4. Studies reporting HS	V-2 seroprevalence	in Eastern Africa.	This table includes	only overall and	l not stratified seroprev	valence measures

Kasubi, 2006(68)	-	Tanzania	Outpatient clinic	CS	Conv	<15 years old children	WB	565	27.3
Kebede, 2004(14)	1997-02	Ethiopia	Community	Cohort	Conv	>19 years old adults	ELISA	1,612	40.9
Kuteesa, 2020(69)	2017-18	Uganda	Community	CS	RS	15-24 years old adults	ELISA	1,270	32.0
Mehta. 2018(70)	2014-16	Kenva	Community	Cohort	Conv	Healthy women	ELISA	252	56.8
Mehta, 2018(70)	2014-16	Kenva	Community	Cohort	Conv	Healthy men	ELISA	252	46.6
MOH Uganda 2006(71)	2004-05	Uganda	Community	CS	CRS	General population	ELISA	17,953	46.1
Msuva 2002(72)	1999	Tanzania	Outpatient clinic	CS	RS	Women attending antenatal clinics	ELISA	382	39.0
Msuva $2007(73)$	1999	Tanzania	Outpatient clinic	CS	Conv	1999 survey of pregnant women	ELISA	382	39.0
Msuya $2009(74)$	2002-04	Tanzania	Outpatient clinic	CS	Conv	2002-04 survey of pregnant women	ELISA	1 271	33.6
Nakku-Ioloba 2014(75)	2004	Uganda	Community	CS	RS	Healthy adults	ELISA	1 124	58.0
Nakubulwa $2015(76)$	2013	Uganda	Hospital	CC	Conv	Pregnant women with PROM	ELISA	87	56.0
Nakubulwa $2015(76)$	2013	Uganda	Hospital	CC	Conv	Pregnant women in labor	FLISA	87	53.0
Nakubulwa $2016(18)$	2013-14	Uganda	Hospital	Cohort	Conv	Pregnant women	FLISA	524	52.9
NASCOP 2009(77)	2013 14	Kenya	Community	CS	CRS	Kenvan population	FLISA	15 707	35.1
Nilsen $2005(78)$	2007	Tanzania	Outpatient clinic	CS CS	Conv	Pregnant women	FLISA	98	34.3
Nilsen $2005(78)$	_	Tanzania	Outpatient clinic	CS	Conv	Blood donors	FLISA	81	34.6
Norris $2009(78)$	2004	Tanzania	Community	CS CS	PS	Male plantation residents	ELISA	232	45.0
Norma $2009(79)$	2004	Tanzania	Community	CS CS		Formale plantation residents	ELISA	232	45.0
Nuiro $2011(80)$	2004	Konvo	Community	CS CS	RS DS	Women participating in a DSS	ELISA	562	32.0
Ny $10, 2011(80)$	2004	Kenya	Outratiant alinia	CS CS	Conv	Women attending a VCT	ELISA	262	32.0
Nyiro, $2011(80)$	2004	Kenya	Community		Conv	Women attending a VC1	ELISA	203	44.0
Oliver, 2018(81)	2014	Kenya	Community	RC1	Conv	women using contraceptives	ELISA	457	55.0
Otieno, 2015(82)	2007-09	Kenya	Community	Conort	Conv	>18 years old men	ELISA	422	13.3
Otieno, 2015(82)	2007-09	Kenya	Community	Cohort	Conv	>18 years old women	ELISA	424	44.8
Reynolds, 2012(83)	2007-08	Uganda	Outpatient clinic	RCT	Conv	>18 years adults in an RCT	ELISA	1,404	88.0
Sivapalasingam, 2014(84)	2010-11	Kenya	Outpatient clinic	CC	Conv	Women reporting intravaginal practices	ELISA	58	48.0
Sivapalasingam, 2014(84)	2010-11	Kenya	Outpatient clinic	CC	Conv	Women reporting no intravaginal practices	ELISA	42	43.0
Tedla, 2011(85)	2002-09	Ethiopia	Community	CC	Conv	Patients with schizophrenia	ELISA	216	7.9
Tedla, 2011(85)	2002-09	Ethiopia	Community	CC	Conv	Patients with bipolar disorder	ELISA	199	15.4
Tedla, 2011(85)	2002-09	Ethiopia	Community	CC	RS	Healthy controls	ELISA	80	10.0
Tobian, 2009(24)	2002-06	Uganda	Community	RCT	RS	15-49 years old men	ELISA	6,396	33.8
Tobian, 2012(25)	2002-07	Uganda	Community	RCT	Conv	Spouses of circumcised men	ELISA/WB	835	55.9
Tobian, 2012(25)	2002-07	Uganda	Community	RCT	Conv	Spouses of uncircumcised men	ELISA/WB	803	53.7
Todd. 2006(86)	1994-95	Tanzania	Community	CC	RS	Healthy women	ELISA	430	63.5
Todd. 2006(86)	1994-95	Tanzania	Community	CC	RS	Healthy men	ELISA	420	46.0
Wagner, 1994(27)	-	Uganda	Community	CS	Conv	>15 years old residents	WB	212	67.9
Wagner $1994(27)$	_	Uganda	Community	CS	Conv	<15 years old children	WB	45	22
Weiss $2001(87)$	1997-98	Kenya	Community	CS	CRS	Women from Kisumu	FLISA	824	68.0
Weiss, $2001(87)$	1997-98	Kenya	Community	CS	CRS	Men from Kisumu	FLISA	583	35.0
Winston $2015(88)$	2011-12	Kenya	Community	CS CS	Conv	21 years old street youth	FLISA	175	19.0
Vahya Malima	2011-12	Tonzonio	Outpatient clinic	CS CS	Conv	Pregnant women	ELISA	1 206	20.7
2008(80)	2003-04	Tanzania	Outpatient ennie	CS	COIIV	r regnant women	LLISA	1,290	20.7
Yegorov, 2018(90)	2015-16	Uganda	Outpatient clinic	CS	Conv	18-45 years old women	ELISA	58	58.6
Intermediate-risk populat	tions	U	•			-			
Ghebrekidan, 1999(57)	1995	Eritrea	Community	CS	Conv	Guerrilla fighters	WB	73	45.0
Ghebrekidan, 1999(57)	1995	Eritrea	Community	CS	Conv	Truck drivers	WB	53	43.0
Ghebrekidan, 1999(57)	1995	Eritrea	Community	CS	Conv	Port workers	WB	48	21.0
Holt. 2003(64)	1992	Ethiopia	Community	CS	Conv	Male Sudanese refugees	WB	211	27.0
Kapiga, $2003(28)$	2000	Tanzania	Community	CS	RS	Bars and hotels workers	ELISA	515	43.5
Kapiga $2003(28)$	2000	Tanzania	Community	CS	RS	Non sexually active bar/hotel workers	ELISA	22	0.0
Kapiga 2013(67)	2008-10	Tanzania	Community	Cohort	Conv	Women working in food and recreational facilities	ELISA	1.376	67.0
$N_{g'avo} = 2008(91)$	2005-06	Kenva	Community	CS	CRS	Fishermen	FLISA	250	63.9
Rakwar 1997(92)	1993	Kenva	Outpatient clinic	Cohort	Conv	Male truck drivers	WR	130	49.0
Riedner $2007(93)$	2000-02	Tanzania	Community	CS	Conv	Women working in bars restaurants and questhouses	FLISA	753	49.0 88.8
Medici, 2007(75)	2000-02	ranzania	Community	0	COILY	momen working in bars, restaurants, and guestilouses	LLISA	155	00.0

Tassiopoulos, 2007(32)	2002-03	Tanzania	Outpatient clinic	Cohort	Conv	Bar and hotel workers	ELISA	1,045	56.3
Vallely, 2007(94)	2002-04	Tanzania	Community	CS CS	Conv	Women working in 100d and recreational facilities	ELISA	1,505	/4.0
Watson-Jones, 2007(95)	2003-05	Tanzania	Community	CS	Conv	women working in service facilities	ELISA	2,719	80.0
Proton 2007(06)	1002	Vanua	Outpatiant alinia	Cohort	Conv	ESWa	ELISA	1 206	80.6
Baeten, 2007(96)	1993	Кепуа	Outpatient clinic	Conort	Conv	FSWS	ELISA	1,206	80.0
Baltzer, 2009(97)	2004-06	Kenya	Outpatient clinic	Conort	Conv	FSWS	ELISA	139	87.1
Braunstein, 2011a(52)	2006-07	Rwanda	Community	CS	Conv	FSWs	ELISA	800	59.8
Ghebrekidan, $1999(57)$	1995	Eritrea	Outpatient clinic	CS	Conv	FSWs	WB	107	80.0
Holt, 2003(64)	1992	Ethiopia	Community	CS	Conv	FSWs	WB	203	65.0
Jespers, 2014(65)	2010-11	Rwanda	Community	CS	Conv	FSWs in Rwanda	ELISA	30	47.0
Kaul, 2007(35)	1998-02	Kenya	Community	RCT	Conv	FSWs	ELISA	443	72.7
Masese, 2015(98)	1993-12	Kenya	Community	Cohort	Conv	FSWs	ELISA	1,964	73.4
Priddy, 2011(99)	2008	Kenya	Community	Cohort	Conv	FSWs	ELISA	200	72.0
Vandenhoudt,	1997	Kenya	Community	CS	Conv	FSWs recruited in 1997	ELISA	286	93.4
2013(100)									
Vandenhoudt,	2008	Kenya	Community	CS	Conv	FSWs recruited in 2008	ELISA	479	83.8
2013(100)									
Vandepitte, 2011(101)	2008-09	Uganda	Community	Cohort	Conv	FSWs	ELISA	1,026	80.0
HIV negative populations									
Mehta, 2008(102)	2002-05	Kenya	Community	RCT	Conv	HIV negative healthy men	ELISA	2,771	27.6
Nakubulwa, 2009(103)	2005	Uganda	Outpatient clinic	CC	Conv	HIV negative pregnant women	ELISA	200	62.5
Serwadda, 2003(104)	1994-98	Uganda	Community	CC	Conv	HIV negative control group	ELISA/WB	496	57.9
HIV positive individuals a	nd individuals	in HIV discordan	t couples						
Baeten, 2004(105)	1999-00	Kenya	Outpatient clinic	RCT	Conv	HIV positive women enrolled in a trial	ELISA	400	94.0
Celum, 2014(45)	2008-10	Kenya and	Community	RCT	RS	Partners of HIV positive patients	ELISA/WB	4,638	67.2
		Uganda	2			1 1		<i>.</i>	
del Mar Pujades,	1991-94	Tanzania	Community	CC	RS	HIV positive females enrolled in a large RCT	ELISA	70	54.3
2002(8)	1001.04	. .	a	66	DC				<i>c</i> 1.4
del Mar Pujades, 2002(8)	1991-94	Tanzania	Community	CC	RS	HIV positive males enrolled in a large RCT	ELISA	57	61.4
Jespers, 2014(65)	2010-11	Rwanda	Community	CS	Conv	HIV positive +women	ELISA	30	83.0
Madebe, 2020(106)	-	Tanzania	Hospital	CS	Conv	>10 years old HIV positive patients	ELISA	180	18.0
McClelland, 2002(107)	1996-99	Kenya	Hospital	CS	Conv	HIV positive women	ELISA	210	95.2
Muiru, 2013(47)	2007-09	Kenya	VCT	CS	Conv	Participants from HIV discordant couples	ELISA	938	58.0
Nakubulwa, 2009(103)	2005	Uganda	Outpatient clinic	CC	Conv	HIV positive pregnant women	ELISA	50	86.0
Roxby, 2011(108)	1999-02	Kenya	Outpatient clinic	Cohort	Conv	HIV positive pregnant women	ELISA	296	85.8
Serwadda, 2003(104)	1994-98	Uganda	Community	CC	Conv	HIV seroconverters	ELISA/WB	248	70.2
Todd, 2006(86)	1994-95	Tanzania	Community	Nested CC	RS	HIV positive women	ELISA	37	70.3
Todd, 2006(86)	1994-95	Tanzania	Community	Nested CC	RS	HIV positive men	ELISA	36	61.1
STI clinic attendees and sy	mptomatic po	pulations [†]	,						
Gorander, 2006(60)	2001	Tanzania	Hospital	CS	Conv	Patients with GUD	WB	198	78.3
Langeland, 1998(109)	1989-93	Tanzania	Outpatient clinic	CS	Conv	STI clinic attendees	ELISA	294	42.9
Mostad. 2000(110)	1994-96	Kenva	Outpatient clinic	ČŠ	Conv	Women attending an STI clinic	EIA	314	93.3
Mwansasu $2002(111)$	-	Tanzania	Community	CS	Conv	Patients with GUD	FLISA	69	797
Nilsen, 2005(78)	-	Tanzania	Outpatient clinic	CS	Conv	STL clinic attendees	ELISA	494	70.4
Suntoke 2009(112)	2002-06	Uganda	Community	CS	Conv	Males and females with GUD	FLISA	95	77.0
Other populations	2002 00	Ogundu	Community	05	COIIV	marcs and remarcs with GOD	LLIGH	15	77.0
Kassa 2019(113)	2005-09	Ethionia	Outpatient	CS	Conv	HIV negative and HIV positive pregnant women	FLISA	2 532	41.5
11000, 2017(113)	2005-07	Lanopia	clinic/Hospital	0	Conv	m, negative and m, positive pregnant women	LLISA	2,332	71.J
Okuku, 2011(48)	2005-08	Kenya	Outpatient clinic	Cohort	Conv	Adults engaging in different risky sexual behaviors	ELISA	1,272	32.6
Van de Wijgert, 2009(26)	1999-04	Uganda	Outpatient clinic	Cohort	Conv	FSWs and healthy women	ELISA	2,199	48.7

*The reported study design is the original study design (case control, cross sectional, longitudinal cohort, or randomized controlled trial). The included seroprevalence measures are those for the baseline measures at the beginning of the study. † Symptomatic populations include patients with clinical manifestations related to an STI. Abbreviations: CC = Case control, Conv = Convenience, CRS = Cluster random sampling, CS = Cross sectional, DSS = Demographic surveillance system, EIA = Enzyme immunosorbent assay, ELISA = Enzyme-linked

immunosorbent assay, FSWs = Female sex workers, GUD = Genital ulcer disease, HIV = Human immunodeficiency virus, HSV-2 = Herpes simplex virus type 2, MOH = Ministry of Health, PROM = Premature rupture of membranes, RCT = Randomized controlled trial, RS = Random sampling, STI = Sexually transmitted infection, VCT = Voluntary counselling and testing, WB = Western blot.

	Year(s) of	G (G4 1 '4	Original	Sampling		HSV-2 serological	Sample	HSV-2
Author, year	data collection	Country	Study site	study design [*]	method	Population	assay	size	seroprevalence (%)
General populations									
Abbai, 2018(114)	2017	South Africa	Outpatient clinic	CS	Conv	Pregnant women	ELISA	248	71.0
Abdool Karim, 2014(4)	2010	South Africa	Community	CS	Conv	>14 years old males	ELISA	1,252	2.6
Abdool Karim, 2014(4)	2017	South Africa	Community	CS	Conv	>13 years old females	ELISA	1,423	10.7
Achilles, 2016(115)	-	Zimbabwe	Community	CS	Conv	18-34 years old Zimbabwean women	ELISA	200	34.0
Austrian, 2016(116)	2016-16	Zambia	Community	RCT	CRS	15-19 years old females	ELISA	2,360	7.0
Baird, 2012(117)	2007	Malawi	Community	RCT	CRS	Schoolgirls as a control group	RDT	796	3.0
Baird, 2012(117)	2007	Malawi	Community	RCT	CRS	School dropouts as a control group	RDT	208	8.0
Birdthistle, 2008(118)	2004	Zimbabwe	Community	CS	CRS	14-20 years old females	ELISA	746	11.7
Bradley, 2018(119)	2013-15	South Africa	Community	RCT	RS	South African women	ELISA	12,179	60.0
Bradley, 2018(119)	2013-15	South Africa	Community	RCT	RS	South African men	ELISA	5,472	27.0
Bradley, 2018(119)	2013-15	Zambia	Community	RCT	RS	Zambian women	ELISA	14,002	50.0
Bradley, 2018(119)	2013-15	Zambia	Community	RCT	RS	Zambian men	ELISA	5,309	22.0
Chatterjee, 2010(120)	1998-01	South Africa	Outpatient clinic	CC	Conv	Women without cervical cancer	ELISA	407	65.1
Cowan, 2008b(121)	2003	Zimbabwe	Community	RCT	RS	Healthy students	ELISA	6,791	0.2
Crucitti, 2011(122)	-	Zambia	Community	CS	Conv	13-16 years old females	ELISA	450	5.6
De Baetselier, 2015(7)	2009-10	South Africa	Outpatient clinic	Cohort	Conv	Healthy women	ELISA	701	41.1
Delany-Moretlwe, 2010(123)	2003	South Africa	Outpatient clinic	CS	Conv	Women at a family planning clinic	ELISA	210	65.7
Fearon, 2017(124)	2011-12	South Africa	Community	RCT	Conv	13-20 years old students	ELISA	2,326	4.6
Ferrand, 2010a(125)	2009	Zimbabwe	Outpatient clinic	CS	Conv	Primary health care attendees	ELISA	506	4.2
Ferrand, 2010a(125)	2009	Zimbabwe	Outpatient clinic	CS	Conv	ANC attendees	ELISA	88	14.0
Ferrand, 2010b(126)	2007-08	Zimbabwe	Hospital	CS	Conv	10-18 years old patients	ELISA	301	1.3
Francis, 2018(127)	2016-17	South Africa	Community	CS	RS	15-24 years old females	ELISA	259	28.7
Francis, 2018(127)	2016-17	South Africa	Community	CS	RS	15-24 years old males	ELISA	188	16.8
Glynn, 2008(128)	1988-90	Malawi	Community	CS	Conv	Sample collected from women in 1988-90	ELISA	343	56.0
Glynn, 2008(128)	1988-90	Malawi	Community	CS	Conv	Samples collected from men in 1988-90	ELISA	334	33.2
Glynn, 2008(128)	1998-01	Malawi	Community	CS	Conv	Samples collected from women in 1998-01	ELISA	384	66.7
Glynn, 2008(128)	1998-01	Malawi	Community	CS	Conv	Samples collected from men in 1998-01	ELISA	335	57.0
Glynn, 2008(128)	2002-05	Malawi	Community	CS	Conv	Samples collected from women in 2002-05	ELISA	205	55.6
Glynn, 2008(128)	2002-05	Malawi	Community	CS	Conv	Samples collected from men in 2002-05	ELISA	178	42.1
Glynn, 2008(128)	1999-00	Malawi	Community	CS	Conv	Samples collected from ANC attendees in 1999-00	ELISA	981	47.6
Glynn, 2014(129)	2007	Malawi	Community	CS	Conv	15-30 years old women	ELISA	3,419	25.5
Gray, 2011(130)	2007	South Africa	Community	RCT	Conv	>18 years old healthy individuals	WB	801	31.0
Gregson, 2001(131)	1998	Zimbabwe	Community	CS	Conv	Healthy population	ELISA	144	63.2
Gwanzura, 2002(132)	2006	Zimbabwe	Community	CS	RS	Blood donors	IB	299	9.7
Hazel, 2015(133)	2009	Namibia	Community	CS	Conv	Mobile rural pastoralists	RDT	402	35.0
Heffron, 2011(10)	2006-07	Zambia	Community	Cohort	Conv	Male sugar cane farmers	ELISA	1,062	54.4
Heffron, 2011(10)	2006-07	Zambia	Community	Cohort	Conv	Male migrant farmers	ELISA	498	62.5
Heffron, 2011(10)	2006-07	Zambia	Community	Cohort	Conv	Male non-migrant farmers	ELISA	564	47.3
Jespers, 2014(65)	2010-11	South Africa	Outpatient clinic	CS	Conv	South African women	ELISA	109	40.0
Jespers, 2014(65)	2010-11	South Africa	Outpatient clinic	CS	Conv	South African pregnant women	ELISA	30	37.0
Jespers, 2014(65)	2010-11	South Africa	Outpatient clinic	CS	Conv	South African adolescents	ELISA	30	3.0
Jespers, 2014(65)	2010-11	South Africa	Outpatient clinic	CS	Conv	South African women engaging in vaginal practices	ELISA	31	45.0
Jewkes, 2008(11)	2003-04	South Africa	Community	RCT	CRS	Women in the intervention arm in a trial	ELISA	715	27.6
Jewkes, 2008(11)	2003-04	South Africa	Community	RCT	CRS	Women in the control arm in a trial	ELISA	701	31.0
Jewkes, 2008(11)	2003-04	South Africa	Community	RCT	CRS	Men in the intervention arm in a trial	ELISA	694	10.3
Jewkes, 2008(11)	2003-04	South Africa	Community	RCT	CRS	Men in the control arm in a trial	ELISA	666	10.0
Kapina, 2009(134)	2003-04	Zambia	Community	Cohort	Conv	Healthy women	ELISA	239	38.9
Kenyon, 2013(135)	2000	South Africa	Community	CS	RS	Students or unemployed women	ELISA	771	53.3

|--|

Kenyon, 2013(135)	2000	South Africa	Community	CS	RS	Students or unemployed men	ELISA	718	17.0
Kharsany, 2020(136)	2014-15	South Africa	Community	CS	RS	Healthy adults	ELISA	9,786	57.8
Kjetland, 2005(137)	1998-99	Zimbabwe	Community	CS	Conv	Women in rural Zimbabwe	ELISA	476	64.5
Kurewa, 2010(138)	2002-03	Zimbabwe	Outpatient clinic	CS	Conv	Pregnant women	ELISA	678	51.1
Luseno, 2014(139)	2012	Zimbabwe	Community	CS	Conv	Female adolescent orphans	ELISA	287	6.0
Mbizvo, 2002(140)	1999-00	Zimbabwe	Outpatient clinic	CS	Conv	Women presenting to polyclinics	ELISA	389	42.2
McFarland, 1999(15)	1993-97	Zimbabwe	Community	CS	Conv	>18 years old male factory workers	IB	2.397	39.8
Menezes 2018(141)	2012-13	South Africa	Outpatient clinic	RCT	Conv	Young healthy females	ELISA	388	46.0
Munioma 2010(17)	2002	Zimbabwe	Outpatient clinic	CS	Conv	Husbands of pregnant women	ELISA	43	46.0
NIMH Collaborative	2001	Zimbabwe	Community	CS	RS	16-30 years old healthy women	ELISA	891	58.6
2007(142)	2001	Ziniouowe	community	CD	Rb	To 50 years one nearring women	LEIGH	071	50.0
NIMH Collaborative,	2001	Zimbabwe	Community	CS	RS	16-30 years old healthy men	ELISA	683	26.6
2007(142)									
Pascoe, 2015(143)	2007	Zimbabwe	Community	CS	RS	18-22 years old females	ELISA	2,505	11.2
Price, 2016(144)	2011-12	South Africa	Community	RCT	RS	Females going to school	ELISA	2,533	5.0
Sobngwi-Tambekou,	2002-04	South Africa	Community	RCT	RS	Healthy males	ELISA	3,274	5.9
2009(22)									
Mensch, 2020(16)	2007-13	Malawi	Community	Cohort	RS	School students	ELISA	2,392	13.4
van de Wijgert, 2009(26)	1999-04	Zimbabwe	Outpatient clinic	Cohort	Conv	18-35 years old women	ELISA	2,240	53.2
Wand, 2012(145)	2002-05	South Africa	Community	Cohort	Conv	Women in Durban	ELISA	3,492	73.0
Weiss, 2001(87)	1997-98	Zambia	Community	CS	CRS	Women from Ndola	ELISA	885	55.0
Weiss, 2001(87)	1997-98	Zambia	Community	CS	CRS	Men from Ndola	ELISA	607	36.0
Intermediate-risk populations									
Meque, 2014(29)	2009-12	Mozambique	Community	CS	Conv	Women working in service facilities	ELISA	409	60.6
Higher-risk populations									
Cowan, 2005(146)	-	Zimbabwe	Community	CS	Conv	FSWs	ELISA	369	77.8
Ramjee, 2005(37)	1996-97	South Africa	Community	RCT	Conv	FSWs	ELISA	416	84.0
HIV negative populations			, in the second s						
Abdool Karim, 2015(147)	2007-10	South Africa	Community	Cohort	Conv	HIV negative women	ELISA	888	51.4
Balkus, 2016(148)	2005-08	4 African countries [†]	Community	RCT	Conv	Adult women from 4 African countries	ELISA	2,830	42.0
Barnabas, 2018(149)	2013-15	South Africa	Community	Cohort	Conv	Young women from Cape Town	ELISA	149	21.0
Benjamin, 2008(150)	2005	South Africa	Community	CC	Conv	HIV negative blood donors	ELISA	102	19.6
Benjamin 2008(150)	2005	South Africa	Community	CS	Conv	Blood donors in 2005	FLISA	200	8.5
Gust 2016(151)	2007-10	Botswana	Community	RCT	Conv	All male and female participants in a study	FLISA	1 201	35.6
Maxed zenge $2011(152)$	2007 10	South Africa	Community	Cohort	Conv	Women in Johannesburg	FLISA	1,008	65 0
Mayedzenge, $2011(152)$	2003-05	Zimbabwa	Community	Cohort	Conv	Women in Herero	ELISA	2,455	51.0
Missing $2012(42)$	2003-05	South A frice	Outpatiant alinia	Conon	Conv	Women in Harare	ELISA	2,433	96.0
$\begin{array}{c} \text{NIIISalla, 2012(43)} \\ \text{Port: 2014(44)} \end{array}$	2004-03	South Africa	Unpatient chine	CS CS	Conv	Healthy wollieli	ELISA	242	42.5
$V_{1} = \frac{1}{2} 2012(152)$	2002.00	South Africa	Communitat	Calvart	Conv	We way have he fame 1000		233	43.5
Wand, 2013(153)	2003-06	South Africa	Community	Cohort	Conv	Women born before 1960	ELISA	110	89.0
Wand, 2013(153)	2003-06	South Africa	Community	Conort	Conv	Women born between 1960-1964	ELISA	257	81.8
wand, 2013(153)	2003-06	South Africa	Community	Conort	Conv	women born between 1965-1969	ELISA	409	81.6
wand, 2013(153)	2003-06	South Africa	Community	Cohort	Conv	women born between 1970-1974	ELISA	559	81.4
Wand, 2013(153)	2003-06	South Africa	Community	Cohort	Conv	Women born between 1975-1979	ELISA	770	76.7
Wand, 2013(153)	2003-06	South Africa	Community	Cohort	Conv	Women born between 1980-1984	ELISA	1,043	66.2
Wand, 2013(153)	2003-06	South Africa	Community	Cohort	Conv	Women born after 1985	ELISA	324	43.3
Sutcliffe, 2002(154)	1998	Malawi	Community	CC	Conv	HIV negative males	ELISA	280	64.3
HIV positive individuals and in	ndividuals in H	IV discordant cou	ples						
Benjamin, 2008(150)	2005	South Africa	Community	CC	Conv	HIV positive blood donors	ELISA	106	72.6
Benjamin, 2008(150)	2001-02	South Africa	Community	CS	Conv	HIV positive blood donors in 2001-2002	ELISA	625	69.3
Cowan, 2008a(46)	1997-00	Zimbabwe	Outpatient clinic	CC	RS	HIV positive mothers with HIV positive infants	ELISA/WB	478	86.2
Cowan, 2008a(46)	1997-00	Zimbabwe	Outpatient clinic	CC	RS	HIV positive mothers with HIV negative infants	ELISA/WB	970	80.7
Lewis, 2012(155)	2007	South Africa	Outpatient clinic	CS	Conv	HIV positive patients	ELISA	1,106	85.2
Lowe, 2019(156, 157)	2016	South Africa	Outpatient clinic	CS	Conv	HIV positive women	ELISA	385	52.5
Perti, 2014(44)	_	South Africa	Hospital	CS	Conv	HIV positive pregnant women	ELISA/WB	132	87.9
· · · · · · /			r			r · · · · · · · · · · · · · · · · · · ·			

Rabenau, 2010(158)	2007	Lesotho	Outpatient clinic	CS	Conv	HIV positive patients	ELISA	205	78.5
Sutcliffe, 2002(154)	1998	Malawi	Community	CC	Conv	HIV positive males	ELISA	279	88.1
Varo, 2016(159)	2008-10	Malawi	Hospital	CS	RS	<14 years old HIV positive children	ELISA	91	4.4
STI clinic attendees and sympto	matic populat	tions‡							
Chen, 2000(160)	1993-94	South Africa	Outpatient clinic	CS	Conv	Men with GUD	WB	498	49.2
Chen, 2000(160)	1993-94	South Africa	Outpatient clinic	CS	Conv	Men with urethritis	WB	554	42.1
Esber, 2017(161)	2015	Malawi	Outpatient clinic	CS	Conv	Symptomatic women attending clinic	ELISA	197	50.0
Hoyo, 2005(162)	1998-99	Malawi	Outpatient clinic	CS	Conv	STI clinic attendees with GUD	WB	136	80.0
Kufa, 2020(157)	2017-19	South Africa	Outpatient clinic	CS	Conv	Men attending an STI clinic	ELISA	847	51.0
Kularatne, 2018(163)	2007-15	South Africa	Outpatient clinic	CS	Conv	Patients attending an STI clinic	ELISA	771	80.2
Lewis, 2008(164)	2006	South Africa	Community	CS	Conv	Male STI clinic attendees	ELISA	303	57.1
Lewis, 2013(165)	2007-12	South Africa	Outpatient clinic	CS	Conv	Men with urethral discharge	ELISA	1,204	55.6
Lewis, 2013(165)	2007-12	South Africa	Outpatient clinic	CS	Conv	Women with vaginal discharge	ELISA	1,216	77.7
Mhlongo, 2010(166)	2006-07	South Africa	Outpatient clinic	CS	Conv	Females in Cape Town with VDS	ELISA	92	38.0
Mhlongo, 2010(166)	2006-07	South Africa	Outpatient clinic	CS	Conv	Males in Cape Town with MUS Syndrome	ELISA	279	30.5
Mhlongo, 2010(166)	2006-07	South Africa	Outpatient clinic	CS	Conv	Females in Johannesburg with VDS	ELISA	199	75.9
Mhlongo, 2010(166)	2006-07	South Africa	Outpatient clinic	CS	Conv	Males in Johannesburg with MUS Syndrome	ELISA	211	59.7
Morse, 1997(167)	1993-94	Lesotho	Outpatient clinic	CS	Conv	Patients with GUD	WB	99	55.0
O'Farrell, 2007(168)	2004	South Africa	Outpatient clinic	CS	Conv	Males with GUD	ELISA	162	86.4
O'Farrell, 2007(168)	2004	South Africa	Outpatient clinic	CS	Conv	Males attending an STI clinic	ELISA	480	72.3
Paz-Bailey, 2009(169)	2005-06	South Africa	Outpatient clinic	RCT	RS	Men with GUD	ELISA	615	70.6
Phiri, 2013(170)	2004-06	Malawi	Outpatient clinic	RCT	Conv	Males and females with GUD	ELISA	417	72.0
Zimba, 2011(171)	2005	Mozambique	Outpatient clinic	CS	Conv	Patients attending a clinic with US or VDS	ELISA	346	85.0
Other populations		•				-			
Chattopadhyay, 2015(172)	1998-01	South Africa	Community	CC	Conv	Women with cervical cancer	ELISA	429	68.0

* The reported study design is the original study design (case control, cross sectional, longitudinal cohort, or randomized controlled trial). The included seroprevalence measures are those for the baseline measures at the beginning of the study. † The four African countries are: Malawi, South Africa, Zambia, and Zimbabwe.

[‡] Symptomatic populations include patients with clinical manifestations related to an STI.

Abbreviations: ANC = Antenatal clinic, CC = Case control, Conv = Convenience, CRS = Cluster random sampling, CS = Cross sectional, DSS = Demographic surveillance system, EIA = Enzyme immunosorbent assay, ELISA = Enzyme-linked immunosorbent assay, FSWs = Female sex workers, GUD = Genital ulcer disease, HIV = Human immunodeficiency virus, HSV-2 = Herpes simplex virus type 2, IB = Immunoblot, US = Urethritis syndrome, NIMH = National Institute of Mental Health, RCT = Randomized controlled trial, RDT = Rapid diagnostic test, RS = Random sampling, STI = Sexually transmitted infection, VCT = Voluntary counselling and testing, VDS = Vaginal discharge syndrome, WB = Western blot.

Author, year	Year(s) of data	Country	Study site	Original study	Sampling	Population	HSV-2 serological	Sample	HSV-2 seroprevalence
	collection			design*	methou		assay	5120	(%)
General populations									
Anaedobe, 2019(173)	2013	Nigeria	Outpatient clinic	CS	Conv	22-44 years old ANC attendees	ELISA	270	33.3
Ashley-Morrow, 2004(174)	2000-01	Nigeria	Community	CS	Conv	>15 years old women	ELISA	1,268	62.0
Béhanzin, 2012(175)	2008	Benin	Community	CS	CS	General population in 2008	ELISA	2,193	26.4
Cisse, 2015(176)	2011-12	Cote D'Ivoire	Outpatient clinic	CS	RS	Pregnant women	ELISA	170	96.5
Cisse, 2015(176)	2011-12	Cote D'Ivoire	Outpatient clinic	CS	RS	≥30 years old pregnant women	ELISA	53	94.3
Eltom, 2002(177)	1991-94	Nigeria	Outpatient clinic	CS	Conv	>15 healthy females	WB	287	17.1
Eltom, 2002(177)	1991-94	Nigeria	Community	CS	Conv	Healthy males	WB	479	11.5
Kane, 2009(178)	2003	Senegal	Outpatient clinic	CS	Conv	Pregnant women approached in 2003	ELISA	260	21.5
Kane, 2009(178)	2006	Senegal	Outpatient clinic	CS	Conv	Pregnant women approached in 2006	ELISA	628	13.2
Katz, 2020(179)	-	Ghana	Community	CS	Conv	Healthy adults	ELISA	406	33.3
Kirakoya-Samadoulougou,	2003	Burkina Faso	Outpatient clinic	CS	Conv	Pregnant women from antenatal clinics	ELISA	2,018	17.9
2011(180)									
Kirakoya-Samadoulougou, 2011(180)	2003	Burkina Faso	Community	CS	CRS	15-49 years old women from urban populations	ELISA	883	23.6
Kirakova-Samadoulougou.	2003	Burkina Faso	Community	CS	CRS	15-49 years old men from urban populations	ELISA	791	15.2
2011(180)						······································			
Lagarde, 2004(181)	2000	Burkina Faso	Community	CS	CRS	Healthy men	ELISA	1,030	12.5
Lagarde, 2004(181)	2000	Burkina Faso	Community	CS	CRS	Healthy women	ELISA	1,210	24.0
Mawak, 2012(182)	-	Nigeria	Community	CS	RS	Healthy adults	ELISA	180	24.4
Patnaik, 2007(183)	1985-97	Mali	Hospital	CC	Conv	Controls in a case-control study of cervical cancer	WB	90	43.3
Shaw, 2001(184)	1998	Gambia	Community	CS	CRS	15-34 years old men	ELISA	432	5.1
Shaw, 2001(184)	1998	Gambia	Community	CS	CRS	15-34 years old women	ELISA	575	28.5
Thomas, 2004(185)	1999-00	Nigeria	Community	CS	Conv	>15 years old sexually active women	ELISA	892	61.3
Walraven, 2001(186)	1999	Gambia	Community	CS	CRS	\geq 15 years old healthy women	ELISA	1,317	31.9
Weiss, 2001(87)	1997-98	Benin	Community	CS	CRS	Women from Cotonou	ELISA	935	30.0
Weiss, 2001(87)	1997-98	Benin	Community	CS	CRS	Men from Cotonou	ELISA	863	12.0
Higher-risk populations			·						
Aho, 2014(187)	2006	Guinea	Outpatient clinic	CS	Conv	FSWs	ELISA	201	84.1
Dada, 1998(188)	1990-91	Nigeria	Community	CS	Conv	FSWs	WB	796	59.0
Eltom, 2002(177)	1991-94	Nigeria	Community	CS	Conv	FSWs	WB	863	60.6
Kane, 2009(178)	2006	Senegal	Community	CS	Conv	FSWs	ELISA	604	88.4
Low, 2011(189)	2003-06	Burkina Faso	Community	Cohort	Conv	FSWs	ELISA	689	62.4
Nagot, 2005(190)	198-02	Burkina Faso	Community	Cohort	Conv	FSWs	ELISA	329	54.7
Traore, 2015(191)	2009-11	Burkina Faso	Community	RCT	Conv	FSWs	ELISA	321	28.0
Wade, 2005(192)	2004	Senegal	Community	CS	Conv	MSM	ELISA	440	22.3
HIV negative populations									
Camara, 2012(193)	-	Senegal	Outpatient clinic	CS	Conv	HIV negative Senegalese males	ELISA	35	11.0
Camara, 2012(193)	-	Senegal	Outpatient clinic	CS	Conv	HIV negative Senegalese females	ELISA	35	23.0
HIV positive individuals and individ	duals in HIV di	scordant couples				0 0			
Camara, 2012(193)	-	Senegal	Outpatient clinic	CS	Conv	Male partners in HIV discordant couples	ELISA	34	44.0
Camara, 2012(193)	-	Senegal	Outpatient clinic	CS	Conv	Female partners in HIV discordant couples	ELISA	34	56.0
Camara, 2012(193)	-	Senegal	Outpatient clinic	CS	Conv	HIV positive males	ELISA	35	60.0
Camara, 2012(193)	-	Senegal	Outpatient clinic	CS	Conv	HIV positive females	ELISA	35	63.0
Obedisi-Omokanye, 2017(194)	-	Nigeria	Outpatient clinic	CS	Conv	HIV positive patients	ELISA	276	42.0
Yunusa, 2019(195)	2014-16	Nigeria	Outpatient clinic	CS	Conv	HIV positive patients	ELISA	16	50.0
STI clinic attendees and symptomat	tic populations [†]	5							
Aryee, 2005(196)	2004	Gambia	Outpatient clinic	CS	Conv	Women attending an STI clinic	ELISA	63	46.0
Eltom, 2002(177)	1991-94	Nigeria	Outpatient clinic	CS	Conv	Females attending an STI clinics	WB	114	44.7
Eltom, 2002(177)	1991-94	Nigeria	Outpatient clinic	CS	Conv	Males attending an STI clinics	WB	259	14.7

Table S6. Studies reporting	HSV-2 seroprevalence	in Western Africa.	This table includes only	v overall and not stratified	seroprevalence measures.
				-	

* The reported study design is the original study design (case control, cross sectional, longitudinal cohort, or randomized controlled trial). The included seroprevalence measures are those for the baseline measures at the beginning of the study. † Symptomatic populations include patients with clinical manifestations related to an STI.

Abbreviations: ANC = Antenatal clinic, CC = Case control, Conv = Convenience, CRS = Cluster random sampling, CS = Cross sectional, ELISA = Enzyme-linked immunosorbent assay, FSWs = Female sex workers, HIV = Human immunodeficiency virus, HSV-2 = Herpes simplex virus type 2, MSM = Men who have sex with men, RCT = Randomized controlled trial, RS = Random sampling, STI = Sexually transmitted infection, WB = Western blot.

Table S7. Studies reporting H	ISV-2 seroprevalence in	Central Africa. This table	includes only overall and ne	ot stratified seroprevalence measures.
-------------------------------	-------------------------	----------------------------	------------------------------	--

Author, year	Year(s) of data collection	Country	Study site	Original study design [*]	Sampling method	Population	HSV-2 serological assay	Sample size	HSV-2 seroprevalence (%)
General populations									
Charpentier,	2007	Chad	Community	CS	CRS	General adult population	ELISA	548	15.7
2011(197)									
Eis-Hubinger,	1998	Cameroon	Outpatient clinic	CS	RS	Patients attending a pulmonary clinic	WB	188	72.3
2002(198)									
Ozouaki, 2006(199)	-	Gabon	Outpatient clinic	CS	Conv	Women of childbearing age	ELISA	355	65.9
Volpi, 2004(200)	1997-98	Cameroon	Outpatient clinic	CS	Conv	Males and females attending general clinic	ELISA	238	34.0
Weiss, 2001(87)	1997-98	Cameroon	Community	CS	CRS	Women from Yaounde	ELISA	1,002	51.0
Weiss, 2001(87)	1997-98	Cameroon	Community	CS	CRS	Men from Yaounde	ELISA	887	27.0
Higher-risk populations									
Longo, 2017(201)	2013	Central African Republic	Community	CS	Conv	FSWs	ELISA	345	11.9
Nzila, 1991(202)	1988	Democratic Republic of Congo	Community	CS	Conv	FSWs	WB	1,233	21.5
HIV negative population	15								
LeGoff, 2011(203)	2009	Central African Republic	Hospital	CS	Conv	≤ 17 years old HIV negative children	ELISA	200	6.0
STI clinic attendees and	symptomatic po	opulations [†]							
Eis-Hubinger,	1998	Cameroon	Outpatient clinic	CS	RS	Patients attending an STI clinic	EIA	161	67.1
2002(198)									
Mbopi-keou,	-	Central African Republic	Outpatient clinic	CS	Conv	Women attending an STI clinic	ELISA	300	82.0
2000(204)									
Vandepitte, 2007(205)	2002	Democratic Republic of Congo	Outpatient clinic	CS	Conv	FSWs attending an STI clinic	ELISA	501	58.5
Other populations									
Eis-Hubinger,	1998	Cameroon	Hospital	CS	RS	Patients with symptoms suggestive of HIV	EIA	61	70.5
2002(198)									

* The reported study design is the original study design (case control, cross sectional, longitudinal cohort, or randomized controlled trial). The included seroprevalence measures are those for the baseline measures at the beginning of the study.

* Symptomatic oppletations include patients with clinical manifestations related to an STI. Abbreviations: Conv = Convenience, CRS = Cluster random sampling, CS = Cross sectional, EIA = Enzyme immunosorbent assay, ELISA = Enzyme-linked immunosorbent assay, FSWs = Female sex workers, HIV = Human immunodeficiency virus, HSV-2 = Herpes simplex virus type 2, RS = Random sampling, STI = Sexually transmitted infection, WB = Western blot.

Table S8. Studies reporting HSV-2 seroprevalence across several regions in sub-Saharan Africa. This table includes only overall and not stratified seroprevalence measures.

Author, year	Year(s) of data collection	Country	Study site	Original study design [*]	Sampling method	Population	HSV-2 serological assay	Sample size	HSV-2 seroprevalence (%)
HIV negative populations									
ECHO trial	2015-17	4 African countries [†]	Community	RCT	Conv	Females using injectable contraceptives	ELISA	2,588	38.7
consortium(206)									
ECHO trial	2015-17	4 African countries [†]	Community	RCT	Conv	Females using intrauterine contraceptives	ELISA	2,587	39.4
consortium(206)									
ECHO trial	2015-17	4 African countries [†]	Community	RCT	Conv	Females using implantable contraceptives	ELISA	2,584	37.4
consortium(206)									
Marrazzo, 2015(207)	2009-11	3 African countries [‡]	Community	RCT	Conv	Female trial participants	ELISA	5,005	46.0
McCormack, 2010(40)	2005-09	4 African countries [§]	Outpatient clinic/Community	RCT	Conv	Female trial participants receiving 2% gel	ELISA	2,725	60.0
McCormack, 2010(40)	2005-09	4 African countries§	Outpatient clinic/Community	RCT	Conv	Female trial participants receiving 0.5% gel	ELISA	3,312	61.0
McCormack, 2010(40)	2005-09	4 African countries [§]	Outpatient clinic/Community	RCT	Conv	Female trial participants receiving placebo	ELISA	3,311	60.0
HIV positive individuals ar	nd individuals	in HIV discordant coup	les						
Heffron, 2012(208)	2004-10	7 African countries [¶]	Community	Cohort	Conv	Males with an HIV positive partner	WB	2,393	60.2
Heffron, 2012(208)	2004-10	7 African countries [¶]	Community	Cohort	Conv	Females with an HIV positive partner	WB	1,283	84.8
STI clinic attendees and syn	mptomatic po	pulations							
LeGoff, 2007(209)	2003-05	2 African countries**	Outpatient clinic	RCT	Conv	Women with GUD	ELISA	437	79.0

The four African countries are South Africa, Tanzania, Uganda, and Zimbabwe.
 Superstance of the four African countries are South Africa, Tanzania, Uganda, and Zimbabwe.

[¶]The seven African countries are: Botswana, Kenya, South Africa, Tanzania, Uganda, and Zambia.

¹ Symptomatic populations include patients with clinical manifestations related to a sexually transmitted infection. ^{**} The two African countries are Ghana and Central African Republic

Abbreviations: Conv = Convenience, ELISA = Enzyme-linked immunosorbent assay, GUD = Genital ulcer disease, HIV = Human immunodeficiency virus, HSV-2 = Herpes simplex virus type 2, RCT = Randomized controlled trial, WB = Western blot.

Table S9. Pooled mean estimates for herpes simplex virus type 2 seroprevalence among general populations by sex stratification in sub-Saharan Africa.

				Among	women			Among men					
		Outcome measures	Sample size	HSV-2 sero (%	prevalence %)	Pooled mean (%) HSV-2 seroprevalence	I ^{2*} (%)	Outcome measures	Sample size	HSV-2 sero (%	prevalence	Pooled mean (%) HSV-2 seroprevalence	I ^{2*} (%)
		Total n	Total N	Range	Median	(95% CI)	(95% CI)	Total n	Total N	Range	Median	(95% CI)	(95% CI)
	Benin	8	2,130	9.0-57.0	34.6	34.3 (24.1-45.3)	95.0 (92.3-96.8)	8	1,861	1.0-42.0	17.5	15.6 (8.0-25.1)	94.9 (92.0-96.7)
	Burkina Faso	9	4,111	6.9-40.5	20.6	21.4 (15.4-28.0)	95.5 (93.2-97.0)	5	1,821	4.1-37.5	12.5	16.3 (8.8-25.4)	94.5 (90.0-97.0)
	Cameroon	8	1,125	14.0-78.0	69.0	58.0 (39.1-100)	97.5 (96.4-98.3)	8	996	3.0-59.0	34.5	31.5 (15.4-50.2)	97.2 (96.0-98.1)
	Ethiopia	6	744	24.4-59.5	33.3	36.4 (22.4-41.8)	92.8 (87.1-96.0)	-	-	-	-	-	-
	Gambia	5	1,892	7.8-47.7	31.9	28.7 (17.4-41.7)	95.4 (91.9-97.4)	4	431	2.6-16.4	4.1	5.5 (1.6-11.3)	76.8 (36.5-91.5)
	Kenya	40	18,863	4.4-91.3	51.0	50.2 (42.2-58.2)	99.1 (99.0-99.2)	30	15,603	1.9-76.0	33.1	27.9 (21.0-35.4)	98.8 (98.6-99.0)
	Malawi	33	7,287	3.0-87.5	56.0	48.7 (39.6-57.9)	98.1 (97.8-98.4)	22	2,013	0.0-77.3	46.5	39.2 (26.9-52.1)	95.5 (94.2-96.5)
	Namibia	4	197	18.0-34.0	24.0	54.6 (28.1-79.9)	92.8 (94.9-96.6)	4	205	13.0-43.0	22.0	23.5 (10.1-40.1)	84.7 (61.8-93.9)
Countries	Nigeria	10	1,661	17.1-61.3	29.9	32.6 (18.9-47.9)	96.5 (95.0-97.6)	4	544	8.7-43.8	15.4	11.3 (8.6-14.4)	71.4 (18.6-90.0)
	Rwanda	3	1,835	41.0-59.0	43.2	47.7 (37.7-57.7)	92.9 (82.5-97.1)	-	-	-	-	-	-
	Senegal	8	888	7.7-27.1	18.4	16.2 (11.6-21.4)	73.4 (45.8-86.9)	-	-	-	-	-	-
	South Africa	49	28,380	1.5-92.5	45.0	43.0 (34.1-52.2)	99.6 (99.5-99.6)	30	16,069	2.0-84.2	14.0	22.1 (14.5-30.6)	99.3 (99.3-99.4)
	Tanzania	25	10,551	7.0-68.0	34.7	37.1 (31.7-42.7)	96.7 (96.0-97.4)	7	5,274	25.0-54.8	39.1	32.4 (28.0-37.0)	96.2 (94.1-97.6)
	Uganda	29	22,622	15.3-90.7	64.0	61.5 (52.4-70.2)	99.5 (99.4-99.5)	27	22,519	9.9-81.9	46.5	41.2 (32.9-49.8)	99.4 (99.3-99.5)
	Zambia	21	17,934	5.6-80.0	44.0	44.7 (32.7-57.1)	99.6 (99.6-99.7)	21	8,039	1.0-62.5	37.1	28.2 (18.5-39.1)	99.1 (98.9-99.2)
	Zimbabwe	27	12,826	0.1-71.0	34.0	26.8 (16.1-39.0)	99.5 (99.5-99.6)	13	3,149	0.1-62.2	41.1	29.5 (13.5-48.7)	99.6 (99.6-99.7)
	Other countries [†]	5	717	23.0-97.4	65.9	68.6 (39.2-91.7)	98.2 (97.3-98.8)	-	-	-	-	-	-
	Eastern Africa	104	54,717	4.4-91.3	49.1	49.1 (44.3-53.9)	99.2 (99.2-99.3)	67	45,022	1.9-81.9	39.1	34.9 (26.7-40.3)	99.3 (99.2-99.3)
African	Southern Africa	134	66,895	0.1-92.5	44.2	41.6 (36.1-47.3)	99.5 (99.5-99.6)	90	33,223	0.0-84.5	25.3	28.4 (23.0-34.0)	99.2 (99.1-99.2)
subregions	Western Africa	43	10,942	6.9-97.4	27.1	30.2 (24.8-35.8)	97.3 (96.9-97.7)	21	4,657	1.0-43.8	12.5	13.6 (9.7-17.9)	92.6 (90.1-94.5)
	Central Africa	9	1,480	14.0-78.0	68.0	58.8 (42.6-74.2)	97.4 (96.4-98.2)	8	996	3.0-59.0	34.5	31.5 (15.4-50.2)	97.2 (96.0-98.1)
	<20 years	55	25,504	2.4-46.0	17.0	16.2 (13.8-18.9)	96.4 (95.8-96.9)	29	13,676	0.0-17.8	6.0	6.1 (4.5-79.7)	93.3 (91.4-94.9)
	20-30 years	63	30,832	7.7-91.3	43.3	44.8 (40.6-49.0)	98.1 (97.9-98.3)	47	18,194	2.9-57.7	20.7	20.3 (16.9-23.9)	96.9 (96.4-97.3)
A go guoun	30-40 years	36	17,033	24.9-90.4	70.5	67.6 (62.8-72.3)	97.6 (97.0-97.8)	31	9,319	16.4-73.1	49.1	47.5 (42.5-52.6)	95.4 (94.3-96.3)
Age group	40-50 years	24	7,592	20.0-92.5	71.9	67.0 (63.3-76.3)	97.0 (96.3-97.6)	22	4,844	37.0-84.2	55.0	56.9 (51.3-62.5)	92.5 (89.9-94.4)
	>50 years	7	2,044	50.6-80.0	60.6	62.3 (52.6-71.6)	94.1 (90.2-96.4)	77	1,989	39.6-69.6	50.0	51.5 (39.7-63.2)	96.1 (94.0-97.5)
	Mixed	105	51,029	0.1-97.4	41.8	41.5 (35.8-47.3)	99.4 (99.4-99.4)	50	35,876	0.1-81.8	30.6	29.5 (22.4-37.0)	99.5 (99.5-99.6)
Year of	≤2005	61	10,907	5.7-88.0	50.0	50.5 (44.4-56.5)	97.4 (97.1-97.7)	51	9,337	1.0-76.0	37.0	30.5 (24.4-37.0)	97.7 (97.3-98.0)
publication	2006-2015	168	79,377	0.1-97.4	41.0	40.3 (36.1-44.6)	99.3 (99.3-99.3)	100	57,869	0.0-81.9	35.2	30.3 (25.5-35.2)	99.3 (99.3-99.4)
category	>2015	61	43,750	1.5-92.5	44.0	43.4 (35.7-51.2)	99.6 (99.6-99.7)	35	16.692	1.9-84.2	18.0	24.0 (17.1-31.7)	99.1 (99.1-99.3)

*12: a measure that assesses the magnitude of between-study variation that is due to actual differences in seroprevalence across studies rather than chance. All meta-analyses had a statistically significant Cochrane's Q-statistic (p<0.001) and a wide prediction interval indicative of strong heterogeneity.

[†]Other countries: Cote d'Ivoire, Eritrea, Gabon, Mali.

Abbreviations: CI = Confidence interval, HSV-2 = Herpes simplex virus type 2.

Figure S2. Forest plots presenting the outcomes of the pooled mean herpes simplex virus type 2 (HSV-2) seroprevalence among the different at risk populations across the sub-Saharan Africa subregions.

Events per 100

A) Eastern Africa

Author, Year	HSV-2 seropositive	Sample size	observations	W(Random)	Prev(%)	95%CI
General populations						
Wagner, 1994 Wagner, 1994	64 72	86 126		0.3%	74.4 57.1	[63.9; 83.2] [48.0: 65.9]
Ghebrekidan, 1999	2	45		0.3%	4.4	[0.5; 15.1]
Ghebrekidan, 1999	23	102		0.3%	22.5	[14.9; 31.9]
Kamali, 1999 Kamali, 1999	10	52		0.3%	26.9	[15.6; 41.0]
Kamali, 1999	42	89		0.3%	47.2	[36.5; 58.1]
Kamali, 1999 Kamali, 1999	32	66 59		0.3%	48.5	[36.0; 61.1]
Kamali, 1999	34	96		0.3%	35.4	[25.9; 45.8]
Kamali, 1999	65	88		0.3%	73.9	[63.4; 82.7]
Kamali, 1999 Kamali, 1999	120	155	· · · ·	0.3%	87.6	[70.0; 83.7] [80.4: 92.9]
Kamali, 1999	62	81		0.3%	76.5	[65.8; 85.2]
Weiss, 2001	83	213		0.3%	39.0	[32.4; 45.9]
Weiss, 2001 Weiss, 2001	121	104		0.3%	78.8	[56.4; 72.6]
Weiss, 2001	92	109		0.3%	84.4	[76.2; 90.6]
Weiss, 2001	60	70		0.3%	85.7	[75.3; 92.9]
Weiss, 2001	42	48		0.3%	87.5	[74.8; 95.3]
Weiss, 2001	12	142	-	0.3%	8.5	[4.4; 14.3]
Weiss, 2001 Weiss, 2001	25	145		0.3%	38.0	[11.5; 24.4]
Weiss, 2001	46	80		0.3%	57.5	[45.9; 68.5]
Weiss, 2001	38	58		0.3%	65.5	[51.9; 77.5]
Weiss, 2001 Weiss, 2001	29	29		0.3%	75.9	[43.2, 71.6]
Kamali, 2002	681	2396		0.3%	28.4	[26.6; 30.3]
Kamali, 2002	674	2417		0.3%	27.9	[26.1; 29.7]
Msuya, 2002	8	35		0.3%	20.1	[10.4; 40.1]
Msuya, 2002	39	124		0.3%	31.5	[23.4; 40.4]
Msuya, 2002 Msuya, 2002	47	110		0.3%	42.7	[33.3; 52.5]
Holt, 2003	22	85		0.3%	25.9	[17.0; 36.5]
Kebede, 2004	242	407	+	0.3%	59.5	[54.5; 64.3]
Kebede, 2004 Nilsen 2005	417	1205	*	0.3%	34.6 34.7	[31.9; 37.4]
Nilsen, 2005	28	81		0.3%	34.6	[24.3; 46.0]
Gorander, 2006	10	40		0.3%	25.0	[12.7; 41.2]
Gorander, 2006 Gorander, 2006	30 43	76		0.3%	37.5 56.6	[26.9; 49.0]
Kapiga, 2006	609	1418	*	0.3%	42.9	[40.4; 45.6]
Kapiga, 2006 Kasubi, 2006	222	566	*	0.3%	39.2	[35.2; 43.4]
Kasubi, 2006 Kasubi, 2006	55	130		0.3%	42.3	[33.7: 51.3]
MOH Uganda, 2006	404	1963		0.3%	20.6	[18.8; 22.4]
MOH Uganda, 2006 MOH Uganda, 2006	675	1757	*	0.3%	38.4	[36.1; 40.7]
MOH Uganda, 2006	826	1344	-	0.3%	61.5	[58.8; 64.1]
MOH Uganda, 2006	688	998	+	0.3%	68.9	[66.0; 71.8]
MOH Uganda, 2006 MOH Uganda, 2006	577 457	788 608	+	0.3%	73.2	[70.0; 76.3]
MOH Uganda, 2006	365	494	-	0.3%	73.9	[69.8; 77.7]
MOH Uganda, 2006	225	310	-	0.3%	72.6	[67.3; 77.5]
MOH Uganda, 2000 MOH Uganda, 2006	311	1146		0.3%	27.1	[24.6; 29.8]
MOH Uganda, 2006	402	1092	*	0.3%	36.8	[33.9; 39.8]
MOH Uganda, 2006 MOH Uganda, 2006	517	1111	+	0.3%	46.5 53.4	[43.6; 49.5] [49.9: 56.8]
MOH Uganda, 2006	434	730	+	0.3%	59.5	[55.8; 63.0]
MOH Uganda, 2006	320	516	+	0.3%	62.0	[57.7; 66.2]
MOH Uganda, 2006 MOH Uganda, 2006	297	442		0.3%	67.2	[62.6; 71.6]
Todd, 2006	273	430	-	0.3%	63.5	[58.7; 68.0]
Todd, 2006	193	420		0.3%	46.0	[41.1; 50.9]
msuya, 2007 msuva. 2007	43	223		0.3%	41.7	[20.3; 34.7]
Yahya-Malima, 2008	17	242	+	0.3%	7.0	[4.1; 11.0]
Yahya-Malima, 2008	76	319	+	0.3%	23.8	[19.3; 28.9]
Yahya-Malima, 2008	37	113		0.3%	32.0	[24.2; 42.2]
Yahya-Malima, 2008	50	249		0.3%	20.1	[15.3; 25.6]
Yahya-Malima, 2008 Amorokul, 2009	26	181		0.3%	14.4	[9.6; 20.3]
Amornkul, 2009	76	101		0.3%	75.2	[65.7; 83.3]
Amornkul, 2009	105	115	-	0.3%	91.3	[84.6; 95.8]
Amornkul, 2009 Amornkul, 2009	54	316	+	0.3%	90.4 17.1	[04.0, 94.4]
Amornkul, 2009	27	106		0.3%	25.5	[17.5; 34.9]
Amornkul, 2009 Amornkul, 2009	75	130		0.3%	57.7	[48.7; 66.3]
Guwatudde, 2009	716	1080	+	0.3%	66.3	[63.4; 69.1]
Guwatudde, 2009	439	945	*	0.3%	46.5	[43.2; 49.7]
Msuya, 2009 Msuya, 2009	183	635	*	0.3%	28.8	[25.3; 32.5]
NASCOP, 2009	165	1314	-	0.3%	12.6	[10.8; 14.5]
NASCOP, 2009	443	1578	*	0.3%	28.1	[25.9; 30.4]
NASCOP, 2009 NASCOP 2009	511 562	1334	*	0.3%	38.3 49.2	[35.7; 41.0] [46.3: 52.2]
NASCOP, 2009	507	936	+	0.3%	54.2	[50.9; 57.4]
NASCOP, 2009	421	736	-	0.3%	57.2	[53.5; 60.8]
NASCOP, 2009 NASCOP, 2009	276	511	+	0.3%	54.0	[49.6: 58.4]
NASCOP, 2009	230	420		0.3%	54.8	[49.9; 59.6]
NASCOP, 2009	116	256	-	0.3%	45.3	[39.1; 51.6]
NASCOP, 2009	54 106	1024	*	0.3%	4.6	[8.6; 12.4]
NASCOP, 2009	176	870	+	0.3%	20.2	[17.6; 23.1]
NASCOP, 2009 NASCOP 2009	219	767	*	0.3%	28.6	[25.4; 31.9] [31.6: 38.01
NASCOP, 2009	253	571		0.3%	44.3	[40.2; 48.5]
NASCOP, 2009	249	548		0.3%	45.4	[41.2; 49.7]
NASCOP, 2009	158	423		0.3%	37.4	[34.7; 44.8]
NASCOP, 2009	121	338		0.3%	35.8	[30.7; 41.2]
Norris, 2009 Norris, 2009	104	232	ŤŤ	0.3%	44.8	[38.3; 51.5] [61.3: 74.0]
Tobian, 2009	140	1487		0.3%	11.2	[9.7; 12.9]
Tobian, 2009	370	1618	=	0.3%	22.9	[20.8; 25.0]
Tobian, 2009 Tobian, 2009	471 1151	1248 2043	*	0.3%	37.7 56.3	[35.0; 40.5] [54.2; 58.5]

biobit. 2010 biobit. 2011 biobit. 2012 biobi	Dhapt 2010	115	201		0.20/	40.0 [25.1:46.0]
Doyle, 2010 1986 3226 0.38 2.2 0.38 2.2 0.38 2.6 0.38 3.6 1.7 0.38 3.6 1.7 0.38 3.6 1.7 0.38 3.7 1.7 0.38 3.7 1.7 0.38 3.7 1.7 0.38 3.7 1.7 0.38 3.7 1.7 0.38 3.7 1.7 0.38 3.7 1.7 0.38 3.7 1.7 0.7 1.8 0.38 3.7 1.8 0.7 1.8 0.7 1.8 1.7 1.8 0.7 1.8 1.7 1.8 </td <td>Dhont 2010</td> <td>59</td> <td>170</td> <td></td> <td>0.3%</td> <td>34 7 [27 6: 42 4]</td>	Dhont 2010	59	170		0.3%	34 7 [27 6: 42 4]
Doyle 2010 228 3463 0.33 26.6 25.1 0.33 42.2 60.4 66 Chebrenchall 2011 31 157 0.33 42.2 60.4 66 Nync 2011 181 563 +- 0.33 42.7 77.6 57.7 Nync 2011 115 263 0.33 43.7 77.6 57.7 1.7 1.7 1.7 1.7 1.7 1.7 0.33 43.7 77.6 59.7 1.7	Dovle 2010	1369	3238	÷	0.3%	42.3 [40.6:44.0]
Braumenten, 2011a 540 1250 * 0.33 422 60.44 Chebremchael, 2011 137 151 - 0.33 421 60.45 Nyro, 2011 116 263 - 0.33 421 60.45 Nyro, 2011 116 263 - 0.33 421 60.45 Nyro, 2011 137 126 - 0.33 131 104.25 Tedle, 2011 17 226 6 - 0.33 315 105.40 Dew Walkue, 2012 228 660 - 0.33 351 105.40 Dew Walkue, 2012 228 660 - 0.33 351 105.27 Dew Walkue, 2012 140 345 - 0.33 41 105.57 Dew Walkue, 2012 140 345 - 0.33 651 55.55 Chebremchael, 2012 140 345 - 0.33 657.55 55.55 Chebremchael, 2012 <td< td=""><td>Doyle, 2010</td><td>928</td><td>3493</td><td></td><td>0.3%</td><td>26.6 [25.1: 28.1]</td></td<>	Doyle, 2010	928	3493		0.3%	26.6 [25.1: 28.1]
Chebremichael, 2011 37 191 0.38 24.5 17.9 Ghebremichael, 2011 98 175 0.38 37.1 19.0 33 37.1 19.0 33 37.1 19.0 33 37.1 19.0 33 37.1 19.0 33 37.1 19.0 33 37.1 19.0 33 37.1 19.0 33 37.1 19.0 33 37.1 19.0 33 37.1 19.0 33 37.1 19.0 33 37.1 19.0 14.1 19.0 33 37.1 19.0 14.1 19.0 14.1 19.0 33 37.1 19.0 33.1 19.0 <td>Braunstein, 2011a</td> <td>540</td> <td>1250</td> <td>-</td> <td>0.3%</td> <td>43.2 [40.4: 46.0]</td>	Braunstein, 2011a	540	1250	-	0.3%	43.2 [40.4: 46.0]
$\begin{array}{c} \label{eq:constraint} \begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	Ghebremichael 2011	37	151	<u> </u>	0.3%	24.5 [17.9: 32.2]
Cheberenchael, 2011 96 17.5 0.39 54.9 17.2 12.3 36.9 17.2 12.3 36.9 17.2 12.3 36.9 17.2 12.3 37.7 12.3 37.7 12.3 37.7 12.3 37.7 17.6 37.7 17.6 37.7 17.6 37.7 17.6 37.7 17.6 37.7 17.6 37.7 17.6 37.7 17.6 37.7 17.6 37.7 17.6 37.7 17.6 37.7 17.6 37.7 17.6 37.7 17.6 37.7 17.6 37.7 17.7 17.6 37.7 17.7 17.7 17.7 17.7 17.7 17.7 17.7 17.7 17.7 17.7 17.7 17.7 17.7 17.7 17.7 17.7 17.7 18.7 17.7 18.7 17.7 18.7 17.7 18.7 17.7 18.7 17.7 18.7 17.7 18.7 17.7 18.7 17.7 18.7 17.7 18.7 17.7 18.7 17.7 18.7 17.7 18.7 17.7 18.	Ghebremichael, 2011	88	237		0.3%	37.1 [31.0: 43.6]
Nyice 2011 115 223 + 0.3% 427 (37.8 ± 0.3\% 427 (37.8 ± 0.3\% 427 (37.8 ± 0.3\% 427 (37.8 ± 0.3\% 427 (37.8 ± 0.3\% 427 (37.8 ± 0.3\% 427 (37.8 ± 0.3\% 427 (37.8 ± 0.3\% 427 (37.8 ± 0.3\% 427 (37.8 ± 0.3\% 427 (37.8 ± 0.3\% 427 (37.8 ± 0.3\% 427 (37.8 ± 0	Ghebremichael, 2011	96	175	· · · · ·	0.3%	54.9 [47.2: 62.4]
Nymc 2011 115 223 4 0 0 3% 42.7 [27.6] Tedla, 2011 30 12 Tedla, 2011 30 12 Tedla, 2011 30 12 Tedla, 2011 30 12 De Wilque, 2012 220 116 4 0 3% 4 0 0 3% 42.7 [27.6] De Wilque, 2012 225 60 + 0 0 3% 52.6 [27.6] De Wilque, 2012 225 60 + 0 0 3% 52.6 [27.6] De Wilque, 2012 220 129 240 - 0 0 3% 52.6 [27.6] De Milque, 2012 120 129 240 - 0 0 3% 52.6 [27.6] Debermichael, 2012 140 229 - 0 0 3% 52.6 [27.6] Chebremichael, 2012 140 259 - 0 0 3% 52.7 [29.7 [29.7] Chebremichael, 2012 140 147.8 [20.5] Chebremichael, 2012 140 159 - 0 0 3% 55.7 [29.7] Chebremichael, 2012 140 159 - 0 0 3% 55.7 [29.7] Toblan, 2012 431 203 0 0 3% 55.7 [29.7] Toblan, 2013 133 641 + 0 0 3% 65.7 [29.7] Tarao, 2013 133 641 + 0 0 3% 65.7 [29.7] Diran, 2013 133 641 + 0 0 3% 65.7 [29.7] Diran, 2013 133 641 + 0 0 3% 65.7 [29.7] Diran, 2013 133 641 + 0 0 3% 65.7 [29.7] Diran, 2013 133 641 + 0 0 3% 65.7 [29.7] Diran, 2013 133 641 + 0 0 3% 65.7 [29.7] Diran, 2013 133 641 + 0 0 3% 65.7 [29.7] Diran, 2013 133 641 + 0 0 3% 65.7 [29.7] Diran, 2013 133 641 + 0 0 3% 65.7 [29.7] Diran, 2013 138 641 + 0 0 3% 65.7 [29.7] Diran, 2013 138 641 + 0 0 3% 65.7 [29.7] Diran, 2013 138 641 + 0 0 3% 65.7 [29.7] Diran, 2013 138 641 + 0 0 3% 65.7 [29.7] Diran, 2013 138 641 + 0 0 3% 65.7 [29.7] Diran, 2013 138 641 + 0 0 3% 65.7 [29.7] Diran, 2013 138 641 + 0 0 3% 65.7 [29.7] Diran, 2013 138 641 + 0 0 3% 65.7 [29.7] Diran, 2013 138 641 + 0 0 3% 65.7 [29.7] Diran, 2013 138 641 + 0 0 3% 65.7 [29.7] Diran, 2013 138 641 + 0 0 3% 65.7 [29.7] Diran, 2013 138 641 + 0 0 3% 65.7 [29.7] Diran, 2013 138 641 + 0 0 3% 65.7 [29.7] Diran, 2013 147 42 138 - 0 0 3% 65.7 [29.7] Diran, 2013 147 44 13 30 - 0 0 3% 65.7 [29.7] Diran, 2015 14 16.7] Diran, 2015 14 16.7] Diran, 2015 14 17.1] Diran, 2015 14 17.1] Diran, 2015 14 17.1] Diran, 2015 14 18.7] Diran, 2015	Nviro. 2011	181	563	-	0.3%	32.1 [28.3: 36.2]
Tedis, 2011 17 216 0.38 17.9 17.1 17.4 0.38 17.0 17.4 17.4 0.38 17.0 17.4 17.4 0.38 17.0 17.4 17.4 0.38 17.0 17.4 17.4 0.38 17.0 17.4	Nviro, 2011	115	263		0.3%	43.7 [37.6: 50.0]
Tedla, 2011 Tedla, 2012 Tedla, 2013 Tedla, 2012 Tedla, 2013 Tedla, 2014 Tedla,	Tedla 2011	17	216	+	0.3%	79 [47:123]
Total 2011 8 80	Tedla 2011	30	199		0.3%	15.1 [10.4:20.8]
be Walque, 2012 380 1124 ** 0.35 33.8 17.02 be Walque, 2012 225 660 ** 0.35 33.7 129.4 De Walque, 2012 225 660 ** 0.35 35.1 140.5 Dom, 2010 130 23.4 * 0.35 51.4 140.5 Chebremchael, 2012 140 25.9 * 0.35 56.6 15.4 46 Chebremchael, 2012 140 25.9 * 0.35 55.9 15.5 59 15.5 19.7 198.7 0.35 50.6 15.4 47 10.5 19.7 198.7 0.35 55.9 15.5 59 15.5 19.7 198.7 0.35 50.6 15.4 7 10.3 13.5 14.4 10.35 10.2 10.7 17.24 10.35 10.2 10.7 17.7 17.7 17.7 19.7 10.3 13.5 11.6 10.35 10.35 10.3 11.7	Tedla 2011	8	80	—	0.3%	10.0 [4.4:18.8]
De Walque, 2012 225 165 ++ 038 367 128-42 Devnt, 2010 180 304 + 038 552 155.5 Dhont, 2010 180 304 + 038 552 155.5 Chebremichael, 2012 199 455 + 038 567.7 158.9 Chebremichael, 2012 140 256 + 038 667.7 158.9 Chebremichael, 2012 140 126 - 038.9 650.7 158.9 Chebremichael, 2012 186 779 185.7 158.9 77 158.7 158.9 77 158.9 77 158.9 77 158.9 77 158.9 77 158.9 77 158.9 77 158.9 77 158.9 77 158.9 77 158.9 77 158.2 77 158.2 77 158.2 77 158.9 77 158.9 77 158.9 77 158.9 77 <td< td=""><td>De Walque 2012</td><td>380</td><td>1124</td><td>-</td><td>0.3%</td><td>33.8 [31.0:36.7]</td></td<>	De Walque 2012	380	1124	-	0.3%	33.8 [31.0:36.7]
be Weing, 2012 225 660 + 038 321 106.57 Dhont, 2010 129 251 - 038 652 655.64 Dhont, 2010 129 251 - 038 654.44 653.46 Chebremichael, 2012 120 186 - 038.44 65.94.67 Chebremichael, 2012 120 186 - 038.67.7 653.46 Chebremichael, 2012 388 677 68.79 - 038.67.7 68.79 Reynolds, 2012 388 425 + 038.67.7 68.79 78.79 Brano, 2013 225 2205 - 038.46.57 18.79 78.79 Brano, 2013 133 641.4 - 038.46.57 18.79 038.46.57 18.79 18.79 18.79 18.79 18.79 18.79 18.79 18.79 18.79 18.79 18.79 18.79 18.79 18.79 18.79 18.79 18.79 18.79 18.79	De Walque, 2012	226	615	-	0.3%	36 7 [32 9: 40 7]
Diront, 2010 Case	De Walque, 2012	225	660	-	0.3%	3/ 1 [30 5: 37 8]
Dindt. 2010 129 251	De Walque, 2012	180	304		0.3%	59.2 [53.5; 64.8]
$ \begin{array}{c} \label{constraints} \begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	Dhont 2010	100	251		0.3%	51 4 [45 0: 57 7]
Other matrix Out Out <thout< th=""> <t< td=""><td>Chebromichael 2012</td><td>129</td><td>452</td><td></td><td>0.3%</td><td>21.0 [19.1:25.0]</td></t<></thout<>	Chebromichael 2012	129	452		0.3%	21.0 [19.1:25.0]
Other minutania 2012 140 203 4 60 55.4 60 Chebronichael, 2012 120 198	Chebremichael, 2012	99	400	-	0.3%	21.9 [10.1, 20.9]
Schebernichten 0.012 100 200	Chebremichael, 2012	140	343		0.3%	40.6 [35.4, 46.0]
Observentation 0.3% 0.2 10.0 11 0.3% 0.2 10.0 11 0.3% 0.2 10.0 12 10.0	Chebromichael, 2012	140	209	-	0.3%	54.1 [47.8, 00.2] 60.6 [52.4:67.5]
Dependix unit 2012 108 107 + 0.3% 0.07 97.75 Paynolds, 2012 487 483 + 0.3% 559 152.55 Diran, 2012 487 483 + 0.3% 559 152.55 Biraro, 2013 123 461 + 0.3% 102 103.17 117.14 Biraro, 2013 123 461 + 0.3% 427 138.247 Biraro, 2013 138 461 + 0.3% 655 153.18 153 118.5 153.18	Chebromichael, 2012	120	150		0.3%	67.7 [50.0: 74.9]
Reprint 2012 State Toban 2012 Construction 2013	Gnebremichael, 2012	109	070		0.3%	07.7 [39.9, 74.0]
Importance 2012 340 423	Reynolds, 2012	888	979	*	0.3%	90.7 [88.7; 92.5]
$ \begin{bmatrix} 1 \text{DB} \text{I} \text{I} \text{I} \text{I} \text{I} \text{I} \text{I} I$	Reynolds, 2012	348	425		0.3%	81.9 [77.9; 85.4]
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Tobian, 2012	467	835	-	0.3%	55.9 [52.5; 59.3]
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Tobian, 2012	431	803		0.3%	53.7 [50.2; 57.2]
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Biraro, 2013	225	2205		0.3%	10.2 [9.0; 11.5]
briano, 2013 118, 2405 480 $-$ 0.3% 624 118, 16 briano, 2013 118, 118 119 $+$ 0.3% 624 118, 16 briano, 2013 120 118, 16 briano, 2013 12090 2543 $-$ 0.3% 625 120, 118, 16 briano, 2013 2090 2543 $-$ 0.3% 622 120, 57 briano, 2014 11 30 $-$ 0.3% 627 199, 56 briano, 2014 147 338 $+$ 0.3% 644 190, 57 briano, 2015 20 139 $-$ 0.3% 644 190, 57 briano, 2015 20 139 $-$ 0.3% 642 192, 77 briano, 2015 466 6302 $-$ 0.3% 74 18 190, 27 briano, 2015 466 6302 $-$ 0.3% 74 18 190, 27 briano, 2015 466 87 $-$ 0.3% 643 193, 67 briano, 2015 466 87 $-$ 0.3% 643 193, 76 briano, 2015 199 402 $+$ 0.3% 653 149, 366 briano, 2015 199 402 $+$ 0.3% 653 149, 366 briano, 2015 199 407 $+$ 0.3% 653 149, 366 briano, 2015 199 407 $+$ 0.3% 653 149, 366 briano, 2015 199 407 $+$ 0.3% 653 149, 366 briano, 2015 11 76 $+$ 0.3% 644 190, 27 briano, 2015 14 33 $-$ 0.3% 653 149, 366 briano, 2015 11 76 $+$ 0.3% 653 149, 366 briano, 2015 11 76 $+$ 0.3% 653 149, 366 briano, 2015 11 76 $+$ 0.3% 652 149, 63 briano, 2015 11 76 $+$ 0.3% 652 149, 63 briano, 2015 11 76 $+$ 0.3% 652 149, 63 briano, 2015 114 226 $+$ 0.3% 652 149, 157 chieno, 2015 14 33 $+$ 0.3% 652 149, 157 chieno, 2015 14 33 $+$ 0.3% 652 149, 157 briano, 2015 14 255 60 chieno, 2015 14 32 $-$ 0.3% 724 147, 114, 24 chieno, 2015 19 27 254 $+$ 0.3% 652 144, 157 chieno, 2015 19 27 52 $-$ 0.3% 724 145, 175 chieno, 2015 19 27 59 briano, 2016 277 524 $+$ 0.3% 653 152, 158 chieno, 2015 19 440 $+$ 177 chieno, 2015 19 440 $+$ 177 chieno, 2015 19 27 254 chieno, 2015 19 27 254 chieno, 2016 277 524 $+$ 0.3% 652 144, 157 chieno, 2015 19 440 $+$ 11039 $+$ 0.3% 652 144, 157 chieno, 2016 277 524 $+$ 0.3% 652 144, 157 chieno, 2016 19 44 $+$ 0.3% 652 144, 157 chieno, 2018 141 42 $+$ 0.3% 652 144, 158 chieno, 2018 141 42 $+$ 0.3% 652 144, 158 chieno, 2016 113 42 $+$ 0.3% 652 144, 158 chieno, 2016 113 4	Biraro, 2013	133	641	*	0.3%	20.7 [17.7; 24.1]
	Biraro, 2013	205	480	-	0.3%	42.7 [38.2; 47.3]
briano, 2013 3, 346 2197 briano, 2013 4, 21 B27 briano, 2013 4, 74 54 B27 briano, 2013 4, 74 7, 71 briano, 2014 1, 71 33 briano, 2014 1, 71 33 briano, 2014 1, 71 33 briano, 2014 1, 71 33 briano, 2014 1, 71 38 , 75 briano, 2015 4, 71 6, 75 briano, 2015 4, 74 64 6, 70 - 0, 35 4, 42 9, 177 , 59 briano, 2015 4, 44 190, 277 , 59 briano, 2015 4, 41 19, 60 chieno, 2015 4, 41 7, 75, 44 - 0, 3% 4, 45 [27, 77 briano, 2015 4, 41 7, 75 - 0, 3% 4, 45 [27, 77 briano, 2015 4, 41 7, 75 - 0, 3% 4, 45 [27, 75 chieno, 2015 4, 41 7, 75 - 0, 3% 4, 42 [25, 56 Chieno, 2015 4, 41 7, 75 - 0, 3% 4, 42 [25, 56 Chieno, 2015 4, 41 7, 75 - 0, 3% 4, 42 [25, 56 Chieno, 2015 4, 41 7, 75 - 0, 3% 4, 42 [25, 56 Chieno, 2015 4, 41 7, 75 - 0, 3% 4, 42 [25, 56 - 0, 3% 4, 42 [25, 56 - 0, 3% 4, 42 [27, 75 54 - 0, 3% 4, 42 [27, 75 54 - 0, 3% 4, 42 [27, 75 54 - 0, 3% 4, 42 [27, 75 54 - 0, 3% 4, 42 [27, 75 54 - 0, 3% 4, 42 [27, 75 54 - 0, 3% 4, 42 [27, 75 54 - 0, 3% 4, 42 [27, 75 54 - 0, 3% 4, 42 [27, 75 54 - 0, 3% 4, 42 [27, 75 54 - 0, 3% 4, 42 [27, 75 54 - 0, 3% 4, 42 [27, 75 54 - 0, 3% 4, 42 [27, 75 54 - 0, 3% 4, 42 [27, 75 54 - 0, 3% 4, 42 [27, 75 54 - 0, 3% 4, 42 [27, 75 54 - 0, 3% 4, 42 [27, 75 54 - 0, 3% 4, 42 [27, 75 54 - 0, 3% 4, 42 [27, 75	Biraro, 2013	1183	1848		0.3%	64.0 [61.8; 66.2]
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Biraro, 2013	336	2197		0.3%	15.3 [13.8; 16.9]
brrano, 2013 4/4 /13 + 0.3% 822 800, 633 Jespers, 2014 31 110 - 0.3% 822 800, 633 Jespers, 2014 11 30 - 0.3% 822 800, 633 Jespers, 2014 117 30 - 0.3% 822 800, 633 Jespers, 2014 117 30 - 0.3% 440 [60, 56 Sinapalaningan, 2014 28 58 - 0.3% 442 [71, 56, 54 Sinapalaningan, 2014 28 58 - 0.3% 442 [72, 75 Duflo, 2015 650 5609 0.3% 425 [77, 59 Behling, 2015 10 435 - 0.3% 442 [72, 59, 39 Nakubuka, 2015 49 87 - 0.3% 442 [71, 15 Otieno, 2015 27 254 + 0.3% 442 [72, 14, 96 Otieno, 2015 11 76 - 0.3% 422 [74, 16, 87 Otieno, 2015 14	Biraro, 2013	421	827	-	0.3%	50.9 [47.4; 54.4]
Biraño, 2013 20190 2243 0.3% 282 2806, 87 Jespers, 2014 31 110 0.3% 282 280, 87 Jespers, 2014 14 5 Nakku-Joioba, 2014 147 338 0.3% 428 220, 37 Nakku-Joioba, 2014 147 338 0.3% 428 220, 37 Nakku-Joioba, 2014 147 338 0.3% 428 277, 59 Behling, 2015 0.0% 429 277, 59 Hallfors, 2015 18 402 - 0.3% 4.5 [27, 7 Hokoron, 2015 111 76 - 0.3% 4.5 [27, 7 Diteno, 2015 114 266 0.3% 4.2 [27, 15 Otieno, 2015 114 266 0.3% 4.2 [27, 15 Otieno, 2015 114 266 0.3% 4.2 [27, 15 Otieno, 2015 14 33 0.3% 4.2 [21, 11 Winston, 2015 28 79 0.3% 5.2 [17, 11 Winston, 2015 29 419, 86 Anjub, 2016 17 40 0.3% 4.2 [27, 05 Anjub, 2016 17 40 0.3% 5.2 [44, 168, 17 Anjub, 2016 17 40 0.3% 5.2 [44, 168, 17 Anjub	Biraro, 2013	474	713	-	0.3%	66.5 [62.9; 69.9]
Jespers, 2014 31 110 - 03% 28 200.3 Jespers, 2014 5 30 - 03% 167 [19.9 6 Nakku-Jokba, 2014 147 338 - 03% 435 [38.1;49 Nakku-Jokba, 2014 1428 58 - 03% 443 [35.0 67 Sivapalasingam, 2014 28 58 - 03% 443 [35.0 67 Sivapalasingam, 2014 28 58 - 03% 443 [24.2 [27.7 5 Dufio, 2015 650 5509 - 03% 142 [27.7 Hokoror, 2015 139 403 - 03% 45 [24.7 7 Hokoror, 2015 14 66 Nakubuka, 2015 48 87 - 03% 56 [45.3 66 Nakubuka, 2015 49 87 - 03% 56 [45.3 66 Nakubuka, 2015 49 87 - 03% 56 [45.3 66 Nakubuka, 2015 49 87 - 03% 56 [45.3 66 Nakubuka, 2015 41 76 - 03% 56 [45.3 66 Otieno, 2015 21 29 - 03% 52 [47.7 15.2 4 Minston, 2015 22 [47.7 15.2 4 Anjulo, 2016 217 252 - 03% 52 [47.1 13. 16 Otieno, 2015 24 [49.6 7] Nimston, 2015 25 96 - 03% 557 [26.8 67 Nimston, 2015 24 [49.6 7] Nimston, 2015 28 79 - 03% 557 [26.4 41.1 (73.9 69 Yegorov, 2018 107 252 - 03% 452 [27.7 15.2 4 Anjulo, 2016 217 524 - 03% 557 [56.4 42] Nakubuka, 2016 217 524 - 03% 557 [56.4 42] Nakubuka, 2016 217 524 - 03% 557 [56.4 42] Nakubuka, 2016 13 42 - 03% 557 [56.4 44] Nakubuka, 2016 277 524 - 03% 557 [56.4 44] Nakubuka, 2016 277 524 - 03% 557 [56.4 44] Nakubuka, 2016 277 524 - 03% 557 [56.4 44] Nakubuka, 2016 13 42 - 03% 557 [56.4 44] Nakubuka, 2016 277 524 - 03% 557 [56.4 44] Nakubuka, 2016 13 42 - 03% 557 [56.4 44] Nakubuka, 2016 14 44 44 44 44 44 44 44 44 44 4	Biraro, 2013	2090	2543	•	0.3%	82.2 [80.6; 83.7]
Jespers, 2014 5 Nakku-Joloba, 2014 147 33 Nakku-Joloba, 2014 147 33 Nakku-Joloba, 2014 503 786 - Nakku-Joloba, 2014 503 786 - Naku-Joloba, 2015 509 - Duflo, 2015 6500 - Naku-Joloba, 2015 10 139 - Naku-Joloba, 2015 10 435 + Hallfors, 2015 139 403 + Hallfors, 2015 139 403 + Hallfors, 2015 139 403 + Hallfors, 2015 139 403 + Hallfors, 2015 148 497 - Naku-Joluba, 2015 46 87 - Otieno, 2015 27 254 + Otieno, 2015 114 76 - Otieno, 2015 144 56 - Otieno, 2015 144 56 - Otieno, 2015 21 129 - Otieno, 2015 21 29 - Otieno, 2015 22 142 - Otieno, 2015 24 - Otieno, 2015 28 79 - Otieno, 2016 21 29 - Otieno, 2016 21 29 - Otieno, 2016 21 29 - Otieno, 2016 21 29 - Otieno, 2016 21 86 - Otieno, 2016 21 86 - Otieno, 2016 21 86 - Otieno, 2016 21 86 - Otieno, 2016 21 74 00 - Otieno, 2016 21 86 - Otieno, 2016 21 86 - Otieno, 2016 277 524 - Otieno, 2016 21 74 20 - Otieno, 2016 277 524 - Otieno, 2018 00 74	Jespers, 2014	31	110		0.3%	28.2 [20.0; 37.6]
Jespers, 2014 117 330 - 0.3% 425 [58]: 49 Nakku-Joloba, 2014 147 338 - 0.3% 425 [58]: 49 Nakku-Joloba, 2014 28 58 Sivapalasingam, 2014 28 58 Behling, 2015 20 139 - 0.3% 42.9 [27, 75] Dufto, 2015 650 509 - 0.3% 14.8 [10, 21] Dufto, 2015 650 509 - 0.3% 14.8 [10, 22] Dufto, 2015 18 460 5002 - 0.3% 74.1 [68, 8 Halffors, 2015 18 402 + 0.3% 42.9 [27, 74] Halffors, 2015 18 402 + 0.3% 45.1 [29, 73] Halffors, 2015 19 49 87 Halffors, 2015 19 414 56 Otheno, 2015 21 27 Otheno, 2015 14 42 56 Otheno, 2015 14 42 56 Otheno, 2015 41 73 Otheno, 2015 41 73 Otheno, 2015 21 72 54 Anjulo, 2016 21 86 Anjulo, 2016 21 86 Anjulo, 2016 277 254 Anjulo, 2016 277 254 Anjulo, 2016 19 422 Halffors, 2029 136 668 + 0.3% 52.9 [48, 56] Othero, 2016 19 42 Halffors, 2029 136 668 + 0.3% 52.9 [48, 56] Othero, 2016 19 42 Halffors, 2020 136 668 + 0.3% 52.9 [48, 56] Collear, 2018 147 252 Othero, 2018 147 252 Othero, 2018 194 217 Anjulo, 2016 19 42 Halffors, 2020 136 668 + 0.3% 42.4 [25, 50.4 Halffors, 2020 136 668 + 0.3% 42.4 [25, 55.7] Chebrekidan, 1999 33 73 Othere, 2018 00 74 Anjulo, 2016 19 43 Halffors, 2003 14 42 Kapiga, 2003 14 42 Kapiga, 2003 14 42 Kapiga, 2003 14 44 Kapiga, 2003 14 44 Kap	Jespers, 2014	5	30	i i	0.3%	16.7 [5.6; 34.7]
Nakku-Joloba, 2014 147 333 + 0,3% 43.5 [28,1;4] Nakku-Joloba, 2014 503 786 + 0,3% 64.0 [26,5;67 Sivapalasingam, 2014 28 Sivapalasingam, 2014 18 42 - 0,3% 42.5 [27,7;59 Behing, 2015 20 139 - 0,3% 11.4 [90,2] Dufo, 2015 650 5000 - 0,3% 11.4 [90,2] Dufo, 2015 10 435 - 0,3% 2.3 [1,1; 4 Halfors, 2015 10 435 - 0,3% 2.5 [29, 39 Nakubulwa, 2015 49 Nakubulwa, 2015 49 Nakubulwa, 2015 49 Nakubulwa, 2015 40 Otieno, 2015 27 Otieno, 2015 11 76 Otieno, 2015 11 76 Otieno, 2015 14 286 Otieno, 2015 21 29 - 0,3% 52.2 [1,7; 11 Otieno, 2015 21 29 - 0,3% 52.2 [1,7; 14 26, 27, 294 Nakubulwa, 2015 14 286 Otieno, 2015 14 286 Otieno, 2015 21 29 - 0,3% 52.2 [1,7; 11 Otieno, 2015 14 286 Otieno, 2015 14 286 Otieno, 2015 21 29 - 0,3% 52.2 [1,7; 14 26, 28, 87 Vinston, 2015 22 [27, 596 Otieno, 2015 14 266 Otieno, 2015 14 265, 60 Otieno, 2015 21 29 - 0,3% 52.2 [1,7; 14 26, 28, 87 Vinston, 2015 22 [27, 596 Otieno, 2015 21 29 Vinston, 2015 22 [27, 596 Otieno, 2015 24 - 0,3% 52.2 [1,7; 11 Otieno, 2015 14 266 Otieno, 2015 22 [27, 596 Otieno, 2015 24 - 0,3% 52.2 [1,7; 11 Otieno, 2015 24 (25, 60 Otieno, 2016 21 86 Anjulo, 2016 21 86 Anjulo, 2016 13 42 Otieno, 2016 13 42 Otieno, 2018 100 Infert Aukubulwa, 2016 277 524 Anjulo, 2016 33 Atau 17, 217 Anjulo, 2016 34 Anjulo, 2016 34 A	Jespers, 2014	11	30		0.3%	36.7 [19.9; 56.1]
Nakku-Jokba. 2014 503 786 + 0.3% 64.0 [60.5] [60.5] [50.6] [50.7]	Nakku-Joloba, 2014	147	338		0.3%	43.5 [38.1; 49.0]
Sivepalasingen, 2014 28 58 - 0,3% 42.3 [35:0; 15] Sivepalasingen, 2014 18 42 0,3% 42.3 [27, 59] Behling, 2015 650 500 0,3% 14.4 [9:0; 27, 59] Behling, 2015 660 5509 0,3% 14.4 [9:0; 27, 59] Dufo, 2015 610 435 - 0,3% 14.4 [9:0; 27, 59] Nakubulwa, 2015 18 402 - 0,3% 45.5 [27, 7] Halfors, 2015 19 403 - 0,3% 45.5 [27, 7] Nakubulwa, 2015 46 87 0,3% 45.5 [29, 39] Nakubulwa, 2015 46 87 0,3% 55.3 [45:3; 66] Otieno, 2015 11 76 - 0,3% 55.3 [45:3; 66] Otieno, 2015 14 286 - 0,3% 45.5 [25, 7] Otieno, 2015 144 26 - 0,3% 55.2 [41:6] Otieno, 2015 144 26 - 0,3% 55.2 [45:86 0] Otieno, 2015 144 26 - 0,3% 55.2 [45:86 0] Otieno, 2015 144 26 - 0,3% 55.2 [45:86 0] Otieno, 2015 21 29 - 0,3% 55.2 [47:11 Winston, 2015 25 96 - 0,3% 55.2 [47:12] Winston, 2015 21 29 - 0,3% 55.2 [47:12] Winston, 2015 21 29 - 0,3% 55.2 [47:12] Makubulwa, 2016 17 40 - 0,3% 45.2 [27:65 4 Anjulo, 2016 17 40 - 0,3% 45.2 [27:65 4 Anjulo, 2016 17 40 - 0,3% 55.2 [47:15] Anjulo, 2016 17 40 - 0,3% 55.2 [27:65 4 Anjulo, 2016 17 40 - 0,3% 55.2 [27:65 4 Anjulo, 2016 17 40 - 0,3% 55.7 [50:4; 25:6 0 Anjulo, 2016 17 40 - 0,3% 55.7 [50:4; 25:6 0 Anjulo, 2016 17 40 - 0,3% 55.7 [50:4; 25:6 0 Anjulo, 2016 13 42 - 0,3% 19 [0,2; 6 Anjulo, 2016 277 524 - 0,3% 65.7 [50:4; 25:6 0 Otiver, 2018 100 165 - 0,3% 65.7 [50:4; 25:6 0 Otiver, 2018 100 165 - 0,3% 65.7 [50:4; 25:6 0 Otiver, 2018 100 165 - 0,3% 65.7 [50:4; 25:6 0,4 Fixed effect model 40776 110399 - 0,3% 55.1 [14:24 Mehta, 2018 117 252 - 0,3% 45.2 [35:75 5 Otiver, 2018 0,3% 57.2 11 - 0,3% 50.0 [41:1; 58 Ghebrekidan, 1999 10 48 - 0,3% 50.0 [41:1; 58	Nakku-Joloba, 2014	503	786	-	0.3%	64.0 [60.5; 67.4]
Sivepalasingam, 2014 18 42 - 0.3% 42.9 [27, 75] Behing, 2015 20 139 - 0.3% 14.4 [90, 21 Dufo, 2015 660 5509 0.3% 7.4 [90, 21 Dufo, 2015 660 5509 0.3% 7.4 [6.8; 8 Halfors, 2015 10 433 - 0.3% 2.3 [1.1; 4 Halfors, 2015 18 402 - 0.3% 45.5 [29, 73 Nakubulwa, 2015 49 87 0.3% 52.9 [41, 96, 21 Nakubulwa, 2015 3 49 - 0.3% 52.9 [41, 96, 21 Otieno, 2015 11 76 - 0.3% 45.5 [29, 73 Nakubulwa, 2015 46 87 Otieno, 2015 11 76 - 0.3% 45.5 [29, 73 Otieno, 2015 17 2254 - 0.3% 42.4 [25, 50 Otieno, 2015 14 56 - 0.3% 42.4 [25, 50 Otieno, 2015 14 266 0.3% 25.9 [41, 96, 23 Otieno, 2015 14 266 0.3% 25.9 [44, 186 Otieno, 2015 14 266 0.3% 25.9 [14, 93 Otieno, 2015 14 266 0.3% 25.9 [14, 93 Otieno, 2015 21 29 Otieno, 2015 24 73 0.3% 52.9 [14, 93 Otieno, 2015 24 73 Otieno, 2015 24 73 Otieno, 2015 24 73 Otieno, 2015 24 73 Otieno, 2015 25 5 96 - 0.3% 25.2 [17, 11 Winston, 2015 5 96 - 0.3% 25.4 [25, 07, 59 Anjulo, 2016 17 40 0.3% 52.7 [25, 44] Anjulo, 2016 17 40 0.3% 52.7 [25, 64 Anjulo, 2016 13 42 0.3% 52.7 [25, 64 Anjulo, 2016 27 75 Akinyi, 2017 24 0.3% 55.7 [50, 46, 17 Otieno, 2018 100 165 Akinyi, 2017 24 0.3% 55.7 [50, 46, 17 Otieno, 2018 100 165 Fixed effect model 40776 110399 1 0.3% 50.0 [41, 158 Akinyi, 2017 24 0.3% 50.0 [41, 158 Akinyi, 2018 100 165 Akinyi, 203 3 [1	Sivapalasingam, 2014	28	58		0.3%	48.3 [35.0; 61.8]
Behling, 2015 20 139 Dufo, 2015 650 509 Dufo, 2015 650 509 Dufo, 2015 650 509 Dufo, 2015 650 509 Dufo, 2015 603 500 Hallfors, 2015 10 435 Hallfors, 2015 10 435 Hallfors, 2015 18 402 Hallfors, 2015 19 49 87 Nakubulwa, 2015 46 87 Olieno, 2015 27 254 + 0.3% 65 165 36 61 1.3 (6 7.4) (15 0.2) (11 3.6) (17 4.1) (15 0.2) (15 0.2) (14 9.8) (25 0.2) (15 0.	Sivapalasingam, 2014	18	42		0.3%	42.9 [27.7; 59.0]
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Behling, 2015	20	139		0.3%	14.4 [9.0; 21.3]
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Duflo, 2015	650	5509	•	0.3%	11.8 [11.0; 12.7]
Hallfors, 2015 10 435 0.3% 2.3 [11:4] Hallfors, 2015 18 402 + 0.3% 4.5 [22:7] Hokororo, 2015 19 403 + 0.3% 4.5 [22:9] 39 Nakubulwa, 2015 46 87 0.3% 55.9 [31:9] 63 Otleno, 2015 27 254 + 0.3% 16.6 [1:13:1] 6 Otleno, 2015 11 76 0.3% 16.6 [1:13:1] 6 Otleno, 2015 14 56 0.3% 25.0 [1:4:4] 38 Otleno, 2015 114 266 0.3% 25.0 [1:4:4] 38 Otleno, 2015 11 27.6 0.3% 52.2 [1:7:1] Vinston, 2015 21 29 0.3% 52.2 [1:7:1] Vinston, 2015 21 29 0.3% 52.2 [1:7:1] Vinston, 2016 13 42 0.3% 35.7 [2:5:6] 46 Anjulo, 2016 13 42 0.3% 35.7 [2:5:6] 46 Anjulo, 2016 13 <td>Duflo, 2015</td> <td>466</td> <td>6302</td> <td>•</td> <td>0.3%</td> <td>7.4 [6.8; 8.1]</td>	Duflo, 2015	466	6302	•	0.3%	7.4 [6.8; 8.1]
Halfors, 2015 18 402 + 0.3% 4.5 [27, 7] Nakubulwa, 2015 49 87 - 0.3% 65.3 [45, 8] 60 Nakubulwa, 2015 46 87 0.3% 61.1 [13, 6] 0.3% 62.9 [41, 8] 60 61.1 [13, 6] 0.3% 62.9 [41, 8] 60 0.3% 62.9 [41, 8] 60 0.3% 62.9 [41, 8] 60 1.1 1.5 1.6 0.3% 62.9 [42, 125, 6] 0.3% 62.9 [14, 3] 0.3% 62.2 [14, 3] 0.3% 62.2 [14, 4] 6 0.3% 62.2 [14, 4] 6 0.3% 62.9 [14, 4] 6.2 0.3% 62.2 [14, 4] 6.2 0.3% 62.2 [14, 4] 6.2 0.3% 62.2 [14, 4] 6.3 0.3% 62.4 [15, 27, 59 6.2 [14, 16] 7.4 1.6 0.3% 62.2 [17, 11 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1	Hallfors, 2015	10	435	•	0.3%	2.3 [1.1; 4.2]
Hokoror, 2015 139 403 0.3% 34.5 [29.9, 30] Nakubulwa, 2015 46 87 0.3% 56.3 [45.3] 66 Olieno, 2015 3 49 0.3% 61.6 [1.3] 16 Otieno, 2015 11 76 0.3% 61.6 [1.3] 16 Otieno, 2015 11 76 0.3% 42.4 [25.6] 00 Otieno, 2015 14 33 0.3% 42.9 [36.8] 49 Otieno, 2015 14 73 0.3% 52.2 [47.1] 72.5 25.0 [47.1] 72.5 25.0 [47.1] 72.5 25.2 [47.1] 72.5 25.2 [47.1] 72.5 25.2 [47.1] 72.5 25.2 [47.1] 72.5 25.2 [47.1] 72.5 25.2 [47.1] 72.5 25.2 [47.1] 72.5 25.2 [47.1] 72.5 25.2 [47.1] 72.5 25.2 [47.1] 72.5 25.2 [47.1] 72.5 25.2 [47.1] 72.5 25.2 [47.1] 72.5 25.2 [47.1] 72.5 25.2 [47.1] 72.5 25.2 [47.1] 72.5 25.2 [47.1] 72.5	Hallfors, 2015	18	402	+	0.3%	4.5 [2.7; 7.0]
Nakubulwa, 2015 49 87 0.3% 56.3 [413; 63 Olieno, 2015 3 49 0.3% 61.1 [13; 63 Olieno, 2015 27 254 0.3% 61.1 [13; 63 Otieno, 2015 11 76 0.3% 42.4 [25, 56] Otieno, 2015 14 33 0.3% 42.2 [25, 66] Otieno, 2015 14 56 0.3% 42.9 [36, 84] [36, 72] Otieno, 2015 14 266 0.3% 42.9 [36, 84] [52, 17] [14, 38] 0.3% 52.9 [14, 4] [36, 84] [52, 17] [17, 11] [37, 16] 0.3% 52.2 [17, 11] Vinston, 2015 28 79 0.3% 52.4 [15, 63, 4] [37, 12] 0.3% 52.9 [14, 38] [17, 17] 0.3% 52.9 [14, 16] [34] Anjulo, 2016 13 42 0.3% 37.1 [17, 64] Anjulo, 2016 13 42 0.3% 57.2 [50, 462] 0.3% 57.2 [50, 462] 0.3% 57.5 [50, 462]	Hokororo, 2015	139	403		0.3%	34.5 [29.9; 39.4]
Nakubulwa, 2015 46 87 0.3% 52.9 [41,9; 62] Otleno, 2015 27 254 + 0.3% 10.6 [7,1; 15] Otleno, 2015 11 76 0.3% 42.9 [36,8; 40] Otleno, 2015 14 33 0.3% 42.4 [25,5; 60] Otleno, 2015 14 56 0.3% 52.0 [14,4; 80] Otleno, 2015 14 73 0.3% 52.0 [14,4; 80] Otleno, 2015 14 73 0.3% 52.2 [14,1; 16] Otleno, 2015 21 29 0.3% 52.2 [14,1; 16] Winston, 2015 28 79 0.3% 52.5 [17,1; 17] Vinston, 2016 27.7 524 0.3% 55.7 [25,0; 47] Anjulo, 2016 13 42 0.3% 57.7 [25,4] 0.3% 57.7 [25,4] 0.3% 57.7 [25,4] 0.3% 57.7 [25,4] 0.3% 57.7 [25,4] 0.3% 57.8 [25,7] [25,7] [25,7] [25,7] <	Nakubulwa, 2015	49	87		0.3%	56.3 [45.3; 66.9]
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Nakubulwa, 2015	46	87	<u> </u>	0.3%	52.9 [41.9; 63.7]
Otheno, 2015 27 254 + 0.3% 10.6 [7,1; 15] Otheno, 2015 11 76 - 0.3% 42.4 [25,5; 04] Otheno, 2015 114 266 0.3% 42.4 [25,5; 04] Otheno, 2015 114 266 0.3% 42.4 [25,6; 04] Otheno, 2015 21 29 0.3% 72.4 [52,8] 7 Winston, 2015 28 79 0.3% 35.4 [25,0;47] Anjulo, 2016 21 86 - 0.3% 35.2 [27,1;5] Anjulo, 2016 21 86 - 0.3% 35.2 [27,1;5] 8.4 Anjulo, 2016 13 42 - 0.3% 35.7 [24,1;6] 8.4 Anjulo, 2016 13 42 - 0.3% 5.2 [44,1;6] 8.4 Anjulo, 2016 13 42 - 0.3% 35.7 [24,6] 6.7 1.6 1.7 1.7 1.9 [24,6] 5.7 1.9 1.9 [25,6] 6.6 1.9	Otieno, 2015	3	49		0.3%	6.1 [1.3; 16.9]
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Otieno, 2015	27	254	-	0.3%	10.6 [7.1; 15.1]
Otieno, 2015 14 33 0.3% 42.4 22.5; 60 Otieno, 2015 14 26 0.3% 42.9 36.8; 49 Otieno, 2015 114 266 0.3% 55.2 14.4; 16.7 Otieno, 2015 21 29 0.3% 56.2 14.4; 16.7 Winston, 2015 5 96 0.3% 56.2 14.4; 16.7 Winston, 2015 28 79 0.3% 52.2 17.1; 11 Winston, 2016 17 40 0.3% 22.4 15.8; 34 Anjulo, 2016 13 42 0.3% 35.7 12.5; 64 Anjulo, 2016 13 42 0.3% 35.7 12.5; 64 Anjulo, 2016 13 42 0.3% 35.7 12.5; 64 Anjulo, 2016 13 42 0.3% 17.0 17.4; 17.3; 17.4; 17.3; 17.4; 12.4; 17.4; 0.3% 13.6; 65.0; 14.9; 44.9; 77	Otieno, 2015	11	76		0.3%	14.5 [7.5; 24.4]
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Otieno, 2015	14	33		0.3%	42.4 [25.5; 60.8]
Otieno, 2015 114 266 0.3% 42.9 36.8,49 Otieno, 2015 21 29 0.3% 56.2 [44.1,67] Winston, 2015 21 29 0.3% 56.2 [17,11] Winston, 2015 28 79 0.3% 56.2 [17,11] Winston, 2016 21 86 0.3% 35.4 [25.0;70,59] Anjulo, 2016 21 86 0.3% 35.7 [25.6; 40] Anjulo, 2016 13 42 0.3% 35.7 [25.6; 40] Anjulo, 2016 13 42 0.3% 35.7 [25.6; 44] Nakubuka, 2016 13 42 0.3% 35.7 [25.6; 44] Nakubuka, 2016 13 42 0.3% 35.7 [25.6; 46] Oliver, 2018 143 252 - 0.3% 19 [0.2; 6 Oliver, 2018 100 165 - 0.3% 60.6 [22.7; 86] Oliver, 2018 60 74 - 0.3% 50.0 [41.1; 62] Kuteesa, 2020 <	Otieno, 2015	14	56	<u> </u>	0.3%	25.0 [14.4; 38.4]
Otieno, 2015 41 73 0.3% 56.2 [44.1; 67] Winston, 2015 21 29 0.3% 72.4 [52.8; 87] Winston, 2015 28 79 0.3% 35.4 [27.0; 59] Anjulo, 2016 17 40 0.3% 35.4 [27.0; 59] Anjulo, 2016 13 42 0.3% 35.7 [25.6; 46] Anjulo, 2016 13 42 0.3% 31.0 [17.6; 47] Nakubulwa, 2016 277 524 0.3% 52.9 [44.5; 67] Akinyi, 2017 2 105 0.3% 35.7 [25.6; 46] Akinyi, 2017 24 139 - 0.3% 52.9 [44.5; 67] Mehta, 2018 117 252 0.3% 56.7 [50.4; 62] Mehta, 2018 100 165 0.3% 46.4 [40.1; 52] Oliver, 2018 94 217 0.3% 43.3 [36.6; 50] Oliver, 2018 0.0 76 1003% 24.9 [17.4; 23] Kuteesa, 2020 126 <td< td=""><td>Otieno, 2015</td><td>114</td><td>266</td><td>- </td><td>0.3%</td><td>42.9 [36.8; 49.0]</td></td<>	Otieno, 2015	114	266	- 	0.3%	42.9 [36.8; 49.0]
Otieno, 2015 21 29 0.3% 72.4 [52.8; 17] Winston, 2015 5 96 0.3% 5.2 [17] Winston, 2015 28 79 0.3% 5.2 [17] 11 Winston, 2016 17 40 0.3% 5.2 [17] 17 Anjulo, 2016 11 86 0.3% 35.7 [256, 47] Anjulo, 2016 13 42 0.3% 35.7 [256, 46] Anjulo, 2016 13 42 0.3% 31.0 [17, 64] Nakubukwa, 2016 277 524 0.3% 31.0 [17, 64] Nakubukwa, 2018 143 252 0.3% 5.6 [50, 46] Akinyi, 2017 2 105 0.3% 5.6 [50, 46] (52, 76] Mehta, 2018 143 252 0.3% 46.4 [40, 17, 32] (46, 40, 17] Oliver, 2018 60 74 0.3% 60.6 [52, 76] (53, 5%] 41.9 (33, 66, 50] Rahom effects model 40776 110399 -	Otieno, 2015	41	73		0.3%	56.2 [44.1; 67.8]
Winston, 2015 5 96 0.3% 5.2 [1.7, 1] Winston, 2015 28 79 0.3% 35.4 [250, 47] Anjulo, 2016 21 86 0.3% 32.4 [250, 47] Anjulo, 2016 30 84 0.3% 35.7 [256, 46] Anjulo, 2016 13 42 0.3% 31.0 [17, 64] Nakubulwa, 2016 277 524 0.3% 51.9 [10, 27, 64] Akinyi, 2017 2 105 + 0.3% 56.7 [50, 46] Mehta, 2018 113 252 0.3% 46.4 [40, 1; 52] Oliver, 2018 100 165 0.3% 43.3 [36, 56] Oliver, 2018 100 165 0.3% 52.9 [40, 1; 52] Oliver, 2018 34 58 0.3% 52.6 [44, 5], 73.89 Yegorov, 2018 34 58 0.3% 50.0 [41, 1; 58] Fixed effect model 40776 110399	Otieno, 2015	21	29	· · · · · · · · · · · · · · · · · · ·	0.3%	72.4 [52.8; 87.3]
Winston, 2015 28 79 0.3% 35.4 125.0.5% Anjulo, 2016 17 40 0.3% 42.5 127.0.59 Anjulo, 2016 21 86 0.3% 35.7 126.5; 4 Anjulo, 2016 13 42 0.3% 35.7 126.5; 6 Anjulo, 2016 277 524 0.3% 35.0 17.6; 47.7 Nakubulwa, 2016 277 524 0.3% 52.9 [48.5; 57.6] 6.5; 67.6] 6.5; 7 Akinyi, 2017 2 105 + 0.3% 17.3 11.4; 24 0.3% 56.7 150.4; 62.5 Mehta, 2018 143 252 0.3% 46.4 10.52 Oliver, 2018 94 217 0.3% 43.3 [36.6; 50.0] Oliver, 2018 60 74 - 0.3% 80.6 [5.7; 68.6] Kuteesa, 2020 136 668 + 0.3% 20.4 [17.4; 23 24.6 Heterogeneity: l^2 = 99%, $l_{12,5}$ = 25111.05 (ρ = 0) - - 35.5 [53.2; 35.57] G10.2	Winston, 2015	5	96		0.3%	5.2 [1.7; 11.7]
Anjulo, 2016 17 40 - 0.3% 42.5 [27.0; S0] Anjulo, 2016 21 86 - 0.3% 34.4 [15.8; 34] Anjulo, 2016 13 42 0.3% 35.7 [26:46] Anjulo, 2016 13 42 0.3% 35.7 [26:46] Akinyi, 2017 2 105 - 0.3% 19.9 [0.2; 6] Akinyi, 2017 24 139 - 0.3% 17.3 [11.4; 24] Mehta, 2018 117 252 - 0.3% 46.4 40.15.2 Oliver, 2018 94 217 - 0.3% 66.6 52.7; 68 Oliver, 2018 100 165 - 0.3% 58.6 [44.9; 71.7; 42.3] Vuteesa, 2020 136 668 + 0.3% 52.2 55 Random effects model 40776 110399 - - 35.5 [53.2; 35.7] Ghebrekidan, 1999 33 73 - 0.3% 43.4 [28.5] 57.5 Ghebrekidan, 1999 33	Winston, 2015	28	79		0.3%	35.4 [25.0; 47.0]
Anjulo, 2016 21 86	Anjulo, 2016	17	40		0.3%	42.5 [27.0; 59.1]
Anjulo, 2016 30 84	Anjulo, 2016	21	86		0.3%	24.4 [15.8; 34.9]
Anjulo, 2016 13 42 0.3% 31.0 [17.6: 47] Nakubulwa, 2016 277 524 0.3% 52.9 [48.5; 57] Akinyi, 2017 2 105 + 0.3% 17.9 [10.2: 6] Akinyi, 2017 24 139 0.3% 17.3 [11.4: 24] Mehta, 2018 143 252 0.3% 46.4 40.1; 52 Oliver, 2018 94 217 0.3% 43.3 [36.6; 50] Oliver, 2018 100 165 0.3% 60.6 [52.7; 68] Oliver, 2018 60 74 0.3% 81.6 [49.9; 71] Kutesa, 2020 136 668 + 0.3% 20.4 [17.4: 23] Kuteesa, 2020 270 602 - 0.3% 43.4 [28.5; 57] Random effects model 40776 110399 - - 35.5 [35.5; 55] Ghebrekidan, 1999 33 73 - 0.3% 43.4 [28.5; 57] Ghebrekidan, 1999 10 48 - 0.3% 20.0 [Anjulo, 2016	30	84		0.3%	35.7 [25.6; 46.9]
Nakubulwa, 2016 277 524 0.3% 52.9 [48.5; 57 Akinyi, 2017 2 105 + 0.3% 1.9 [0.2; 6] Akinyi, 2017 24 139 0.3% 56.7 [50.4; 62] Mehta, 2018 143 252 0.3% 56.7 [50.4; 62] Oliver, 2018 94 217 0.3% 61.6 [52.7; 68] Oliver, 2018 100 165 0.3% 81.1 [70.3] 81.1 [70.3] 81.1 [70.3] 81.1 [70.3] 81.1 [70.3] 81.1 [70.3] 81.1 [70.3] 85.6 [44.9; 71 0.3% 80.6 [52.7; 68] 0.3% 20.4 [17.4; 23] Kuteesa, 2020 136 668 +- 0.3% 20.4 [17.4; 23] Kuteesa, 2020 270 602 0.3% 45.2 [33.5; 54] 55.5 55.2; 35 55 Radwar, 1997 65 130 3.3% 45.2 [33.5; 57] 71 0.3% 45.2 <t< td=""><td>Anjulo, 2016</td><td>13</td><td>42</td><td></td><td>0.3%</td><td>31.0 [17.6; 47.1]</td></t<>	Anjulo, 2016	13	42		0.3%	31.0 [17.6; 47.1]
Akinyi 2017 2 105 + 0.3% 1.9 [0.2; 6 Akinyi 2017 24 139 + 0.3% 17.3 [11.4; 24 Mehta, 2018 143 252 - 0.3% 46.4 [40:1; 52 Oliver, 2018 94 217 0.3% 43.3 136.6; 50 0.3% 81.1 [70.3; 89 Oliver, 2018 100 165 - 0.3% 81.1 [70.3; 89 Oliver, 2018 60 74 - 0.3% 81.1 [70.3; 89 Yegorov, 2018 34 58 0.3% 81.1 [70.3; 89 Yegorov, 2018 34 58 0.3% 84.49. [74.23 Kuteesa, 2020 136 668 + 0.3% 20.4 [17.4; 23 Kuteesa, 2020 270 602 0.3% 41.9 [38.4; 45 Heterogeneity: l ² = 99%, $\chi^2_{187} = 25111.05$ ($p = 0$) - 33.5 50.0 [41.1; 58 Ghebrekidan, 1999 23 53 - 0.3% 50.0 [21.1; 33 Ghebrekidan, 1999 10 48 - <td>Nakubulwa, 2016</td> <td>277</td> <td>524</td> <td>-</td> <td>0.3%</td> <td>52.9 [48.5; 57.2]</td>	Nakubulwa, 2016	277	524	-	0.3%	52.9 [48.5; 57.2]
Akinyi, 2017 24 139 0.3% 17.3 11.4; 24 Mehta, 2018 143 252 0.3% 56.7 150.4; 62. Oliver, 2018 94 217 0.3% 46.4 [40.1; 52 Oliver, 2018 100 165 0.3% 61.52.7; 65. Oliver, 2018 60 74 0.3% 81.1 [70.3; 89 Yegorov, 2018 34 58 0.3% 81.1 [70.3; 89 Yegorov, 2018 34 58 Viteesa, 2020 136 668 + 0.3% 20.4 [71.7; 23 Kuteesa, 2020 270 602 0.3% 44.9 [40.8; 48 Heterogeneity: I ² = 99%, χ^2_{187} = 25111.05 (p = 0) 51.55 [23.5; 57 53.57 Schebrekidan, 1999 33 73 0.3% 43.4 [29.8; 57 Ghebrekidan, 1999 33 73 0.3% 45.2 [35.5; 55 Ghebrekidan, 1999 10 48 0.3% 45.2 [35.5; 57 Ghebr	Akinyi, 2017	2	105	- !!	0.3%	1.9 [0.2; 6.7]
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Akinyi, 2017	24	139		0.3%	17.3 [11.4; 24.6]
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Mehta, 2018	143	252		0.3%	56.7 [50.4; 62.9]
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Mehta, 2018	117	252	+	0.3%	46.4 [40.1; 52.8]
Oliver, 2018 100 165 0.3% 60.6 [52.7; 68] Oliver, 2018 60 74 0.3% 81.1 [70.3; 89] Yegorov, 2018 34 58 0.3% 81.4 [70.3; 89] Kuteesa, 2020 136 668 0.3% 20.4 [17.4; 23] Kuteesa, 2020 270 602 0.3% 44.9; 71 40.8; 44 Fixed effect model 40776 110399 -35.5; 55.2; 35 55 Random effects model 40776 110399 63.5% 41.9; 13.4; 45 Heterogeneity: $l^2 = 99\%$, $\chi_{187}^2 = 25111.05$ ($p = 0$) 0.3% 50.0 [41.1; 58 Ghebrekidan, 1999 33 73 0.3% 43.4 [29.8; 57] Ghebrekidan, 1999 10 48 0.3% 20.2 [10.5; 35] Holt, 2003 57 211 0.3% 33.3 [10.6; 49] Kapiga, 2003 14 42 0.3% 45.1 [35.8; 54]	Oliver, 2018	94	217		0.3%	43.3 [36.6; 50.2]
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Oliver, 2018	100	165		0.3%	60.6 [52.7; 68.1]
Yegorov, 2018 34 58 0.3% 58.6 [44.9; 71] Kuteesa, 2020 136 668 - 0.3% 58.6 [44.9; 71] Kuteesa, 2020 270 602 0.3% 20.4 [17.4; 23] Fixed effect model 40776 110399 - - 35.5 [35.2; 35] Random effects model 40776 110399 - - 35.5 [35.2; 35] Rakwar, 1997 65 130 - 0.3% 50.0 [41.1; 58] Ghebrekidan, 1999 33 73 - 0.3% 45.2 [33.5; 57] Ghebrekidan, 1999 10 48 - 0.3% 43.4 [28.8; 77] Ghebrekidan, 1999 10 48 - 0.3% 43.4 [28.8; 77] Ghebrekidan, 1999 10 48 - 0.3% 43.4 [28.8; 67] Ghebrekidan, 1999 10 48 - 0.3% 27.0 [27.1; 13] Kapiga, 2003 14 42 - 0.3% 27.0 [27.1; 13] K	Oliver, 2018	60	74	· · · · ·	0.3%	81.1 [70.3; 89.3]
Kuteesa, 2020 136 668 - 0.3% 20.4 [17.4; 23] Kuteesa, 2020 270 602 0.3% 44.9 [40.8; 48] Fixed effect model 40776 110399 - - 35.5 [35.2; 35] Random effects model 65 110399 + - - 63.5% 41.9 [38.4; 45] Heterogeneity: l^2 = 99%, χ^2_{187} = 25111.05 (p = 0) - 0.3% 50.0 [41.1; 58] Ghebrekidan, 1999 33 73 - 0.3% 45.2 [33.5; 57] Ghebrekidan, 1999 23 53 - 0.3% 43.4 [29.8; 57] Ghebrekidan, 1999 10 48 - 0.3% 20.8 [10.5; 35] Holt, 2003 57 211 - 0.3% 27.0 [21.1; 33] Kapiga, 2003 14 42 - 0.3% 33.3 [19.6; 49] Kapiga, 2003 21 32 - 0.3% 95.2 [46.8; 70] Kapiga, 2003 21 32 - 0.3%	Yegorov, 2018	34	58		0.3%	58.6 [44.9; 71.4]
Kuteesa, 2020 270 602	Kuteesa, 2020	136	668	-	0.3%	20.4 [17.4; 23.6]
Fixed effect model 40776 110399 + 35.5 [35.2; 35 Random effects model 63.5% 41.9 [38.4; 45] Heterogeneity: $l^2 = 99\%$, $l_{157}^2 = 25111.05$ ($p = 0$) 65 130 63.5% 41.9 [38.4; 45] Intermediate-risk populations 8 0.3% 50.0 [41.1; 58] (41.9; 138.4; 45] Rakwar, 1997 65 130 0.3% 50.0 [41.1; 58] (45, 25] Ghebrekidan, 1999 33 73 0.3% 45.2 [33.5; 67] Ghebrekidan, 1999 10 48 0.3% 20.8 [10.5; 35] Holt, 2003 57 211 0.3% 27.0 [27.1; 33] Kapiga, 2003 14 42 0.3% 33.3 [19.6; 49] Kapiga, 2003 21 32 0.3% 65.6 [46.8; 70] Kapiga, 2003 21 32 0.3% 65.6 [46.8; 81] Kapiga, 2003 1 11 0.3% 9.2 [46.9; 28] Kapiga, 2003 1 11 0.3% 9.2 [46.9; 28]<	Kuteesa, 2020	270	602		0.3%	44.9 [40.8; 48.9]
Random effects model Heterogeneity: $l^2 = 99\%$, $\chi^2_{187} = 25111.05$ ($p = 0$) 63.5% 41.9 [38.4; 45 Intermediate-risk populations Rakwar, 1997 65 130 0.3% 50.0 [41.1; 58 Ghebrekidan, 1999 33 73 0.3% 45.2 [33.5; 57 Ghebrekidan, 1999 23 53 0.3% 43.4 [29.8; 57 Ghebrekidan, 1999 10 48 0.3% 20.8 [10.5; 35] Holt, 2003 57 211 0.3% 27.0 [21.1; 33] Kapiga, 2003 14 42 0.3% 33.3 [19.6; 49] Kapiga, 2003 21 32 0.3% 45.1 [25.8; 54] Kapiga, 2003 21 32 0.3% 65.6 [46.8; 61] Kapiga, 2003 1 11 0.3% 9.1 [0.2; 41] Kapiga, 2003 1 11 0.3% 9.2 [46.8; 70] Kapiga, 2003 1 11 0.3%	Fixed effect model	40776	110399	+		35.5 [35.2; 35.8]
Heterogeneity: $l^* = 99\%$, $\chi^*_{187} = 25111.05$ ($p = 0$) Intermediate-risk populations Rakwar, 1997 65 130 0.3% 50.0 [41.1; 58 Ghebrekidan, 1999 33 73 0.3% 45.2 [33.5; 57 Ghebrekidan, 1999 23 53 0.3% 45.2 [33.5; 57 Ghebrekidan, 1999 10 48 0.3% 20.8 [10.5; 35 Holt, 2003 57 211 - 0.3% 27.0 [21:1; 33 Kapiga, 2003 14 42 0.3% 33.3 [19.6; 44 Kapiga, 2003 14 42 0.3% 45.1 [35.8; 54 Kapiga, 2003 21 32 - 0.3% 59.2 [46.8; 70] Kapiga, 2003 21 32 - 0.3% 70.6 [56.2; 82] Kapiga, 2003 1 11 - 0.3% 9.1 [10.2; 41] Kapiga, 2003 8 52 - 0.3% 70.6 [56.2; 82] Kapiga, 2003 13 49 - 0.3% 2	Random effects model			\$	63.5%	41.9 [38.4; 45.3]
Intermediate-risk populations Rakwar, 1997 65 130 0.3% 50.0 [41.1; 58 Ghebrekidan, 1999 33 73 0.3% 45.2 [33.5; 57 Ghebrekidan, 1999 23 53 0.3% 45.2 [33.5; 57 Ghebrekidan, 1999 10 48 0.3% 20.8 [10.5; 35 Holt, 2003 57 211 0.3% 32.0 [10.5; 35 Kapiga, 2003 14 42 0.3% 33.3 [19.6; 49 Kapiga, 2003 51 113 0.3% 45.1 [58.5; 44 Kapiga, 2003 42 71 0.3% 65.6 [46.8; 81 Kapiga, 2003 21 32 0.3% 65.6 [46.8; 81 Kapiga, 2003 1 11 0.3% 9.1 [0.2; 41 Kapiga, 2003 8 52 0.3% 9.1 [0.2; 41 Kapiga, 2003 13 49 0.3% 26.5 [14.9; 41 Kapiga, 2003 <	Heterogeneity: / ² = 99%, χ ² ₁₈₇ = 2	25111.05 (p = 0)				
Intermediate-risk populations 0.3% 50.0 [41.1;68 Rakwar, 1997 65 130 0.3% 50.0 [41.1;68 Ghebrekidan, 1999 33 73 0.3% 45.2 [33:5;67 Ghebrekidan, 1999 23 53 0.3% 43.4 [29:8;57 Ghebrekidan, 1999 10 48 0.3% 20.8 [10:5;35 Holt, 2003 57 211 0.3% 33.3 [10:6;35 Kapiga, 2003 14 42 0.3% 33.3 [10:6;35 Kapiga, 2003 21 32 0.3% 45.1 [25:8;54 Kapiga, 2003 21 32 0.3% 65.6 [46:8;70 Kapiga, 2003 21 32 0.3% 65.6 [46:8;70 Kapiga, 2003 1 11 0.3% 9.1 [0:2;41 Kapiga, 2003 8 52 0.3% 65.6 [46:8;20 Kapiga, 2003 13 49 0.3% 26.5 [14:9;41						
Rakwar, 1997 65 130 0.3% 50.0 [41.1; 88] Ghebrekidan, 1999 33 73 0.3% 45.2 [33.5; 57] Ghebrekidan, 1999 23 53 0.3% 45.2 [33.5; 57] Ghebrekidan, 1999 10 48 0.3% 20.8 [77] Ghebrekidan, 1999 10 48 0.3% 20.8 [77] Kapiga, 2003 57 21.1 0.3% 20.8 [10.5; 35] Kapiga, 2003 14 42 0.3% 27.0 [21.1; 33] Kapiga, 2003 14 42 0.3% 59.2 [46.8; 70] Kapiga, 2003 21 32 0.3% 59.2 [46.8; 70] Kapiga, 2003 21 32 0.3% 70.6 [56.2; 82] Kapiga, 2003 1 11 0.3% 70.6 [56.2; 82] Kapiga, 2003 8 52 0.3% 70.6 [56.2; 82] <td>Intermediate-risk population</td> <td>s</td> <td></td> <td></td> <td></td> <td></td>	Intermediate-risk population	s				
Ghebrekidan, 1999 33 73	Rakwar, 1997	65	130		0.3%	50.0 [41.1; 58.9]
Ghebrekidan, 1999 23 53 0.3% 43.4 [29.8; 57] Ghebrekidan, 1999 10 48 0.3% 20.8 [10.5; 35] Holt, 2003 57 21.1 0.3% 27.0 [27.1; 33] Kapiga, 2003 14 42 0.3% 33.3 [19.6; 49] Kapiga, 2003 51 113 0.3% 59.2 [46.8; 70] Kapiga, 2003 21 32 0.3% 59.2 [46.8; 70] Kapiga, 2003 21 32 0.3% 65.6 [46.8; 70] Kapiga, 2003 21 32 0.3% 65.6 [46.8; 70] Kapiga, 2003 1 11 0.3% 70.6 [56.2; 82] Kapiga, 2003 8 52 0.3% 15.4 [6.9; 28] Kapiga, 2003 13 49 0.3% 26.5 [14.9; 41] Kapiga, 2003 11 34 0.3% 32.4 [17.4; 50] Kapiga, 2003 11 34 0.3% 32.2 [17.4; 50] Kapiga, 2003 27 60 0.3% </td <td>Ghebrekidan, 1999</td> <td>33</td> <td>73</td> <td></td> <td>0.3%</td> <td>45.2 [33.5; 57.3]</td>	Ghebrekidan, 1999	33	73		0.3%	45.2 [33.5; 57.3]
Ghebrekidan, 1999 10 48 0.3% 20.8 [10.5; 35] Holt, 2003 57 211 0.3% 27.0 [21.1; 33] Kapiga, 2003 14 42 0.3% 33.3 [19.6; 49] Kapiga, 2003 51 113 0.3% 45.1 [35.8; 54] Kapiga, 2003 42 71 0.3% 59.2 [46.8; 70] Kapiga, 2003 21 32 0.3% 70.6 [56.2; 82] Kapiga, 2003 36 51 0.3% 70.6 [56.2; 82] Kapiga, 2003 1 11 0.3% 9.1 [0.2; 41] Kapiga, 2003 13 49 0.3% 26.5 [14.9; 41] Kapiga, 2003 11 34 0.3% 32.4 [17.4; 50] Kapiga, 2003 27 60 0.3% 32.1; 58] Kapiga, 2003 0 22 0.3% 0.0 [0.0; 15] Kapiga, 2003	Ghebrekidan, 1999	23	53		0.3%	43.4 [29.8; 57.7]
Holt, 2003 57 211 0.3% 27.0 [21:1;33] Kapiga, 2003 14 42 0.3% 33.3 [19:6;49] Kapiga, 2003 51 113 0.3% 45.1 [35:8;54] Kapiga, 2003 42 71 0.3% 59.2 [46:8;70] Kapiga, 2003 21 32 0.3% 65.6 [46:8;81] Kapiga, 2003 36 51 0.3% 65.6 [46:8;81] Kapiga, 2003 1 11 0.3% 70.6 [56:2;82] Kapiga, 2003 1 11 0.3% 9.1 [0.2;41] Kapiga, 2003 13 49 0.3% 15.4 [6.9;28] Kapiga, 2003 11 34 0.3% 32.4 [17.4;50] Kapiga, 2003 27 60 0.3% 45.0 [3.2;1;58] Kapiga, 2003 0 22 0.3% 0.0 [0.0;15]	Ghebrekidan, 1999	10	48		0.3%	20.8 [10.5; 35.0]
Kapiga, 2003 14 42 0.3% 33.3 [19.6; 49] Kapiga, 2003 51 11.3 0.3% 45.1 [15.8; 54] Kapiga, 2003 42 71 0.3% 65.6 [46.8; 70] Kapiga, 2003 21 32 0.3% 65.6 [46.8; 70] Kapiga, 2003 21 32 0.3% 65.6 [46.8; 70] Kapiga, 2003 36 51 0.3% 65.6 [46.8; 81] Kapiga, 2003 36 51 0.3% 70.6 [56.2; 82] Kapiga, 2003 1 11 0.3% 9.1 [0.2; 41] Kapiga, 2003 8 52 0.3% 15.4 [6.9; 28] Kapiga, 2003 13 49 0.3% 26.5 [14.9; 41] Kapiga, 2003 11 34 0.3% 32.4 [17.4; 50] Kapiga, 2003 27 60 0.3% 32.4 [17.4; 50] Kapiga, 2003 0 22 0.3% 0.0 [0.0; 15]	Holt, 2003	57	211		0.3%	27.0 [21.1; 33.5]
Kapiga, 2003 51 113	Kapiga, 2003	14	42		0.3%	33.3 [19.6; 49.5]
Kapiga, 2003 42 71 0.3% 59.2 [46.8; 70] Kapiga, 2003 21 32 0.3% 65.6 [46.8; 81] Kapiga, 2003 36 51 0.3% 70.6 [56.2; 82] Kapiga, 2003 1 11 0.3% 9.1 [0.2; 41] Kapiga, 2003 8 52 0.3% 15.4 [6.9; 28] Kapiga, 2003 13 49 0.3% 26.5 [14.9; 41] Kapiga, 2003 11 34 0.3% 32.4 [17.4; 50] Kapiga, 2003 27 60 0.3% 45.0 [32.1; 58] Kapiga, 2003 0 22 0.3% 0.0 [0.0; 15]	Kapiga, 2003	51	113		0.3%	45.1 [35.8; 54.8]
Kapiga, 2003 21 32 0.3% 65.6 [46.8; 81 Kapiga, 2003 36 51 0.3% 70.6 [56.2; 82 Kapiga, 2003 1 11 0.3% 70.6 [56.2; 82 Kapiga, 2003 1 11 0.3% 9.1 [0.2; 41 Kapiga, 2003 8 52 0.3% 15.4 [6.9; 28 Kapiga, 2003 13 49 0.3% 26.5 [14.9; 41 Kapiga, 2003 11 34 0.3% 32.4 [17.4; 50 Kapiga, 2003 27 60 0.3% 45.0 [32.1; 58 Kapiga, 2003 0 22 0.3% 0.0 [0.0; 15	Kapiga, 2003	42	71	· · · · · ·	0.3%	59.2 [46.8; 70.7]
Kapiga, 2003 36 51 0.3% 70.6 [56.2; 82] Kapiga, 2003 1 11 0.3% 9.1 [0.2; 41] Kapiga, 2003 8 52 0.3% 9.1 [0.2; 41] Kapiga, 2003 13 49 0.3% 26.5 [14.9; 41] Kapiga, 2003 11 34 0.3% 32.4 [17.4; 50] Kapiga, 2003 27 60 0.3% 45.0 [32.1; 58] Kapiga, 2003 0 22 0.3% 0.0 [0.0; 15]	Kapiga, 2003	21	32		0.3%	65.6 [46.8; 81.4]
Kapiga, 2003 1 11 0.3% 9.1 [0.2; 41] Kapiga, 2003 8 52 0.3% 15.4 [6.9; 28] Kapiga, 2003 13 49 0.3% 26.5 [14.9; 41] Kapiga, 2003 11 34 0.3% 32.4 [17.4; 50] Kapiga, 2003 27 60 0.3% 45.0 [32.1; 58] Kapiga, 2003 0 22 0.3% 0.0 [0.0; 15]	Kapiga, 2003	36	51	· · · · · · · · · · · · · · · · · · ·	0.3%	70.6 [56.2; 82.5]
Kapiga, 2003 8 52 0.3% 15.4 [6.9; 28] Kapiga, 2003 13 49 0.3% 26.5 [14.9; 41] Kapiga, 2003 11 34 0.3% 32.4 [17.4; 50] Kapiga, 2003 27 60 0.3% 45.0 [32.1; 58] Kapiga, 2003 0 22 0.3% 0.0 [0.0; 15]	Kapiga, 2003	1	11		0.3%	9.1 [0.2; 41.3]
Kapiga, 2003 13 49 0.3% 26.5 [14.9; 41] Kapiga, 2003 11 34 0.3% 32.4 [17.4; 50] Kapiga, 2003 27 60 0.3% 45.0 [32.1; 58] Kapiga, 2003 0 22 0.3% 0.0 [0.0; 15]	Kapiga, 2003			I (0.3%	15/ [69.281]
Kapiga, 2003 11 34 0.3% 32.4 [17.4; 50] Kapiga, 2003 27 60 0.3% 45.0 [32.1; 58] Kapiga, 2003 0 22 0.3% 0.0 [0.0; 15]	Kapiga 2003	8	52			15.4 [0.5, 20.1]
Kapiga, 2003 27 60 0.3% 45.0 [32.1; 58 Kapiga, 2003 0 22 0.3% 0.0 [0.0; 15	rtapiga, 2000	8 13	52 49		0.3%	26.5 [14.9; 41.1]
Kapiga, 2003 0 22 0.3% 0.0 [0.0; 15	Kapiga, 2003	8 13 11	52 49 34		0.3% 0.3%	26.5 [14.9; 41.1] 32.4 [17.4; 50.5]
000 750 11 000 11 10 10 10 10 10 10 10 10 10 1	Kapiga, 2003 Kapiga, 2003	8 13 11 27	52 49 34 60		0.3% 0.3% 0.3%	13.4 [0.3, 20.1] 26.5 [14.9; 41.1] 32.4 [17.4; 50.5] 45.0 [32.1; 58.4]

Riedner, 2007 Tassiopoulos, 2007 Tassiopoulos, 2007 Tassiopoulos, 2007 Tassiopoulos, 2007 Tassiopoulos, 2007 Tassiopoulos, 2007 Tassiopoulos, 2007 Vallely, 2007 Vallely, 2007 Vallely, 2007 Vallely, 2007	669 17 27 132 164 57 59 64 59 40 213 571 342 170	753 83 297 283 73 73 73 73 113 354 705 391 382		0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3%	88.8 [86.4; 91.0] 20.5 [12.4; 30.8] 32.5 [22.6; 43.7] 44.4 [38.7; 50.3] 58.0 [52.0; 63.8] 78.1 [66.9; 86.9] 80.8 [69.9; 89.1] 87.7 [77.9; 94.2] 80.8 [69.9; 89.1] 35.4 [26.6; 45.0] 60.2 [54.9; 65.3] 81.0 [77.9; 83.8] 87.5 [83.8; 90.6] 41.8 52.00
Watson-Jones, 2007 Watson-Jones, 2007 Watson-Jones, 2007	574 712 710	766 801 770	* *	0.3% 0.3% 0.3%	74.9 [71.7; 78.0] 88.9 [86.5; 91.0] 92.2 [90.1; 94.0]
Ng'ayo, 2008 Ng'ayo, 2008 Ng'ayo, 2008 Ng'ayo, 2008	10 36 39 28	36 67 51 43		0.3% 0.3% 0.3% 0.3%	27.8 [14.2; 45.2] 53.7 [41.1; 66.0] 76.5 [62.5; 87.2] 65.1 [49.1; 79.0]
Ng'ayo, 2008 Kapiga, 2013 Kapiga, 2013 Kapiga, 2013	46 274 229 292	52 375 305	 + 	0.3% 0.3% 0.3%	88.5 [76.6; 95.6] 73.1 [68.3; 77.5] 75.1 [69.8; 79.8] 76.0 [71.5: 80.2]
Kapiga, 2013 Kapiga, 2013 Fixed effect model Random effects model	214 6169	412 8850	*	0.3% 0.3% 13.8%	51.9 [47.0; 56.9] 71.6 [70.6; 72.5] 56.5 [49.2; 63.7]
Heterogeneity: $I^2 = 98\%$, $\chi^2_{41} = 1846$.	.26 (p = 0)				
Ghebrekidan, 1999 Holt, 2003	86 132	107 203		0.3% 0.3%	80.4 [71.6; 87.4] 65.0 [58.0; 71.6]
Baeten, 2007 Kaul, 2007	972 322	1206 443	-+-*	0.3%	80.6 [78.3; 82.8] 72.7 [68.3; 76.8]
Baltzer, 2009 Braunstein, 2011a	121 478	139 800	+	0.3% 0.3%	87.1 [80.3; 92.1] 59.8 [56.3: 63.2]
Priddy, 2011	144	200		0.3%	72.0 [65.2; 78.1]
Vandepitte, 2011	821	1026	*	0.3%	80.0 [77.4; 82.4]
Vandenhoudt, 2013	404	200 479		0.3%	84.3 [80.8: 87.5]
Jespers, 2014	14	30		0.3%	46.7 [28.3; 65.7]
Masese, 2015	1442	1964	=	0.3%	73.4 [71.4; 75.4]
Fixed effect model Random effects model	5203	6883		 4 1%	76.2 [75.2; 77.2]
Heterogeneity: $I^2 = 96\%$, $\chi^2_{11} = 261.1$	9 (p < 0.01)			4.170	10.4 [10.0, 01.0]
HIV negative populations					
Serwadda, 2003 Mebta, 2008	287	496 317		0.3%	57.9 [53.4; 62.3]
Mehta, 2008	140	532	-	0.3%	26.3 [22.6; 30.3]
Mehta, 2008	147	562	-#-	0.3%	26.2 [22.6; 30.0]
Mehta, 2008	129	519		0.3%	24.9 [21.2; 28.8]
Menta, 2008 Mehta, 2008	93	374 294		0.3%	32.9 [28.1; 37.9]
Mehta, 2008	74	173		0.3%	42.8 [35.3; 50.5]
Nakubulwa, 2009	125	200		0.3%	62.5 [55.4; 69.2]
Fixed effect model Random effects model	1178	3467		 31%	33.5 [31.9; 35.1]
Heterogeneity: $I^2 = 97\%$, $\chi_8^2 = 278.22$	2 (p < 0.01)			01170	
HIV positive individuals and ind	lividuals in HIV o	liscordant	couples		
del Mar Pujades, 2002	38	70		0.3%	54.3 [41.9; 66.3]
del Mar Pujades, 2002 McClelland, 2002	200	57 210		0.3%	61.4 [47.6; 74.0] 95.2 [91.4:97.7]
Serwadda, 2003	174	248		0.3%	70.2 [64.0; 75.8]
Baeten, 2004	376	400	+	0.3%	94.0 [91.2; 96.1]
Todd, 2006	26	37		0.3%	70.3 [53.0; 84.1]
Nakubulwa, 2009	43	50 50		0.3%	86.0 [73.3: 94.2]
Roxby, 2011	254	296	-	0.3%	85.8 [81.3; 89.6]
Muiru, 2013	310	469		0.3%	66.1 [61.6; 70.4]
Mulru, 2013 Celum, 2014	232	469		0.3%	49.5 [44.9; 54.1]
Celum, 2014	964	1548	-	0.3%	62.3 [59.8; 64.7]
Celum, 2014	1012	1548	*	0.3%	65.4 [62.9; 67.7]
Jespers, 2014 Mebada, 2020	24	30		0.3%	80.0 [61.4; 92.3]
Mabede, 2020 Mabede, 2020	13	39		0.3%	33.3 [19.1.50.2]
Fixed effect model	4712	7140	۵		67.0 [65.9; 68.1]
Random effects model			\diamond	5.7%	67.4 [59.7; 74.6]
Heterogeneity: $I^{-} = 97\%$, $\chi_{16}^{-} = 620.4$	9 (p < 0.01)				

			i i		
STI clinic attendees and sy	mptomatic populat	ions			
Langeland, 1998	25	43		0.3%	58.1 [42.1; 73.0]
Langeland, 1998	26	36	· · · · · · · · · · · · · · · · · · ·	0.3%	72.2 [54.8; 85.8]
Langeland, 1998	13	61		0.3%	21.3 [11.9; 33.7]
Langeland, 1998	62	143	<u> </u>	0.3%	43.4 [35.1; 51.9]
Mostad, 2000	293	314	+	0.3%	93.3 [90.0; 95.8]
Mwansasu, 2002	16	19	· · · · · · · · · · · · · · · · · · ·	0.3%	84.2 [60.4; 96.6]
Mwansasu, 2002	39	50	· · · · · · · · · · · · · · · · · · ·	0.3%	78.0 [64.0; 88.5]
Nilsen, 2005	18	40		0.3%	45.0 [29.3: 61.5]
Nilsen, 2005	28	40	· · · · · · · · · · · · · · · · · · ·	0.3%	70.0 [53.5; 83.4]
Nilsen, 2005	31	40		0.3%	77.5 [61.5: 89.2]
Nilsen, 2005	32	40	· · · · · · · · · · · · · · · · · · ·	0.3%	80.0 [64.4; 90.9]
Nilsen, 2005	30	40		0.3%	75.0 [58.8: 87.3]
Nilsen, 2005	9	59		0.3%	15.3 7.2: 27.0
Nilsen, 2005	32	59	<u>+ -</u>	0.3%	54.2 [40.8: 67.3]
Nilsen, 2005	35	59	· · · · · · · · · · · · · · · · · · ·	0.3%	59.3 [45.7: 71.9]
Nilsen 2005	41	59	· · · · · · · · · · · · · · · · · · ·	0.3%	69.5 [56.1 80.8]
Nilsen 2005	35	59	÷	0.3%	59.3 [45.7:71.9]
Gorander 2006	106	129		0.3%	82 2 [74 5: 88 3]
Gorander, 2006	49	69		0.3%	71.0 [58.8; 81.3]
Suntoke 2009	73	95		0.3%	76.8 [67.1:84.9]
Fixed effect model	993	1454	•		70 2 [67 8: 72 6]
Random effects model	000	1404	\sim	6.5%	65 0 [53 6: 75 6]
Heterogeneity: $I^2 = 95\%$, $\chi^2_{19} =$	355.71 (p < 0.01)			0.070	
Other populations					
Van de Wijgert, 2009	1071	2199	÷ .	0.3%	48.7 [46.6; 50.8]
Okuku, 2011	34	304	+	0.3%	11.2 [7.9; 15.3]
Okuku, 2011	79	333	-	0.3%	23.7 [19.3; 28.7]
Okuku, 2011	64	166		0.3%	38.6 [31.1; 46.4]
Okuku, 2011	77	201		0.3%	38.3 [31.6; 45.4]
Okuku, 2011	98	191		0.3%	51.3 [44.0; 58.6]
Okuku, 2011	63	77		0.3%	81.8 [71.4; 89.7]
Kassa, 2019	500	1052	÷	0.3%	47.5 [44.5; 50.6]
Kassa, 2019	399	930	+	0.3%	42.9 [39.7; 46.2]
Kassa, 2019	153	550	-	0.3%	27.8 [24.1; 31.8]
Fixed effect model	2538	6003	\$		41.9 [40.6; 43.1]
Random effects model				3.4%	40.2 [31.7; 49.0]
Heterogeneity: $I^2 = 98\%$, $\chi_9^2 = 3\%$	376.05 (p < 0.01)				
Fixed effect model	61569	1//100			A1 7 [A1 5· 42 0]
Random effects model	01009	144130	'	100 0%	48.0 [41.0, 42.0]
Prediction interval			<u> </u>	100.0 /6	-0.0 [44.0, 51.0] [56.02.21
Heterogeneity: $I^2 = 99\% r^2$	= 39810.67 (n = 0)	Г			[5.6, 92.5]
Posidual hotorogonaity: $l^2 = 0.0$	-33010.07 (p - 0)	- 0) 0	20 40 60 80 400		
Residual helelogeneity. r = 98	, χ ₂₉₁ - 20040.97 (p	- 0, 0	40 00 00 100		
		1	13v-z seroprevalence (95% CI)		

B) Southern Africa

		.	Events per 100			
Author, Year	HSV-2 seropositive	Sample size	observations	W(Random)	Prev(%)	95%CI
General populations			1.1			
McFarland 1999	10	154	+	0.3%	6.5	[32:116]
McFarland 1999	124	731	+	0.3%	17.0	[14.3: 19.9]
McFarland, 1999	178	433	-	0.3%	41.1	[36.4: 45.9]
McFarland, 1999	186	332		0.3%	56.0	[50.5: 61.4]
McFarland, 1999	182	306		0.3%	59.5	[53.7: 65.0]
McFarland, 1999	123	200		0.3%	61.5	[54.4: 68.3]
McFarland, 1999	150	241		0.3%	62.2	[55.8; 68.4]
Gregson, 2001	34	59		0.3%	57.6	[44.1; 70.4]
Gregson, 2001	57	85		0.3%	67.1	[56.0; 76.9]
Weiss, 2001	51	221		0.3%	23.1	[17.7; 29.2]
Weiss, 2001	124	214		0.3%	57.9	[51.0; 64.6]
Weiss, 2001	107	167		0.3%	64.1	[56.3; 71.3]
Weiss, 2001	80	111		0.3%	72.1	[62.8; 80.2]
Weiss, 2001	66	82		0.3%	80.5	[70.3; 88.4]
Weiss, 2001	35	51	· · · · · · · · · · · · · · · · · · ·	0.3%	68.6	[54.1; 80.9]
Weiss, 2001	24	39		0.3%	61.5	[44.6; 76.6]
Weiss, 2001	1	106	-	0.3%	0.9	[0.0; 5.1]
Weiss, 2001	23	133		0.3%	17.3	[11.3; 24.8]
vveiss, 2001	49	117		0.3%	41.9	[32.8; 51.4]
Weiss, 2001	57	103		0.3%	55.3	[45.2; 65.1]
Weiss, 2001	30	40		0.3%	57.4	[44.1, 70.0]
Weiss, 2001 Woiss, 2001	30	49		0.3%	55.2	[40.2, 74.0]
Gwanzura 2002	21	105		0.3%	57	[30.3, 71.4]
Gwanzura, 2002	23	103	+	0.3%	11 9	[77:173]
Mbizvo 2002	12	44		0.3%	27.3	[15.0: 42.8]
Mbizvo 2002	62	169		0.3%	36.7	[29.4: 44.4]
Mbizvo 2002	90	180		0.3%	50.0	[42 5: 57 5]
Kietland, 2005	59	119		0.3%	49.6	[40.3: 58.9]
Kjetland, 2005	74	119		0.3%	62.2	[52.8; 70.9]
Kjetland, 2005	84	119		0.3%	70.6	[61.5; 78.6]
Kjetland, 2005	77	119		0.3%	64.7	[55.4; 73.2]
NIMH Collaborative HIV/STD Prevention Trial Group, 200	7 522	891	-	0.3%	58.6	[55.3; 61.8]
NIMH Collaborative HIV/STD Prevention Trial Group, 200	7 182	683	-	0.3%	26.6	[23.4; 30.1]
Birdthistle, 2008	87	746	+	0.3%	11.7	[9.4; 14.2]
Birdthistle, 2008	9	234	+	0.3%	3.8	[1.8; 7.2]
Birdthistle, 2008	8	134		0.3%	6.0	[2.6; 11.4]
Birdthistle, 2008	7	146	-	0.3%	4.8	[1.9; 9.6]
Birdthistle, 2008	15	137		0.3%	10.9	[6.3; 17.4]
Birdthistle, 2008	10	91		0.3%	11.0	[5.4; 19.3]
Birdthistle, 2008	9	26		0.3%	34.6	[17.2; 55.7]
Birdthistle, 2008	20	45		0.3%	44.4	[29.6; 60.0]
Birathistie, 2008	20	49		0.3%	40.8	[27.0; 55.8]
Cowan, 2008	2	1604		0.3%	0.1	[0.0; 0.4]
Cowan, 2008	2	1///		0.3%	0.1	[0.0, 0.4]
Cowan, 2008	0	1744		0.3%	0.4	[0.1, 0.0]
Glynn 2008	13	44		0.3%	29.5	[16.8: 45.2]
Glynn, 2008	10	43		0.3%	39.5	[25.0: 55.6]
Glynn 2008	30	55		0.3%	54.5	[40.6: 68.0]
Glynn, 2008	40	67		0.3%	59.7	[47.0: 71.5]
Glynn, 2008	46	70		0.3%	65.7	[53.4; 76.7]
Glynn, 2008	46	64		0.3%	71.9	[59.2; 82.4]
Glynn, 2008	12	75	_ 	0.3%	16.0	[8.6; 26.3]
Glynn, 2008	10	54		0.3%	18.5	[9.3; 31.4]
Glynn, 2008	22	52		0.3%	42.3	[28.7; 56.8]
Glynn, 2008	17	48		0.3%	35.4	[22.2; 50.5]
Glynn, 2008	25	52		0.3%	48.1	[34.0; 62.4]
Glynn, 2008	25	53		0.3%	47.2	[33.3; 61.4]
Glynn, 2008	8	20		0.3%	40.0	[19.1; 63.9]
Glynn, 2008	28	50		0.3%	56.0	[41.3; 70.0]
Glynn, 2008	33	54		0.3%	61.1	[46.9; 74.1]
Glynn, 2008	52	75		0.3%	69.3	[57.6; 79.5]
Glynn, 2008	42	57		0.3%	79.0	[60.3, 64.5]
Glypp, 2008	39	25		0.3%	70.0	[50.6: 87.9]
Glynn, 2008	10	20		0.3%	80.0	[56.3: 07.3]
Glynn, 2008	20	20		0.3%	60.6	[42 1. 77 1]
Glynn, 2008	20	13		0.3%	15.4	[1.9: 45 4]
Glvnn, 2008	4	15		0.3%	26.7	[7.8: 55.1]
Glynn, 2008	11	24		0.3%	45.8	[25.6; 67.2]
Glynn, 2008	27	55		0.3%	49.1	[35.4; 62.9]
Glynn, 2008	32	52		0.3%	61.5	[47.0; 74.7]
Glynn, 2008	22	41	· · · · · · · · · · · · · · · · · · ·	0.3%	53.7	[37.4; 69.3]
Glynn, 2008	34	44	· · · · · · · · · · · · · · · · · · ·	0.3%	77.3	[62.2; 88.5]
Glynn, 2008	11	22		0.3%	50.0	[28.2; 71.8]
Glynn, 2008	48	69		0.3%	69.6	[57.3; 80.1]
Glynn, 2008	66	246		0.3%	26.8	[21.4; 32.8]
Glynn, 2008	136	316		0.3%	43.0	[37.5; 48.7]
Glynn, 2008	124	208		0.3%	59.6	[52.6; 66.3]
Glynn, 2008	84	118		0.3%	71.2	[62.1; 79.2]
01 0000	10	70		0.00/	~ ~ ~	154 7. 74 01

30

Glynn, 2008
Glynn, 2008
Glynn, 2008 Glynn, 2008
Glynn 2008
Glynn, 2008
Glynn, 2008
Glynn, 2008
Glynn, 2008 Glynn, 2008
Glynn, 2008
Glynn, 2008
Glynn, 2008
Glynn, 2008
Jewkes, 2008
Jewkes, 2008
Jewkes, 2008
Benjamin, 2008
Benjamin, 2008
Kapina, 2009 Sobnawi-Tambekou, 2009
van de Wijgert. 2009
Chatterjee, 2010
Chatterjee, 2010
Delany-Moretlwe, 2010
Ferrand, 2010a
Ferrand, 2010b
Kurewa, 2010
Munjoma, 2010
Crucitti, 2011
Heffron 2011
Heffron, 2011
Gray, 2011
Gray, 2011
Gray, 2011
Baird 2012
Baird, 2012
Kenyon, 2013
Kenyon, 2013
Abdool Karim, 2014 Abdool Karim, 2014
Abdool Karim, 2014
Abdool Karim, 2014
Abdool Karim, 2014
Abdool Karim, 2014
Glynn, 2014 Glynn, 2014
Glynn, 2014
Luseno, 2014
Jespers, 2014
Jespers, 2014
Jespers, 2014
De Baetselier, 2015
Hazel, 2015
Hazel, 2015
Hazel, 2015
Hazel, 2015
Hazel, 2015
Hazel, 2015
Hazel, 2015 Passoe, 2015
Austrian, 2016
Achilles, 2016
Fearon, 2017
Fearon, 2017
Fearon, 2017 Fearon, 2017
Abbai, 2018
Abbai, 2018
Abbal, 2018
Abbai, 2018 Abbai, 2018



0.3% 52.9 $[27.8, 77.0]$ $0.3%$ 5.0 $[0.1; 24.9]$ $0.3%$ 53.0 $[40.3; 65.4]$ $0.3%$ 53.0 $[40.3; 65.4]$ $0.3%$ 62.2 $[46.5; 76.2]$ $0.3%$ 62.2 $[46.5; 76.2]$ $0.3%$ 0.0 $[0.0; 24.7]$ $0.3%$ 0.0 $[0.0; 24.7]$ $0.3%$ 0.7 $[3.6; 41.4]$ $0.3%$ 53.8 $[37.2; 69.9]$ $0.3%$ 53.1 $[34.7; 70.9]$ $0.3%$ 53.1 $[34.7; 70.9]$ $0.3%$ 53.1 $[34.7; 70.9]$ $0.3%$ 53.1 $[34.7; 70.9]$ $0.3%$ 53.1 $[34.7; 70.9]$ $0.3%$ 53.1 $[34.7; 70.9]$ $0.3%$ 53.1 $[7.6; 12.3]$ $0.3%$ 9.8 $[7.6; 12.3]$ $0.3%$ 9.8 $[7.6; 12.3]$ $0.3%$ 9.8 $[7.6; 12.3]$ $0.3%$ 9.8 $[7.6; 12.3]$ $0.3%$ 9.8 $[7.6; 22.6]$ $0.3%$ 9.8 $[7.6; 22.6]$ $0.3%$ 5.2 $[51.1; 55.3]$ $0.3%$ 5.2 $[51.1; 55.3]$ $0.3%$ 5.5 $[31.2; 22.6]$ $0.3%$ 5.5 $[31.2; 22.6]$ $0.3%$ 5.6 $[3.6; 8.1]$ $0.3%$ 5.6 $[3.6; 8.1]$ $0.3%$ 5.6 $[3.6; 8.1]$ $0.3%$ 5.6 $[3.6; 8.1]$ $0.3%$ 5.6 $[3.2; 23.7]$ $0.3%$ 5.6 $[3.2; 24.5]$ $0.3%$ 5.6 <th>0.3%</th> <th>63.9</th> <th>[51.7;</th> <th>74.9]</th>	0.3%	63.9	[51.7;	74.9]
0.3% 5.0 $[0.1; 24.9]$ $0.3%$ 44.4 $[25.5; 64.7]$ $0.3%$ 62.2 $[46.5; 76.2]$ $0.3%$ 62.2 $[46.5; 76.2]$ $0.3%$ 73.9 $[51.6; 89.8]$ $0.3%$ 0.0 $[0.0; 24.7]$ $0.3%$ 0.0 $[0.0; 24.7]$ $0.3%$ 66.7 $[48.2; 82.0]$ $0.3%$ 53.1 $[34.7; 70.9]$ $0.3%$ 53.1 $[34.7; 70.9]$ $0.3%$ 53.1 $[34.7; 70.9]$ $0.3%$ 53.1 $[34.7; 70.9]$ $0.3%$ 53.1 $[34.7; 70.9]$ $0.3%$ 66.7 $[4.9; 15.8]$ $0.3%$ 69.9 $[2.3; 15.5]$ $0.3%$ 69.9 $[5.1; 6.8]$ $0.3%$ 59.9 $[5.1; 6.8]$ $0.3%$ 59.9 $[5.1; 6.8]$ $0.3%$ 51.0 $[4.2; 45.4]$ $0.3%$ 51.0 $[4.2; 45.4]$ $0.3%$ 51.0 $[4.5; 14.$	0.3%	52.9	[27.8;	77.0]
0.3% 44.4 [2.0.3, 64.1] 0.3% 62.2 [40.3; 65.4] 0.3% 62.2 [46.5; 76.2] 0.3% 73.9 [51.6; 89.8] 0.3% 0.0 [0.0; 24.7] 0.3% 16.7 [3.6; 41.4] 0.3% 27.9 [15.3; 43.7] 0.3% 66.7 [48.2; 82.0] 0.3% 53.1 [34.7; 70.9] 0.3% 53.1 [34.7; 70.3] 0.3% 66.7 [48.2; 82.0] 0.3% 30.4 [27.0; 33.9] 0.3% 9.4 [4.9; 15.8] 0.3% 9.8 [7.6; 12.3] 0.3% 9.8 [7.6; 12.3] 0.3% 9.4 [4.9; 15.8] 0.3% 9.8 [51.1; 55.3] 0.3% 9.52 [51.1; 56.3] 0.3% 53.2 [51.7; 63.1] 0.3% 55.2 [51.7; 63.1] 0.3% 55.2 [51.7; 63.1] 0.3% 55.4 [3.6; 81.1] 0.3% 54.2 [2.2; 64.9] 0.3% 55.2 </td <td>0.3%</td> <td>5.0</td> <td>[0.1;</td> <td>24.9</td>	0.3%	5.0	[0.1;	24.9
0.3%62.2[46.5; 76.2]0.3%73.9[51.6; 89.8]0.3%87.5[67.6; 97.3]0.3%0.0[0.0; 24.7]0.3%16.7[3.6; 41.4]0.3%27.9[15.3; 43.7]0.3%53.8[37.2; 69.9]0.3%66.7[48.2; 82.0]0.3%27.1[23.9] 30.6]0.3%27.1[23.9] 30.6]0.3%30.4[27.0; 33.9]0.3%10.1[7.9; 12.6]0.3%9.8[7.6; 12.3]0.3%9.8[7.6; 12.3]0.3%9.9[5.1; 6.8]0.3%53.2[51.1; 55.3]0.3%53.2[51.7; 6.31]0.3%53.2[51.7; 6.31]0.3%55.2[51.7; 6.31]0.3%55.1[5.6]0.3%13.6[7.2; 22.6]0.3%13.6[7.2; 22.6]0.3%13.6[7.2; 22.6]0.3%13.6[7.2; 22.6]0.3%56.6[3.6; 8.1]0.3%54.4[51.4; 57.5]0.3%54.4[51.4; 57.5]0.3%54.4[51.4; 57.5]0.3%54.4[51.4; 57.5]0.3%54.4[51.4; 57.5]0.3%54.4[51.4; 57.5]0.3%54.6[3.2; 23.7]0.3%54.6[1.2; 24.9]0.3%54.7[2.2; 4.9]0.3%54.6[1.2; 24.9]0.3%54.6[1.2; 24.9]0.3%54.7[2.2; 4.8] </td <td>0.3%</td> <td>53.0</td> <td>[40.3]</td> <td>65.41</td>	0.3%	53.0	[40.3]	65.41
0.3% 73.9 $[51.6; 89.8]$ $0.3%$ 87.5 $[67.6; 97.3]$ $0.3%$ 0.0 $[0.0; 24.7]$ $0.3%$ 16.7 $[3.6; 41.4]$ $0.3%$ 53.8 $[37.2; 69.9]$ $0.3%$ 53.8 $[37.2; 69.9]$ $0.3%$ 53.1 $[34.7; 70.9]$ $0.3%$ 53.1 $[34.7; 70.9]$ $0.3%$ 27.1 $[23.9; 30.6]$ $0.3%$ 27.1 $[23.9; 30.6]$ $0.3%$ 27.1 $[23.9; 30.6]$ $0.3%$ 9.8 $[7.6; 12.3]$ $0.3%$ 9.8 $[7.6; 12.3]$ $0.3%$ 9.8 $[7.6; 12.3]$ $0.3%$ 9.4 $[4.9; 15.8]$ $0.3%$ 9.9 $[5.1; 6.8]$ $0.3%$ 5.2 $[51.7; 6.3]$ $0.3%$ 5.2 $[51.7; 6.3]$ $0.3%$ 5.2 $[51.7; 6.3]$ $0.3%$ 5.2 $[51.7; 6.3]$ $0.3%$ 5.6 $[3.6; 8.1]$ $0.3%$ 4.2 $[2.6; 6.3]$ $0.3%$ 13.6 $[7.2; 22.6]$ $0.3%$ 13.6 $[7.2; 22.6]$ $0.3%$ 5.6 $[3.6; 8.1]$ $0.3%$ 5.6 $[3.6; 8.1]$ $0.3%$ 5.6 $[3.6; 8.1]$ $0.3%$ 5.6 $[3.6; 8.1]$ $0.3%$ 5.6 $[3.2; 2.7]$ $0.3%$ 5.6 $[3.2; 2.7]$ $0.3%$ 5.6 $[3.2; 2.7]$ $0.3%$ 5.6 $[3.2; 2.7]$ $0.3%$ 5.6 $[3.2; 2.7]$ $0.3%$ 5.6 $[3.2; 2.7]$	0.3%	62.2	[46.5;	76.2
0.3% 87.5 $[67.6; 97.3]$ $0.3%$ 0.0 $[0.0; 24.7]$ $0.3%$ 16.7 $[3.6; 41.4]$ $0.3%$ 53.8 $[37.2; 69.9]$ $0.3%$ 53.1 $[34.7; 70.9]$ $0.3%$ 53.1 $[34.7; 70.9]$ $0.3%$ 53.1 $[23.9; 30.6]$ $0.3%$ 30.4 $[27.0; 33.9]$ $0.3%$ 30.4 $[27.0; 33.9]$ $0.3%$ 9.8 $[7.6; 12.3]$ $0.3%$ 9.8 $[7.6; 12.3]$ $0.3%$ 9.4 $[4.9; 15.8]$ $0.3%$ 9.9 $[5.1; 6.8]$ $0.3%$ 5.9 $[5.1; 6.8]$ $0.3%$ 5.2 $[51.7; 63.7]$ $0.3%$ 5.2 $[51.7; 63.7]$ $0.3%$ 5.2 $[51.7; 63.7]$ $0.3%$ 65.7 $[58.9; 72.1]$ $0.3%$ 4.2 $[2.6; 6.3]$ $0.3%$ 4.2 $[2.6; 6.3]$ $0.3%$ 4.5 $[31.2; 62.3]$ $0.3%$ 5.6 $[3.6; 8.1]$ $0.3%$ 5.6 $[3.6; 8.1]$ $0.3%$ 5.6 $[3.2; 8.7]$ $0.3%$ 5.6 $[3.2; 8.7]$ $0.3%$ 5.6 $[3.2; 8.9]$ $0.3%$ 5.6 $[3.2; 8.9]$ $0.3%$ 5.6 $[3.2; 8.9]$ $0.3%$ 5.6 $[3.2; 8.9]$ $0.3%$ 5.6 $[3.2; 8.9]$ $0.3%$ 5.6 $[3.2; 8.9]$ $0.3%$ 5.6 $[3.2; 8.9]$ $0.3%$ 5.7 $[5.5; 12.7]$ $0.3%$ 5.7 $[2.2; 2.4.8]$	0.3%	73.9	[51.6;	89.8
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	87.5	[67.6;	97.3]
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	0.0	[0.0;	24.7]
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	16.7	[3.6;	41.4
3.3%66.7[48.2; 82.0]0.3%53.1[34.7; 70.9]0.3%27.1[23.9; 30.6]0.3%30.4[27.0; 33.9]0.3%9.8[7.6; 12.3]0.3%9.8[7.6; 12.3]0.3%9.9[2.3; 15.5]0.3%9.4[4.9; 15.8]0.3%5.9[5.1; 6.8]0.3%5.9[5.1; 6.6]0.3%5.9[5.1; 6.6]0.3%5.2[51.1; 55.3]0.3%5.2[51.7; 63.1]0.3%6.7[58.9; 72.1]0.3%6.7[58.9; 72.1]0.3%4.2[2.6; 6.3]0.3%13.6[7.2; 22.6]0.3%13.6[7.2; 24.9]0.3%5.10[47.2; 54.9]0.3%5.6[3.6; 8.1]0.3%5.6[3.6; 8.1]0.3%5.6[3.6; 8.1]0.3%5.6[3.6; 8.1]0.3%5.6[43.0; 56.3]0.3%47.8[40.4; 55.3]0.3%5.3[49.7; 56.9]0.3%3.4[2.2; 4.9]0.3%8.6[6.3; 11.3]0.3%2.6[17.2; 28.9]0.3%3.6.1[25.9; 47.4]0.3%2.6[17.2; 28.9]0.3%3.6.1[25.9; 47.4]0.3%2.6[17.2; 28.9]0.3%3.6.1[25.9; 47.0]0.3%3.6.1[3.8; 9.2]0.3%4.1[37.4; 44.8]0.3%4.2[2.2; 4.9]0.3% <td>0.3%</td> <td>53.8</td> <td>[37 2·</td> <td>69.91</td>	0.3%	53.8	[37 2·	69.91
0.3% 53.1 $[34.7; 70.9]$ $0.3%$ 27.1 $[23.9; 30.6]$ $0.3%$ 27.1 $[23.9; 30.6]$ $0.3%$ 10.1 $[7.9; 12.6]$ $0.3%$ 9.8 $[7.6; 12.3]$ $0.3%$ 9.4 $[4.9; 15.8]$ $0.3%$ 9.4 $[4.9; 15.8]$ $0.3%$ 5.2 $[51.1; 55.3]$ $0.3%$ 5.2 $[51.7; 6.3, 1]$ $0.3%$ 5.2 $[51.7; 6.3, 1]$ $0.3%$ 5.2 $[51.7; 6.3, 1]$ $0.3%$ 5.2 $[51.7; 63.1]$ $0.3%$ 5.6 $[3.6; 8.72.1]$ $0.3%$ 4.2 $[2.6; 6.3]$ $0.3%$ 4.2 $[2.6; 6.3]$ $0.3%$ 4.5 $[31.2; 62.3]$ $0.3%$ 4.5 $[31.2; 62.3]$ $0.3%$ 4.5 $[31.2; 62.3]$ $0.3%$ 5.6 $[3.2; 2.5.6]$ $0.3%$ 5.6 $[3.2; 2.5.7]$ $0.3%$ 5.6 $[3.2; 2.5.7$	0.3%	66.7	[48.2;	82.0
0.3% 27.1 $[23.9; 30.6]$ $0.3%$ 30.4 $[27.0; 33.9]$ $0.3%$ 10.1 $[7.9; 12.6]$ $0.3%$ 9.8 $[7.6; 12.3]$ $0.3%$ 9.8 $[7.6; 12.3]$ $0.3%$ 9.4 $[4.9; 15.8]$ $0.3%$ 5.9 $[5.1; 6.8]$ $0.3%$ 5.9 $[5.1; 6.3]$ $0.3%$ 5.2 $[51.7; 63.1]$ $0.3%$ 5.2 $[51.7; 63.1]$ $0.3%$ 5.2 $[5.7; 63.1]$ $0.3%$ 5.2 $[5.7; 63.1]$ $0.3%$ 13.6 $[7.2; 22.6]$ $0.3%$ 13.6 $[7.2; 24.9]$ $0.3%$ 45.5 $[31.2; 62.3]$ $0.3%$ 5.6 $[3.3], [3.5]$ $0.3%$ 5.6 $[3.3], [3.5]$ $0.3%$ 45.2 $[34.9]$ $0.3%$ 45.5 $[31.2; 62.3]$ $0.3%$ 5.6 $[3.2; 23.7]$ $0.3%$ 5.6 $[3.2; 23.7]$ <td>0.3%</td> <td>53.1</td> <td>[34.7;</td> <td>70.9</td>	0.3%	53.1	[34.7;	70.9
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	27.1	[23.9;	30.6]
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	30.4	[27.0;	33.9]
$\begin{array}{llllllllllllllllllllllllllllllllllll$	0.3%	10.1	[7.9;	12.6
3.3% 9.4 $[4.9]$ 15.8 $0.3%$ 9.4 $[4.9]$ 15.8 $0.3%$ 5.9 $[5.1;$ 6.8 $0.3%$ 5.2 $[51.7;$ 6.3 $0.3%$ 5.2 $[51.7;$ 6.3 $0.3%$ 5.5 $[51.7;$ 6.3 $0.3%$ 65.7 $[58.9;$ 72.1 $0.3%$ 4.2 $[2.6;$ 6.3 $0.3%$ 4.2 $[2.6;$ 6.3 $0.3%$ 4.2 $[2.6;$ 6.3 $0.3%$ 51.0 $[47.2;$ 54.9 $0.3%$ 51.0 $[47.2;$ 54.9 $0.3%$ 54.4 $[51.4;$ 57.5 $0.3%$ 54.4 $[51.4;$ 57.5 $0.3%$ 54.4 $[51.4;$ 57.5 $0.3%$ 56.6 $[3.2;$ 38.11 $0.3%$ 56.6 $[4.3.2;$ 56.9 $0.3%$ 53.3 $[49.7$	0.3%	9.0 6.9	[23	15.5
0.3% 38.9 52.7 ; 45.4 $0.3%$ 5.9 $[5.1;$ 6.8 $0.3%$ 5.2 $[51.1;$ 65.3 $0.3%$ 55.2 $[51.7;$ 63.11 $0.3%$ 65.7 $[58.9;$ 72.11 $0.3%$ 42.2 $[2.6;$ 6.31 $0.3%$ 42.2 $[2.6;$ 6.31 $0.3%$ 42.5 $[31.2;$ 62.31 $0.3%$ 51.0 $[47.2;$ 54.91 $0.3%$ 54.4 $[51.4;$ 57.5 $0.3%$ 54.4 $[51.4;$ 57.51 $0.3%$ 54.4 $[51.4;$ 57.51 $0.3%$ 62.4 $[58.0;$ 66.71 $0.3%$ 47.3 $[43.2;$ 51.66 $0.3%$ 47.3 $[43.2;$ 36.11 $0.3%$ 47.8 $[40.4;$ 55.31 $0.3%$ 3.4 $[2.2;$ 4.99 $0.3%$ 3.4 $[$	0.3%	9.4	[4.9;	15.8
$\begin{array}{llllllllllllllllllllllllllllllllllll$	0.3%	38.9	[32.7;	45.4
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	5.9	[5.1;	6.8]
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	53.2	[51.1;	55.3]
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	57.5	[51.7;	63.1]
0.3% 0.1 $0.3%$ 1.2 $[2.6; 6.3]$ $0.3%$ 1.36 $[7.2; 22.6]$ $0.3%$ 1.36 $[7.2; 22.6]$ $0.3%$ 1.36 $[7.2; 22.6]$ $0.3%$ 1.36 $[7.2; 22.6]$ $0.3%$ 51.00 $[47.2; 54.9]$ $0.3%$ 46.5 $[3.12; 62.3]$ $0.3%$ 56.6 $[3.6; 8.1]$ $0.3%$ 62.4 $[58.0; 66.7]$ $0.3%$ 62.4 $[58.0; 66.7]$ $0.3%$ 47.3 $[43.2; 51.6]$ $0.3%$ 62.4 $[58.0; 66.7]$ $0.3%$ 14.6 $[10.2; 20.0]$ $0.3%$ 14.6 $[10.2; 20.0]$ $0.3%$ 47.8 $[40.4; 55.3]$ $0.3%$ 14.6 $[10.2; 20.0]$ $0.3%$ 53.3 $[49.7; 56.9]$ $0.3%$ 8.2 $[4.8; 12.8]$ $0.3%$ 61.1 13.8 92.9 $0.3%$ 22.6 $[17.2; 28.9]$ $0.3%$ 45.2 $[27.3; 64.0]$ $0.3%$ 42.3 $[39.3; 45.2]$	0.3%	88.9	[81.0;	94.3
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	4 2	[20.9,	6.3
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	13.6	[7.2;	22.6
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	1.3	[0.4;	3.4
$\begin{array}{llllllllllllllllllllllllllllllllllll$	0.3%	51.0	[47.2;	54.9]
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	46.5	[31.2;	62.3]
$\begin{array}{llllllllllllllllllllllllllllllllllll$	0.3%	5.6	[3.6;	8.1]
$\begin{array}{llllllllllllllllllllllllllllllllllll$	0.3%	54.4	[51.4;	57.5
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	02.4 17 3	[00.0;	51 6
14.6[10.2; 20.0] 0.3% 50.6[43.0; 58.1] 0.3% 50.6[43.0; 58.1] 0.3% 3.4[2.2; 4.9] 0.3% 3.4[2.2; 4.9] 0.3% 53.3[49.7; 56.9] 0.3% 7.0[14.3; 19.9] 0.3% 8.2[4.8; 12.8] 0.3% 7.0[14.3; 19.9] 0.3% 8.6[6.3; 11.3] 0.3% 22.6[17.2; 28.9] 0.3% 20[1.0; 3.6] 0.3% 6.1[3.8; 9.2] 0.3% 6.1[3.2; 8.9] 0.3% 42.3[39.3; 45.2] 0.3% 42.3[39.3; 45.2] 0.3% 42.3[39.3; 45.2] 0.3% 42.3[3.2; 8.9] 0.3% 42.3[3.2; 8.9] 0.3% 45.2[27.3; 64.0] 0.3% 45.2[27.3; 64.0] 0.3% 45.2[27.3; 64.0] 0.3% 41.1[37.4; 44.8] 0.3% 41.4[3.2; 70.3] 0.3% 44.4[13.2; 70.3] 0.3% 44.4[29.6; 60.0] 0.3% 41.1[9.9; 12.4] 0.3% 7.0[6.0; 8.1] 0.3% 7.0[6.0; 8.1] 0.3% 7.0[6.0; 8.1] 0.3% 7.0[6.0; 8.1] 0.3% 7.0[6.0; 8.1] 0.3% 7.0[6.0; 7.7; 6.2] 0.3% 6.2[4.4; 8.4] 0.3% 9.2[6.7; 12.2] 0.3% 9.2[6.7; 12.2] 0.3	0.3%	18.0	[13.2]	23 7
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	14.6	[10.2;	20.0
$\begin{array}{llllllllllllllllllllllllllllllllllll$	0.3%	50.6	[43.0;	58.1
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	47.8	[40.4;	55.3]
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	3.4	[2.2;	4.9]
$\begin{array}{llllllllllllllllllllllllllllllllllll$	0.3%	8.2	[4.8;	12.8
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	53.3 17.0	[49.7,	10 01
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	8.6	[63	11 3
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	22.6	[17.2;	28.9
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	36.1	[25.9;	47.4]
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	2.0	[1.0;	3.6]
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	6.1	[3.8;	9.2]
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	4.7	[1.5;	10.7
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	25.7	[23.2]	28.5
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	42.3	[39.3;	45.2
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	5.6	[3.2;	8.9
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	40.4	[31.1;	50.2]
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	36.7	[19.9;	56.1]
$\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$	0.3%	3.3	[0.1;	17.2
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	45.Z	[27.3,	04.0J
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	9.7	[3.6:	19.9
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	16.4	[8.2;	28.1
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	29.7	[15.9;	47.0]
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	44.4	[29.6;	60.0]
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	21.8	[13.2;	32.6]
0.3% 63.3 [43.9] 80.1 0.3% 63.3 [43.9] 80.1 0.3% 11.1 [9.9] 12.4] 0.3% 7.0 [6.0] 8.1] 0.3% 7.0 [6.0] 8.1] 0.3% 7.0 [6.0] 8.1] 0.3% 2.4 [1.3] 3.9] 0.3% 6.2 [4.4] 8.4] 0.3% 6.2 [4.4] 8.4] 0.3% 6.2 [4.4] 75.0] 0.3% 6.2 [50.7] 73.6] 0.3% 60.0 [67.7] 89.6] 0.3% 80.0 [68.7] 88.6] 0.3% 80.0 [68.7] 88.6] 0.3% 46.1 [41.1] 51.2]	0.3%	57.1	[43.2;	70.3
0.3% 11.1 [9.9] 12.4 0.3% 7.0 [6.0; 8.1] 0.3% 34.0 [27.5; 41.0] 0.3% 1.5 [0.7; 2.8] 0.3% 2.4 [1.3; 3.9] 0.3% 6.2 [4.4; 8.4] 0.3% 9.2 [6.7; 12.2] 0.3% 62.7 [50.7; 73.6] 0.3% 80.0 [67.7; 89.2] 0.3% 80.0 [68.7; 88.6] 0.3% 46.1 [41.1; 51.2]	0.3%	63.3	[43.9	80 1
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	11.1	[9.9;	12.4
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	7.0	[6.0;	8.1
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.3%	34.0	[27.5;	41.0]
0.3% 2.4 [1.3; 3.9] 0.3% 6.2 [4.4; 8.4] 0.3% 9.2 [6.7; 12.2] 0.3% 60.5 [44.4; 75.0] 0.3% 60.5 [44.4; 75.0] 0.3% 60.7 [50.7; 73.6] 0.3% 80.0 [67.7; 89.2] 0.3% 46.1 [41.1; 51.2]	0.3%	1.5	[0.7;	2.8]
0.3% 0.2 [4.4, 8.4] 0.3% 9.2 [6.7; 12.2] 0.3% 60.5 [44.4; 75.0] 0.3% 62.7 [50.7; 73.6] 0.3% 80.0 [67.7; 89.2] 0.3% 80.0 [68.7; 88.6] 0.3% 46.1 [41.1; 51.2]	0.3%	2.4	[1.3;	3.9] o /1
0.3% 60.5 [44.4] 75.0] 0.3% 62.7 [50.7] 73.6] 0.3% 80.0 [67.7] 89.2] 0.3% 80.0 [68.7] 88.6] 0.3% 46.1 [41.1] 51.2]	0.3%	0.2 9.2	[4.4; [6.7·	12 21
0.3% 62.7 [50.7; 73.6] 0.3% 80.0 [67.7; 89.2] 0.3% 80.0 [68.7; 88.6] 0.3% 46.1 [41.1; 51.2]	0.3%	60.5	[44.4	75.01
0.3% 80.0 [67.7; 89.2] 0.3% 80.0 [68.7; 88.6] 0.3% 46.1 [41.1; 51.2]	0.3%	62.7	[50.7:	73.6
0.3% 80.0 [68.7; 88.6] 0.3% 46.1 [41.1; 51.2]	0.3%	80.0	[67.7;	89.2]
0.3% 46.1 [41.1; 51.2]	0.3%	80.0	[68.7;	88.6]
	0.3%	46.1	[41.1;	51.2]

Bradley, 2018 Bradley, 2018 Br	$\begin{array}{c} 109\\ 147\\ 150\\ 212\\ 268\\ 263\\ 325\\ 1749\\ 1648\\ 1356\\ 1025\\ 15\\ 19\\ 18\\ 38\\ 34\\ 49\\ 295\\ 364\\ 320\\ 304\\ 121\\ 191\\ 247\\ 295\\ 309\\ 309\\ 283\\ 1657\\ 1539\\ 1192\\ 810\\ 15\\ 18\\ 19\\ 300\\ 30\\ 30\\ 34\\ 35\\ 209\\ 264\\ 279\\ 223\\ 22\\ 65\\ 15\\ 17\\ 17\\ 41\\ 50\\ 24\\ 55\\ 189\\ 306\\ 316\\ 297\\ 261\\ 223\\ 22\\ 65\\ 15\\ 17\\ 41\\ 55\\ 189\\ 306\\ 316\\ 297\\ 261\\ 223\\ 22\\ 65\\ 15\\ 17\\ 41\\ 55\\ 189\\ 306\\ 316\\ 297\\ 261\\ 220\\ 265\\ 746\\ 840\\ 713\\ 665\\ 604\\ 655\\ 604\\ 655\\ 208\\ 316\\ 316\\ 297\\ 261\\ 220\\ 265\\ 746\\ 840\\ 316\\ 297\\ 261\\ 200\\ 265\\ 746\\ 840\\ 316\\ 297\\ 261\\ 200\\ 200\\ 265\\ 746\\ 840\\ 316\\ 297\\ 261\\ 200\\ 200\\ 200\\ 200\\ 200\\ 200\\ 200\\ 20$	541 + 539 + 556 - 589 - 589 - 579 - 2317 - 1761 - 1427 - 311 + 294 + 340 + 314 + 301 + 292 + 266 + 1191 = 894 - 669 - 600 - 902 = 1057 = 908 = 907 = 894 - 894 - 669 - 600 - 902 = 1057 = 908 = 907 = 861 = 908 = 861 = 761 - 639 - 3034 - 2335 - 1574 - 1022 - 408 + 516 = 4577 = 711 - 556 - 4277 + 711 - 556 - 4277 + 124 + 64 - 1075 = 5577 = 124 + 64 - 1075 = 5577 = 124 + 64 - 4075 = 5577 = 124 + 64 - 1075 = 5577 = 124 + 64 - 1075 = 5577 = 124 + 64 - 1075 = 557 = 126 - 1226 = 1262 - 1262 - 1262 - 1262 - 1262 - 1262 - 1262 - 1262 - 1262 - 1266 - 1166 - 1266 - 1		0.3% 0.3%	$\begin{array}{c} 20.1 & [16.8; 23.8]\\ 27.3 & [23.6; 31.2]\\ 29.4 & [25.5; 33.6]\\ 38.1 & [34.1; 42.3]\\ 34.5 & [41.4; 49.6]\\ 45.4 & [41.3; 49.6]\\ 56.0 & [51.9; 60.1]\\ 63.0 & [61.1; 64.8]\\ 71.1 & [69.2; 73.0]\\ 77.0 & [75.0; 78.9]\\ 71.8 & [69.4; 74.2]\\ 4.8 & [2.7; 7.8]\\ 6.5 & [3.9; 9.9]\\ 5.3 & [3.2; 8.2]\\ 5.7 & [3.4; 8.9]\\ 12.6 & [9.1; 16.9]\\ 11.6 & [8.2; 15.9]\\ 18.4 & [13.9; 23.6]\\ 24.8 & [22.3; 27.3]\\ 40.7 & [37.5; 44.0]\\ 47.8 & [44.0; 51.7]\\ 50.7 & [46.6; 54.7]\\ 30.7 & [37.5; 44.0]\\ 47.8 & [44.0; 51.7]\\ 50.7 & [46.6; 54.7]\\ 51.7 & [44.0; 41.2]\\ 4.8 & [22.3; 27.3]\\ 40.7 & [37.5; 44.0]\\ 47.8 & [44.0; 41.2]\\ 51.7 & [44.0; 51.7]\\ 50.7 & [46.6; 54.7]\\ 52.7 & [24.3; 30.2]\\ 32.5 & [29.5; 35.7]\\ 35.9 & [32.7; 39.2]\\ 40.6 & [37.1; 44.2]\\ 44.3 & [40.4; 48.2]\\ 54.6 & [52.8; 56.4]\\ 75.9 & [63.9; 67.8]\\ 77.7 & [73.5; 77.8]\\ 79.3 & [76.6; 81.7]\\ 79.3 & [76.6; 81.7]\\ 71.1 & [3.8, 14.5]\\ 14.2 & [10.1; 19.2]\\ 21.8 & [19.3] & 24.6]\\ 57.1 & [33.6; 40.8]\\ 50.2 & [45.9; 54.4]\\ 52.2 & [47.4; 57.0]\\ 12.1 & [6.9; 19.2]\\ 26.6 & [16.3] & 39.1]\\ 3.8 & [2.8; 51.1]\\ 9.0 & [6.7; 11.7]\\ 18.8 & [12.4; 26.6]\\ 8.4 & [6.4; 10.8]\\ 50.2 & [45.9; 55.4]\\ 52.2 & [47.4; 57.0]\\ 12.1 & [6.9; 19.2]\\ 26.6 & [16.3] & 39.1]\\ 3.8 & [2.8; 51.1]\\ 9.0 & [6.7; 11.7]\\ 18.8 & [7.1; 85.9]\\ 7.3 & [76.2; 72.9]\\ 7.3 & [64.2; 72.9]\\ 7.3 & [64.2; 72.9]\\ 7.3 & [64.2; 72.9]\\ 7.3 & [74.7; 79.8]\\ 85.6 & [83.0; 87.9]\\ 91.5 & [89.1; 93.5]\\ 93.1 & [91.0; 94.9]\\ 17.0 & [14.9; 19.2]\\ 9.7 & [8.1; 11.5]\\ 9.7 & [8.1; 11.5]\\ 9.7 & [8.1; 11.5]\\ 9.7 & [8.1; 11.5]\\ 9.7 & [8.1; 11.5]\\ 9.7 & [8.1; 93.5]\\ 9.3 & [91.5] & [91.9]\\ 9.7 & [8.1; 11.5]\\ 9.7 & $
Mensch, 2020 Mensch, 2020 Fixed effect model	208 113 35427	1226 1166 100925 ↓		0.3% 0.3% 	17.0 [14.9; 19.2] 9.7 [8.1; 11.5] 31.3 [31.0; 31.6]
Random effects model Heterogeneity: l^2 = 99%, χ^2_{225} = 43422.5 (<i>p</i> = 0)		<	×	70.9%	35.8 [31.6; 40.0]
Intermediate-risk populations Meque, 2014 Meque, 2014 Meque, 2014 Fixed effect model Random effects model Heterogeneity: $l^2 = 95\%$, $\chi^2_2 = 42.06$ ($p < 0.01$)	78 102 68 248	179 145 85 409	*	0.3% 0.3% 0.3% 0.9%	43.6 [36.2; 51.2] 70.3 [62.2; 77.6] 80.0 [69.9; 87.9] 61.2 [56.4; 65.9] 65.0 [42.5; 84.6]

Higher-risk populations Cowan, 2005 Cowan, 2005 Cowan, 2005 Cowan, 2005 Cowan, 2005 Cowan, 2005 Ramjee, 2005 Fixed effect model Random effects model Heterogeneity: $I^2 = 91\%$, $\chi^2_6 = 69.16$ ($p < 0.01$)	25 71 70 46 48 30 348 638	54 — 90 85 47 50 30 416 772	♦ + 1 + 1 + 1	0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3%	46.3 [32.6; 60.4] 78.9 [69.0; 86.8] 82.4 [72.6; 89.8] 97.9 [88.7; 99.9] 96.0 [86.3; 99.5] 100.0 [88.4; 100.0] 83.7 [79.7; 87.1] 84.3 [81.6; 86.8] 86.5 [75.6; 94.7]
HIV negative populations Sutclife, 2002 Sutclife, 2002 Sutclife, 2002 Benjamin, 2008 Benjamin, 2008 Mavedzenge, 2011 Mavedzenge, 2011 Misana, 2012 Wand, 2013 Wand, 2013 Balkus, 2016 Balkus,	37 43 53 46 9 11 655 1250 208 333 455 591 690 140 141 454 186 2324 163 138 68 77 208 220 31 7038	$\begin{array}{cccccccccccccccccccccccccccccccccccc$		0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3%	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
HIV positive individuals and individuals in HIV discordant couples Sutclife, 2002 Sutclife, 2002 Sutclife, 2002 Benjamin, 2008 Benjamin, 2008 Benjamin, 2008 Cowan, 2008 Cowan, 2008 Cowan, 2008 Rabenau, 2010 Rabenau, 2010 Lewis, 2012a Lewis, 2012a Lewis, 2012a Perti, 2014 Lowe, 2019 Fixed effect model Random effects model Heterogeneity: $I^2 = 94\%$, $\chi^2_{15} = 270.74$ ($p < 0.01$)	62 59 60 63 40 37 258 175 412 783 119 42 479 463 116 202 3370	67 67 67 54 52 328 297 478 970 152 53 556 550 132 385 4275	+ + + + + + + + + + + + + + + + + + +	0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3%	92.5 [83.4; 97.5] 88.1 [77.8; 94.7] 94.0 [85.4; 98.3] 74.1 [60.3; 85.0] 71.2 [56.9; 82.9] 78.7 [73.6; 83.0] 58.9 [53.1; 64.6] 80.7 [78.3; [70.9; 84.6] 79.2 [65.9; 89.2] 86.0; 88.9] 84.2 [80.9; 87.1] 87.9 [81.1; 92.9] 52.5 [47.3; 57.6] 79.8 [78.5; 81.0] 80.9 [75.2; 86.0] [75.2; 86.0]

STI clinic attendees and symptomatic populations					
Morse, 1997	30	68		0.3%	44.1 [32.1; 56.7]
Morse, 1997	24	31	· · · · · · · · · · · · · · · · · · ·	0.3%	77.4 [58.9; 90.4]
Chen, 2000	13	45		0.3%	28.9 [16.4; 44.3]
Chen, 2000	90	226		0.3%	39.8 [33.4; 46.5]
Chen, 2000	78	161		0.3%	48.4 [40.5; 56.4]
Chen, 2000	41	60	· · · · · · · · · · · · · · · · · · ·	0.3%	68.3 [55.0; 79.7]
Chen, 2000	14	26		0.3%	53.8 [33.4: 73.4]
Chen 2000	10	15	·	0.3%	66 7 [38 4 88 2]
Chen 2000	10	21		0.3%	47.6 [25.7: 70.2]
Chen 2000	4	27 -		0.3%	14.8 [4.2: 33.7]
Chen 2000	59	212		0.3%	27.8 [21.9: 34.4]
Chen, 2000	92	209		0.3%	44.0 [37.2: 51.0]
Chen 2000	44	74	· · · · · · · · · · · · · · · · · · ·	0.3%	59.5 [47.4: 70.7]
Chen, 2000	10	21		0.3%	61 2 [42 2: 78 2]
Chen, 2000	13	10		0.3%	57 0 [22 5· 70 7]
Chen, 2000	10	19		0.3%	57.9 [55.5, 79.7]
	10	17		0.3%	JO.O [JZ.9, 01.0]
	31	41		0.3%	
Hoyo, 2005	76	95		0.3%	80.0 [70.5; 87.5]
O'Farrell, 2007	140	162		0.3%	86.4 [80.2; 91.3]
O'Farrell, 2007	347	480		0.3%	72.3 [68.1; 76.3]
Lewis, 2008	173	303		0.3%	57.1 [51.3; 62.7]
Paz-Bailey, 2009	216	309		0.3%	69.9 [64.5; 75.0]
Paz-Bailey, 2009	218	306		0.3%	71.2 [65.8; 76.2]
Mhlongo, 2010	35	92	-+	0.3%	38.0 [28.1; 48.8]
Mhlongo, 2010	85	279		0.3%	30.5 [25.1; 36.2]
Mhlongo, 2010	151	199		0.3%	75.9 [69.3; 81.6]
Mhlongo, 2010	126	211		0.3%	59.7 [52.8; 66.4]
Zimba, 2011	294	346		0.3%	85.0 [80.8; 88.6]
Lewis, 2013	670	1204	-	0.3%	55.6 [52.8; 58.5]
Lewis, 2013	945	1216	-	0.3%	77.7 [75.3; 80.0]
Phiri, 2013	85	105	_ 	0.3%	81.0 [72.1; 88.0]
Phiri, 2013	214	312		0.3%	68.6 [63.1; 73.7]
Esber, 2017	99	197		0.3%	50.3 [43.1; 57.4]
Kularatne, 2018	618	771	-	0.3%	80.2 [77.2: 82.9]
Kufa, 2020	68	155	<u>+</u>	0.3%	43.9 [35.9: 52.1]
Kufa, 2020	179	351		0.3%	51.0 [45.6: 56.3]
Kufa 2020	185	330		0.3%	56 1 [50 5: 61 5]
Fixed effect model	5504	8706	•		64 0 [63 0 65 0]
Random effects model			\diamond	11 5%	59 3 [53 5: 65 0]
Heterogeneity: $l^2 = 96\%$, $\chi^2_{36} = 977.26$ ($p < 0.01$)			-	11.070	00.0 [00.0, 00.0]
Other populations					
Chattenedbyoy, 2015	02	104		0.20/	90 / 191 0: 04 61
Chattopadhyay, 2015	109	220		0.3%	69.4 [01.9, 94.0]
Chattopadhyay, 2015	198	330		0.3%	56.6 [53.1; 63.9]
Fixed effect model	291	442	✓		66.9 [62.4; 71.2]
Heterogeneity: $l^2 = 98\%$, $\chi_1^2 = 41.9 (p < 0.01)$				0.6%	75.4 [41.0; 97.6]
		100005			
Fixed effect model	52516	128395	'		37.9 [37.6; 38.2]
Random effects model			\diamond	100.0%	44.1 [40.4; 47.8]
Prediction interval		=			[0.1; 96.9]
Heterogeneity: $I^{2} = 99\%$, $\chi^{2}_{318} = 56366.16 (p = 0)$		-			
Residual neterogeneity: $I^{-} = 99\%$, $\chi_{312}^{-} = 46303.38$ ($p = 0$)		0	20 40 60 80 100		
		H	SV-2 seroprevalence (95% CI)		

C) Western Africa

Author Year	HSV-2 seronositive	Sample size	Events per 100 observations	W(Random)	Prev(%)	95%CI
Concret nonviotione		oumple size	i	W(Random)	1100(70)	00/101
Shaw 2001	5	191	+	1 1%	26	[0.9 [,] 6.0]
Shaw, 2001	3	104	+-	1.0%	2.9	[0.6: 8.2]
Shaw, 2001	4	75		1.0%	5.3	[1.5; 13.1]
Shaw, 2001	10	61		1.0%	16.4	[8.2; 28.1]
Shaw, 2001	12	154	-	1.1%	7.8	[4.1; 13.2]
Shaw, 2001	32	153		1.1%	20.9	[14.8; 28.2]
Shaw, 2001	63	151		1.1%	41.7	[33.8; 50.0]
Shaw, 2001	57 420	11/		1.0%	48.7	[39.4; 58.1]
Weiss 2001	420	200		1.1%	90	[29.4, 34.3]
Weiss, 2001	34	195		1.1%	17.4	[12.4: 23.5]
Weiss, 2001	55	189	-	1.1%	29.1	[22.7; 36.1]
Weiss, 2001	41	114		1.0%	36.0	[27.2; 45.5]
Weiss, 2001	47	94		1.0%	50.0	[39.5; 60.5]
Weiss, 2001	39	68		1.0%	57.4	[44.8; 69.3]
Weiss, 2001	42	75		1.0%	56.0	[44.1; 67.5]
Weiss, 2001	2	172	*	1.1%	1.2	[0.1; 4.1]
	9	203	+	1.1%	5.4	[2.7, 9.0]
Weiss 2001	22	132		1.1%	16.7	[2.0, 0.0]
Weiss, 2001	22	82		1.0%	26.8	[17.6: 37.8]
Weiss, 2001	18	43		1.0%	41.9	[27.0; 57.9]
Weiss, 2001	19	52		1.0%	36.5	[23.6; 51.0]
Eltom, 2002	49	287	-	1.1%	17.1	[12.9; 21.9]
Eltom, 2002	55	479	*	1.1%	11.5	[8.8; 14.7]
Ashley-Morrow, 2004	28	97		1.0%	28.9	[20.1; 39.0]
Lagarde, 2004	129	1030		1.1%	12.5	[10.6; 14.7]
Thomas 2004	547	892		1.1%	61.3	[21.0, 20.3] [58.0 [.] 64.5]
Patnaik 2007	39	90		1.0%	43.3	[32.9: 54.2]
Kane, 2009	14	65		1.0%	21.5	[12.3; 33.5]
Kane, 2009	18	157		1.1%	11.5	[6.9; 17.5]
Kane, 2009	11	65		1.0%	16.9	[8.8; 28.3]
Kane, 2009	13	65		1.0%	20.0	[11.1; 31.8]
Kane, 2009	18	65		1.0%	27.7	[17.3; 40.2]
Kane, 2009 Kana, 2009	18	157		1.1%	11.5	[6.9; 17.5]
Kane, 2009 Kane, 2009	12	157		1.1%	0.7 21.7	[4.0, 13.0]
Kirakova-Samadoulougou 2011	35	438	+	1.1%	80	[56:109]
Kirakoya-Samadoulougou, 2011	196	1041	+	1.1%	18.8	[16.5; 21.3]
Kirakoya-Samadoulougou, 2011	117	469		1.1%	24.9	[21.1; 29.1]
Kirakoya-Samadoulougou, 2011	14	70		1.0%	20.0	[11.4; 31.3]
Kirakoya-Samadoulougou, 2011	18	260	+	1.1%	6.9	[4.2; 10.7]
Kirakoya-Samadoulougou, 2011	64	310	-	1.1%	20.6	[16.3; 25.6]
Kirakoya-Samadoulougou, 2011	87	214		1.1%	40.7	[34.0; 47.6]
Kirakoya-Samadoulougou, 2011	40	99 193	+	1.0%	40.4	[30.7, 50.7]
Kirakova-Samadoulougou 2011	38	358	+	1.1%	10.6	[76.143]
Kirakoya-Samadoulougou, 2011	39	144		1.1%	27.1	[20.0; 35.1]
Kirakoya-Samadoulougou, 2011	36	96	+	1.0%	37.5	[27.8; 48.0]
Béhanzin, 2012	397	1195	-	1.1%	33.2	[30.6; 36.0]
Béhanzin, 2012	181	998	+	1.1%	18.1	[15.8; 20.7]
Mawak, 2012	9	30		1.0%	30.0	[14.7; 49.4]
Mawak, 2012 Mawak, 2012	9	49		1.0%	18.4	[8.8; 32.0]
Mawak, 2012 Mawak, 2012	5	22		- 0.9%	22.7 50.0	[7.6, 45.4]
Mawak, 2012 Mawak 2012	2	23		0.9%	87	[23.0, 77.0]
Mawak, 2012 Mawak, 2012	7	16		0.9%	43.8	[19.8; 70.1]
Mawak, 2012	5	26	_	0.9%	19.2	[6.6; 39.4]
Cisse, 2015	50	53		─ + 1.0%	94.3	[84.3; 98.8]
Cisse, 2015	114	117		1.0%	97.4	[92.7; 99.5]
Anaedobe, 2019	17	56		1.0%	30.4	[18.8; 44.1]
Anaedobe, 2019	45	151		1.1%	29.8	[22.6; 37.8]
Anaedope, 2019 Katz, 2020	28	63		1.0%	44.4	[31.9; 57.5]
Nalz, 2020 Katz 2020	32	81 71	!	1.0%	39.5 15 5	[20.0, 51.0] [8.0·26.01
Katz, 2020	51	81		1.0%	63.0	[51.5: 73.4]
Katz, 2020	37	173		1.1%	21.4	[15.5; 28.3]
Fixed effect model	3959	16005	٥		23.1	[22.4; 23.7]
Random effects model			\diamond	70.6%	25.0	[20.9; 29.4]
Heterogeneity: $I^2 = 97\%$, $\chi^2_{67} = 244$	2.96 (p = 0)					

i.

Higher-risk populations					
Dada 1998	37	81		1 0%	45 7 [34 6· 57 1]
Dada, 1990	310	521	-	1 10/	50.5 [55.1:63.7]
Dada, 1990	100	164		1.170	55.5 [55.1, 05.7] 66 5 [59 7: 72 6]
Dada, 1990	109	104		1.170	
	14	30		1.0%	40.7 [20.3, 05.7]
Eltom, 2002	523	863	=	1.1%	60.6 [57.3; 63.9]
Nagot, 2005	206	329		1.1%	62.6 [57.1; 67.9]
Wade, 2005	98	440	+	1.1%	22.3 [18.5; 26.5]
Kane, 2009	3	12 ·		0.8%	25.0 [5.5; 57.2]
Kane, 2009	33	54		1.0%	61.1 [46.9; 74.1]
Kane, 2009	75	88		1.0%	85.2 [76.1; 91.9]
Kane, 2009	423	450	-	1.1%	94.0 [91.4; 96.0]
Low, 2011	430	689	-	1.1%	62.4 [58.7: 66.0]
Aho, 2014	170	201		1.1%	84.6 [78.8: 89.3]
Traore 2015	91	321		1 1%	28.3 [23.5: 33.6]
Fixed effect model	2522	4243	•		60 6 [59 1 62 1]
Pandom offects model	LULL	4245		14 5%	50 3 [/6 /· 71 6]
Hotorogonoity: $l^2 = 98\% m^2 = 860.83$ (n < 0.01)				14.5%	59.5 [40.4, 71.0]
Therefore the second s					
HIV pagative populations					
	4	05		4.00/	44 4 5 0 0 00 71
	4	35 -		1.0%	11.4 [3.2, 20.7]
Camara, 2012	8	35		1.0%	22.9 [10.4; 40.1]
Fixed effect model	12	70			16.8 [8.7; 26.7]
Random effects model			\diamond	2.0%	16.8 [7.1; 29.2]
Heterogeneity: $I^2 = 34\%$, $\chi_1^2 = 1.52$ ($p = 0.22$)					
HIV positive individuals and individuals in I	HIV discore	dant couples			
Camara, 2012	15	34	+	1.0%	44.1 [27.2; 62.1]
Camara, 2012	19	34		1.0%	55.9 [37.9; 72.8]
Camara, 2012	21	35		1.0%	60.0 [42.1; 76.1]
Camara, 2012	22	35		1.0%	62.9 [44.9; 78.5]
Obedisi-Omokanve, 2017	78	214		1.1%	36.4 [30.0: 43.3]
Obedisi-Omokanye, 2017	38	62		1.0%	61.3 [48.1: 73.4]
Yunusa 2019	3	49 -	<u> </u>	1.0%	61 [13:169]
	2	37 -+		1.0%	5.4 [0.7; 18.2]
	1	19 -	İ	0.9%	53 [01:260]
	1	20		1.0%	
Fixed affect model	100	20 ·		1.070	0.0 [0.0, 12.3]
Pixed effect model	199	547		0.0%	33.0 [29.7; 37.0]
Random effects model $\frac{2}{100}$ $\frac{100}{100}$ $\frac{100}{100}$				9.8%	29.9 [15.1; 47.1]
Heterogeneity: $I^{-} = 93\%$, $\chi_{9}^{-} = 135.59$ ($p < 0.01$)					
CTI aliais attendance and assure to matic second					
S I I clinic attendees and symptomatic popu	liations			4 00/	
Eltom, 2002	51	114		1.0%	44.7 [35.4; 54.3]
Eltom, 2002	38	259	-#-	1.1%	14.7 [10.6; 19.6]
Aryee, 2005	29	63	i — • —	1.0%	46.0 [33.4; 59.1]
Fixed effect model	118	436	\diamond		25.7 [21.7; 30.0]
Random effects model				3.1%	33.8 [12.4; 59.2]
Heterogeneity: $I^2 = 96\%$, $\chi_2^2 = 49.66$ ($p < 0.01$)					
-					
Fixed effect model	6810	21301	¢		30.2 [29.6; 30.8]
Random effects model			\diamond	100.0%	30.3 [25.5; 35.3]
Prediction interval		_			[0.1: 79.4]
Heterogeneity: $l^2 = 98\%$. $\gamma_{cc}^2 = 5506.65$ ($p = 0$)					
Residual heterogeneity: $I^2 = 97\%$, $\gamma_{ee}^2 = 3490.57$ ((0 = 0	0	20 40 60 80 100		
	,	ц	SV-2 seroprevalence (95% CI)		

D) Central Africa

Author Year	HSV-2 seropositive S	ample size	Events per 100 observations	W(Random)	Prev(%)	95%CI
Addiol, real	nov-z scropositive o	ampic size	observations	W(Random)	1100(70)	557601
General populations						
Weiss, 2001	34	238	*	2.2%	14.3	[10.1; 19.4]
Weiss, 2001	90	232		2.2%	30.0 68.5	[32.5, 45.4] [61.2: 75.1]
Weiss, 2001	92	131		2.2%	70.2	[61.6:77.9]
Weiss, 2001	70	90		2.2%	77.8	[67.8; 85.9]
Weiss, 2001	60	77		2.2%	77.9	[67.0; 86.6]
Weiss, 2001	37	50		2.1%	74.0	[59.7; 85.4]
Weiss, 2001	5	189	-	2.2%	2.6	[0.9; 6.1]
Weiss, 2001	15	207	*	2.2%	7.2	[4.1; 11.7]
Weiss, 2001	47	101		2.2%	29.2	[22.3; 30.9]
Weiss, 2001	54	92		2.2%	58.7	[47.9:68.9]
Weiss, 2001	37	67		2.1%	55.2	[42.6; 67.4]
Weiss, 2001	31	53		2.1%	58.5	[44.1; 71.9]
Eis-Hubinger, 2002	16	34		2.1%	47.1	[29.8; 64.9]
Eis-Hubinger, 2002	27	39		2.1%	69.2	[52.4; 83.0]
Eis-Hubinger, 2002	21	26		2.0%	80.8	[60.6; 93.4]
Eis-Hubinger, 2002	20	23		2.1%	82.6	[56.6, 69.5] [61.2: 95.0]
Eis-Hubinger, 2002	10	11		1.8%	90.9	[58.7: 99.8]
Eis-Hubinger, 2002	17	21		2.0%	81.0	[58.1; 94.6]
Volpi, 2004	54	123		2.2%	43.9	[35.0; 53.1]
Volpi, 2004	27	109		2.2%	24.8	[17.0; 34.0]
Ozouaki, 2006	234	355	-	2.2%	65.9	[60.7; 70.8]
Charpentier	86	548	*	2.2%	15.7 27 0	[12.7; 19.0]
Pixed effect model	1202	3212		53.2%	52 /	[30.1; 39.5]
Heterogeneity: $I^2 = 98\%$, γ	$\chi^2_{24} = 1064.99 \ (p < 0.01)$			55.270	52.4	[40.4, 04.0]
linker det servicter	-					
Higner-risk population	I S	1000		2 20%	21.5	[10.2:22.0]
longo 2017	203	48		2.2%	42	[19.2, 23.9]
longo, 2017	8	64		2.1%	12.5	[5.6; 23.2]
longo, 2017	11	72		2.1%	15.3	[7.9; 25.7]
longo, 2017	7	54		2.1%	13.0	[5.4; 24.9]
longo, 2017	6	41		2.1%	14.6	[5.6; 29.2]
longo, 2017	9	66 1579		2.1%	13.6	[6.4; 24.3]
Random effects model	300 I	15/0		15.0%	13.9	[17.0; 21.0]
Heterogeneity: $I^2 = 69\%$, ;	χ ₆ ² = 19.27 (ρ < 0.01)		-	10.070	10.0	[0.0, 10.0]
	200					
LeGoff, 2011	1	18		1.9%	5.6	[0.1; 27.3]
Fixed effect model	1	18 ·	\sim		5.6	[0.0; 22.3]
Random effects model	I		\sim	1.9%	5.6	[0.0; 22.3]
Heterogeneity: not applica	able					
STI clinic attendees an	nd symptomatic popula	tions				
Mbopi-keou, 2000	247	300		2.2%	82.3	[77.5; 86.5]
Eis-Hubinger, 2002	24	52		2.1%	46.2	[32.2; 60.5]
Eis-Hubinger, 2002	37	47		2.1%	/8./	[64.3; 89.3]
Eis-Hubinger, 2002	20	25		2.0%	80.0	[59.3, 93.2] [56.3: 94.3]
Eis-Hubinger, 2002	10	17		1.9%	64.7	[38.3: 85.8]
Vandepitte, 2007	13	17	· · · · · · · · · · · · · · · · · · ·	1.9%	76.5	[50.1; 93.2]
Vandepitte, 2007	109	146		2.2%	74.7	[66.8; 81.5]
Vandepitte, 2007	5	10		1.7%	50.0	[18.7; 81.3]
Vandepitte, 2007	21	40		2.1%	52.5	[36.1; 68.5]
Fixed offect model	145	289		2.2%	50.2	[44.3; 56.1]
Random effects model	040	305	\sim	22.4%	67.8	[56.6: 78.1]
Heterogeneity: $I^2 = 90\%$, ;	χ ₁₀ ² = 96.41 (<i>p</i> < 0.01)					[0010, 1011]
Other negulations						
Eis-Hubinger 2002	7	15		1.9%	46 7	[21.3: 73.4]
Eis-Hubinger, 2002	, 10	14		1.9%	71.4	[41.9: 91.6]
Eis-Hubinger, 2002	10	12		1.8%	83.3	[51.6; 97.9]
Eis-Hubinger, 2002	16	20		2.0%	80.0	[56.3; 94.3]
Fixed effect model	43	61	\sim		71.2	[58.7; 82.5]
Heterogeneity: $I^2 = 41\%$	$y_2^2 = 5.1 (p = 0.16)$			7.5%	71.1	[54.4; 85.5]
	ng 0.100					
Fixed effect model	. 2282	5832	٥		37.3	[36.1; 38.6]
Random effects model	I		\diamond	100.0%	49.6	[41.0; 58.3]
Heterogeneity: 1 ² = 97%	$x_{-}^{2} = 1854.63 (n = 0)$	ſ				[2.0; 97.1]
Residual heterogeneity: /2	$\chi^{4}_{42} = 96\%, \chi^{2}_{42} = 1185.77 \ (p - 3)^{2}$	< 0.01) C	0 20 40 60 80 10	0		
- /		l l	HSV-2 seroprevalence (95% CI)			

E) Mixed regions in sub-Saharan Africa

Author, Year	HSV-2 seropositive	Sample size	Events per 100 observations	W(Random)	Prev(%)	95%CI
HIV negative populations			ų g			
LeGoff, 2007	1001	2588	+	7.2%	38.7	[36.8; 40.6]
McCormack, 2010	1020	2587	+ 4	7.2%	39.4	[37.5; 41.3]
McCormack, 2010	967	2584	+ 8	7.2%	37.4	[35.6; 39.3]
McCormack, 2010	482	1002		7.1%	48.1	[45.0; 51.2]
Heffron, 2012	449	997	₩	7.1%	45.0	[41.9; 48.2]
Heffron, 2012	455	1006	-	7.1%	45.2	[42.1; 48.4]
Marazzo, 2015	438	1004	-	7.1%	43.6	[40.5; 46.8]
Marazzo, 2015	465	996	- 5	7.1%	46.7	[43.6; 49.8]
Marazzo, 2015	1622	2725	i i i i i i i i i i i i i i i i i i i	7.2%	59.5	[57.7; 61.4]
Marazzo, 2015	2029	3312	ц +	7.2%	61.3	[59.6; 62.9]
Marazzo, 2015	1982	3311	<u>i</u> +	7.2%	59.9	[58.2; 61.5]
Fixed effect model	10910	22112	<u>ه ا</u>		49.3	[48.7; 50.0]
Random effects model Heterogeneity: $I^2 = 99\%$, $\chi^2_{10} = 8$	857.87 (p < 0.01)		.	78.7%	47.7	[41.6; 53.9]
HIV positive individuals and	d individuals in HIV d	liscordant cou	uples			
ECHO trial consortium, 2019	1441	2393	+	7.2%	60.2	[58.2; 62.2]
ECHO trial consortium, 2019	1088	1283		7.1%	84.8	[82.7; 86.7]
Fixed effect model	2529	3676	♦		69.6	[68.1; 71.1]
Random effects model			1	14.3%	73.4	[46.7; 93.1]
Heterogeneity: $I^2 = 100\%$, $\chi_1^2 = 100\%$	265.18 (p < 0.01)					
STI clinic attendees and sv	mptomatic populatio	ns	С С С			
ECHO trial consortium. 2019	345	437	÷	7.0%	78.9	[74.8: 82.7]
Fixed effect model	345	437	\diamond		78.9	[75.0: 82.6]
Random effects model				7.0%	78.9	[75.0: 82.6]
Heterogeneity: not applicable			6 6 6 6			,
Fixed effect model	13784	26225	i. G		52.8	[52.2; 53.4]
Random effects model				100.0%	53.8	[46.6: 61.0]
Prediction interval						[24.2; 82.1]
Heterogeneity: $I^2 = 99\%$. $\gamma_{42}^2 = 2$	1807.60 (p = 0)					,, - --
Residual heterogeneity: $I^2 = 99$	%, $\chi^2_{11} = 1123.06 \ (p < 0)$.01) (0 20 40 60 80 10	0		
			HSV-2 seroprevalence (95% CI)			

Table S10. Univariable and multivariable meta-regression analyses for herpes simplex virus type 2 seroprevalence among the different at risk populations in sub-Saharan Africa using the year of data collection as a categorical variable or as a linear term (in replacement of year of publication).

			Outcome measures	Sample size	τ	Univariable analysis				Multivariab	le analysis	
			Total n	Total N	PP (05% CI)	n voluo	LR test	Adjusted	Model 1*		Model 2 [†]	
			Total II	Total N	KK (95 /6C1)	p-value	p-value	R ² (%)	ARR (95% CI)	p-value	ARR (95% CI)	p-value
		General populations	507	230,541	1.00	-	< 0.001	12.9	1.00	-	1.00	-
		Intermediate-risk populations	45	9,259	1.73 (1.35-2.21)	< 0.001			1.59 (1.31-1.92)	< 0.001	1.53 (1.26-1.85)	< 0.001
		Higher-risk populations	40	13,476	1.70 (1.31-2.20)	< 0.001			1.63 (1.33-2.01)	< 0.001	1.61 (1.31-1.98)	< 0.001
	Population	HIV negative populations	51	38,533	1.41 (1.12-1.78)	0.003			1.32 (1.08-1.62)	0.006	1.32 (1.08-1.61)	0.006
	type	HIV positive individuals and individuals	42	15,521	2.18 (1.70-2.80)	< 0.001			2.16 (1.77-2.64)	< 0.001	2.22 (1.82-2.72)	< 0.001
		STI clinic attendees and symptomatic populations	72	11,996	1.88 (1.54-2.28)	< 0.001			1.84 (1.56-2.17)	< 0.001	1.83 (1.55-2.15)	< 0.001
		Other populations	16	6,506	1.53 (1.03-2.27)	0.033			1.19 (0.88-1.61)	0.241	1.23 (0.91-1.66)	0.176
tic		<20 years	108	42,984	1.00	-	< 0.001	32.6	1.00	-	1.00	-
iris		20-30 years	144	55,344	2.49 (2.07-3.00)	< 0.001			2.49 (2.14-2.91)	< 0.001	2.52 (2.17-2.94)	< 0.001
cte	A go group	30-40 years	84	27,875	4.26 (3.46-5.24)	< 0.001			4.38 (3.68-5.21)	< 0.001	4.45 (3.74-5.30)	< 0.001
ıra	Age group	40-50 years	52	12,650	4.62 (3.64-5.86)	< 0.001			5.15 (4.21-6.29)	< 0.001	5.28 (4.32-6.45)	< 0.001
chɛ		>50 years	16	4,127	4.30 (2.96-6.24)	< 0.001			4.62 (3.39-6.30)	< 0.001	4.70 (3.45-6.41)	< 0.001
g		Mixed ages	369	182,852	3.10 (2.64-3.64)	< 0.001			2.39 (2.07-2.76)	< 0.001	2.38 (2.06-2.75)	< 0.001
ati		Women	447	204,899	1.00	-	< 0.001	4.7	1.00	-	1.00	-
TR.	Sex	Men	269	100,000	0.68 (0.60-0.78)	< 0.001			0.61 (0.56-0.68)	< 0.001	0.61 (0.56-0.67)	< 0.001
log		Mixed sexes	57	20,933	0.89 (0.70-1.12)	0.337			0.79 (0.65-0.95)	0.012	0.76 (0.63-0.93)	0.008
-		Eastern Africa	298	144,196	1.00	-	< 0.001	3.3	1.00	-	1.00	-
	African	Southern Africa	319	128,395	0.82 (0.72-0.94)	0.006			0.82 (0.73-0.93)	0.002	0.85 (0.75-0.95)	0.008
	subregion	Western Africa	94	21,301	0.63 (0.52-0.77)	< 0.001			0.60 (0.52-0.69)	< 0.001	0.60 (0.51-0.69)	< 0.001
	subregion	Central Africa	48	5,832	1.01 (0.78-1.31)	0.909			0.72 (0.58-0.89)	0.003	0.77 (0.62-0.95)	0.017
		Mixed regions	14	26,225	1.23 (0.79-1.91)	0.347			1.00 (0.47-2.15)	0.982	1.01 (0.47-2.17)	0.972
		LIC	326	123,156	1.00	-	0.027	0.7	1.00	-	1.00	-
	Country's	LMIC	285	107,905	0.86 (0.75-0.98)	0.030			0.98 (0.88-1.09)	0.763	0.97 (0.87-1.08)	0.665
	income	UMIC	145	63,908	0.89 (0.75-1.05)	0.195			1.16 (0.99-1.35)	0.062	1.14 (0.97-1.33)	0.100
		Mixed	17	30,863	1.35 (0.90-2.03)	0.141			0.85 (0.42-1.70)	0.657	0.87 (0.43-1.74)	0.701
		Western Blot	82	19,787	1.00	-	0.089	0.5	1.00	-	1.00	-
è.	Assay type	ELISA	681	304,639	0.86 (0.71-1.05)	0.157			1.05 (0.90-1.23)	0.510	1.02 (0.86-1.20)	0.784
cs log		Rapid test	10	1,406	0.55 (0.31-0.97)	0.041			0.75 (0.49-1.15)	0.198	0.73 (0.48-1.12)	0.160
isti	Somple size	≥100	740	324,163	1.00	-	0.634	0.0	-	-	-	-
the	Sample size	<100	33	1,669	1.07 (0.79-1.45)	0.654			-	-	-	-
act	Sampling	Probability based	311	165,963	1.00	-	< 0.001	3.6	1.00	-	1.00	-
ly i	method	Non-probability based	462	159,869	1.35 (1.20-1.53)	< 0.001			1.05 (0.93-1.17)	0.390	1.04 (0.92-1.16)	0.493
c Ĕ	Desponse	≥80%	255	142,489	1.00	-	< 0.001	4.0	1.00	-	1.00	-
Ś	response	<80%	153	57,722	0.95 (0.80-1.12)	0.564			1.17 (1.03-1.32)	0.015	1.18 (1.04-1.34)	0.007
	Tate	Unclear	365	125,621	1.34 (1.17-1.53)	< 0.001			1.27 (1.14-1.42)	< 0.001	1.27 (1.14-1.42)	< 0.001
es	Year of data	<2000	239	47,629	1.00	-	< 0.001	3.4	1.00	-	-	-
10C	collection	2000-2010	393	206,142	0.82 (0.71-0.99)	0.032			0.82 (0.73-0.92)	0.001	-	-
iria	category [§]	>2010	141	72,061	0.68 (0.56-0.80)	< 0.001			0.79 (0.68-0.92)	0.002		-
Te va	Year of data co	ollection	773	325,832	0.98 (0.97-0.99)	< 0.001	< 0.001	3.1	-	-	0.98 (0.98-0.99)	0.009

^{*}Variance explained by the multivariable model (adjusted R^2) = 57.68%.

[†] Variance explained by multivariable model 2 (adjusted R^2) = 57.58%.

 ‡ Sample size denotes the sample size of each study population found in the original publication.

⁸ The categories were set based on the observed median time between the year of publication and year of data collection of 5 years.

Abbreviations: ARR = Adjusted risk ratio, CI = Confidence interval, ELISA = Enzyme-linked immunosorbent assay, HSV-2 = Herpes simplex virus type 2, HIV = human immunodeficiency virus, LIC = Low-income country, LMIC = Lower-middle-income country, LR = Likelihood ratio, RR = Risk ratio, STI = Sexually transmitted infection, UMIC = Upper-middle-income country.

Table S11. Studies reporting proportions of HSV-2 virus isolation in clinically-diagnosed genital ulcer disease and in clinically-diagnosed genital herpes in sub-Saharan Africa.

Author, year	Year(s) of data collection	Country	Study site	Study design	Sampling method	Population	HSV-2 biological assay	Sample size	Proportion of HSV-2 detection (%)
Patients with clinically	v-diagnosed GUD						v		
Ahmed, 2003(210)	1999	Tanzania	Outpatient clinic	CS	Conv	Patients with GUD	PCR	50	73.0
Ahmed, 2003(210)	1999	Tanzania	Outpatient clinic	CS	Conv	Patients with GUD	PCR	52	42.0
Chen. 2000(160)	1993-94	South Africa	Outpatient clinic	CS	Conv	Men with GUD	PCR	538	35.9
Grav. 2009(211)	2002-06	Uganda	Community	CS	Conv	Circumcised men with GUD	PCR	25	48.0
Gray, 2009(211)	2002-06	Uganda	Community	CS	Conv	Uncircumcised men with GUD	PCR	56	39.4
Kamya 1995(212)	1990-91	Uganda	Outpatient clinic	CS	Conv	Patients with GUD	IF	98	32.7
Kularatne, 2018(163)	2007-15	South Africa	Outpatient clinic	CS	Conv	Patients with GUD	PCR	771	60.7
LeGoff 2007(209)	2003-05	Ghana and Central	Outpatient clinic	CS	Conv	Women with GUD	PCR	422	50.0
	2003 03	African Republic		65	Conv			422	50.0
Masaka, 2012(213)	2010	Zambia	Outpatient clinic	CS	Conv	Patients with GUD	PCR	200	28.0
Mayaud, 2008(214)	-	Burkina Faso	Community	CS	Conv	Women with GUD	PCR	37	49.0
Mungati, 2018(215)	2014-15	Zimbabwe	Outpatient clinic	CS	Conv	Patients with GUD	PCR	200	38.5
Mwansasu, 2002(111)	-	Tanzania	Community	CS	Conv	Patients with GUD	PCR	70	64.3
Nilsen, 2007(216)	1999-01	Tanzania	Outpatient clinic	CS	Conv	Patients with GUD	PCR	301	64.0
O'Farrell, 2007(168)	2004	South Africa	STI clinic	CS	Conv	Males with GUD	PCR	162	52.7
Oni, 1997(217)	1992	Nigeria	Outpatient clinic	CS	Conv	Males attending an STI clinic	CF and IF	24	8.3
Paz-Bailey.	2001-02	Botswana	Outpatient clinic	CS	Conv	Patients with GUD	PCR	137	58.0
2005(218)			· F						• • • •
Paz-Bailey	2005-06	South Africa	Outpatient clinic	CS	RS	Men with GUD taking acyclovir	PCR	309	69.9
2009(169)	2002 00	South Finited	o utpatient ennie	00	110		ron	207	0717
Paz-Bailey	2005-06	South Africa	Outpatient clinic	CS	RS	Men with GUD taking a placebo	PCR	306	72.2
2009(169)	2005 00	South / Infou	Outputient ennie	CD	itib	then will GOD taking a placebo	ren	500	, 2.2
Phiri $2013(170)$	2004-06	Malawi	Outpatient clinic	CS	Conv	Males and Females with GUD	PCR	398	67.0
Pickering $2005(219)$	1999-01	Uganda	Outpatient clinic	CS	Conv	Adult males and females presenting with GUD	PCR	202	47.0
Suptoke $2009(112)$	2002.06	Uganda	Community	CS CS	Conv	>10 years old patients with GUD	PCP	100	47.0 62.0
$T_{anton} = 2010(220)$	2002-00	Tanzania	Community		Conv	Women working in regreational facilities	PCP	22	18.2
Van dank andt	2004-00	I alizalila	Community	CS CS	DDC	ESW- with CUD	PCR	22	10.2
2013(100)	2008	Кепуа	Community	CS	KDS	FSWs with GOD	PCK	22	40.9
Vandepitte,	2008-09	Uganda	Community	CS	Conv	FSWs with GUD	PCR	62	35.0
2011(101)		6	-						
Zimba, 2011(171)	2005	Mozambique	Outpatient clinic	CS	Conv	Patients with GUD	PCR	76	62.0
Patients with clinically	v-diagnosed genital	herpes*							
Chen. 2000(160)	1993-94	South Africa	Outpatient clinic	CS	Conv	Men with genital herpes	PCR	193	100.0
Kamya, 1995(212)	1990-91	Uganda	Outpatient clinic	CS	Conv	Males and females with genital herpes	IF	35	91.4
Kularatne, 2018(163)	2007-15	South Africa	Outpatient clinic	CS	Conv	Patients with genital herpes	PCR	468	100.0
Lai. 2003(221)	1998	South Africa	Outpatient clinic	ČŠ	Conv	Genital herpes swabs collected in 1998	PCR	57	100.0
Lai 2003(221)	1993-94	South Africa	Outpatient clinic	CS	Conv	Genital herpes swabs collected in 1993	PCR	14	100.0
Morse $1997(167)$	1993-94	Lesotho	Outpatient clinic	CS	Conv	Patients with genital hernes	PCR	20	95.0
Mungati 2018(215)	2014-15	Zimbahwe	Outpatient clinic		Conv	Patients with genital herpes	PCP	20	98 7
Paz-Bailey	2014-15	South Africa	Outpatient clinic		Re	Men with genital herpes	PCP	//	53.0
2009(169)	2005-00	South Annea	Outpatient ennic	C3	Кð	men with genital herpes	FUK	431	55.0
Suntoke, 2009(112)	2002-06	Uganda	Community	CS	Conv	Patients with GUD testing positive for HSV	PCR	65	95.4

* Included studies did not distinguish between primary and recurrent genital herpes cases. Abbreviations: CF = Complement fixation, Conv = Convenience, CS = Cross sectional, FSWs = Female sex workers, GUD = Genital ulcer disease, HSV-2 = Herpes simplex virus type 2, IF = Immunofluorescence, PCR = Polymerase chain reaction, RCT = Randomized controlled trial, RS = Random sampling, STI = Sexually transmitted infections.

Figure S3. Forest plots presenting the outcomes of the pooled mean proportions of HSV-2 virus isolation in clinically-diagnosed genital ulcer disease (GUD) and in clinically-diagnosed genital herpes in sub-Saharan Africa.

A) Patients with GUD

			Events per 100			
Author, Year	HSV-2 positive	Sample size	observations	W(Random)	Prev(%)	95%CI
Kamya, 1995	32	98		3.4%	32.65	[23.52; 42.87]
Oni, 1997	2	24		2.6%	8.33	[1.03; 27.00]
Chen, 2000	43	180		3.5%	23.89	[17.86; 30.80]
Chen, 2000	78	159		3.5%	49.06	[41.05; 57.09]
Chen, 2000	72	199		3.5%	36.18	[29.50; 43.28]
Mwansasu, 2002	19	19		→ 2.5%	100.00	[82.35; 100.00]
Mwansasu, 2002	26	51		3.1%	50.98	[36.60; 65.25]
Ahmed, 2003	38	50		3.1%	76.00	[61.83; 86.94]
Ahmed, 2003	21	52		3.1%	40.38	[27.01; 54.90]
Paz-Bailey, 2005	80	137		3.5%	58.39	[49.67; 66.75]
Pickering, 2005	95	202		3.6%	47.03	[39.99; 54.16]
LeGoff, 2007	211	422		3.6%	50.00	[45.13; 54.87]
O'Farrell, 2007	87	162		3.5%	53.70	[45.71; 61.56]
Mayaud, 2008	18	37		2.9%	48.65	[31.92; 65.60]
Suntoke, 2009	33	50		3.1%	66.00	[51.23; 78.79]
Gray, 2009	12	25		2.7%	48.00	[27.80; 68.69]
Gray, 2009	22	56		3.2%	39.29	[26.50; 53.25]
Paz-Bailey, 2009	216	309		3.6%	69.90	[64.45; 74.97]
Paz-Bailey, 2009	221	306		3.6%	72.22	[66.84; 77.17]
Suntoke, 2009	29	50		3.1%	58.00	[43.21; 71.81]
Vandepitte, 2011	22	62		3.2%	35.48	[23.74; 48.66]
Zimba, 2011	47	76		3.3%	61.84	[49.98; 72.75]
Masaka, 2012	28	125		3.4%	22.40	[15.43; 30.72]
Masaka, 2012	9	17		2.4%	52.94	[27.81; 77.02]
Masaka, 2012	15	37		2.9%	40.54	[24.75; 57.90]
Phiri, 2013	83	104		3.4%	79.81	[70.81; 87.04]
Vandenhoudt, 2013	9	22		2.6%	40.91	[20.71; 63.65]
Phiri, 2013	184	294		3.6%	62.59	[56.78; 68.13]
Mungati, 2018	39	100		3.4%	39.00	[29.40; 49.27]
Mungati, 2018	38	100		3.4%	38.00	[28.48; 48.25]
Kularatne, 2018	468	771		3.7%	60.70	[57.15; 64.17]
Fixed effect model	2297	4296	\$		53.63	[52.11; 55.14]
Random effects model			$\overset{\cdot }{\diamondsuit}$	100.0%	50.75	[44.73; 56.77]
Prediction interval						[19.70; 81.49]
Heterogeneity: $I^2 = 93\%$, χ	$\chi^2_{30} = 423.64 \ (p < 0.12)$.01) [[]		Г		•
		C	0 20 40 60 80 1	00		

HSV-2 proportion (95% CI)

Abbreviations: HSV-2 = Herpes simplex virus type 2.

B) Patients with genital herpes

Author, Year	HSV-2 positive	Sample size	E	Events per 10 observations	10 5	W(Random)
Kamya, 1995	32	35				9.0%
Morse, 1997	19	20				8.7%
Chen, 2000	43	43			e	9.1%
Chen, 2000	78	78				9.2%
Chen, 2000	72	72				9.2%
Lai, 2003	57	57				9.2%
Lai, 2003	14	14				8.4%
Paz-Bailey, 2009	239	451				9.4%
Suntoke, 2009	62	65				9.2%
Kularatne, 2018	468	468			4	9.4%
Mungati, 2018	76	77				9.2%
Fixed effect model	1160	1380			\$	
Random effects model			_		\checkmark	100.0%
Heterogeneity: $I^2 = 98\%$, γ	$\chi^2_{10} = 586.51 \ (p < 0.51)$.01)				
- • • • •	-10		20	40 60	80 100)

HSV-2 proportion (95% CI)

Prev(%)

95%CI

91.43 [76.94; 98.20] 95.00 [75.13; 99.87] 100.00 [91.78; 100.00] 100.00 [95.38; 100.00] 100.00 [95.01; 100.00] 100.00 [93.73; 100.00] 100.00 [76.84; 100.00] 52.99 [48.27; 57.68] 95.38 [87.10; 99.04] 100.00 [99.21; 100.00] 98.70 [92.98; 99.97] 92.32 [90.76; 93.76] 97.28 [84.45; 100.00] [22.76; 100.00]

Abbreviations: HSV-2 = Herpes simplex virus type 2.
Quality assessment	HSV-2 seroprevalence measures	
	Number of studies	%
Precision of seroprevalence measures ^a		
Low precision	34	10.6
High precision	288	89.4
Risk of bias quality domain ^b		
Sampling method		
Low risk of bias	88	27.3
High risk of bias	234	72.7
Response rate		
Low risk of bias	85	26.4
High risk of bias	45	14.0
Unclear risk of bias	192	59.6
Summary of the risk of bias assessment		
Low risk of bias		
In at least one quality domain	107	33.2
In both quality domains	39	12.1
High risk of bias		
In at least one quality domain	91	28.3
In both quality domains	23	7.1
Seroprevalence studies where risk of bias assessment was possible	322	100

Table S12. Summary of the precision assessment and risk of bias assessment for the studies reporting HSV-2 seroprevalence in sub-Saharan Africa.

^a Precision was assessed based on the overall sample size (not each stratum subsample size) of the study as reported in the record/publication.

^bRisk of bias was assessed based on the overall sample size (not each stratum subsample size) of the study as reported in the record/publication.

Abbreviations: HSV-2 = Herpes simplex virus type 2.

References

1. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine. 2009;6(7):e1000097.

2. West Africa Brief (Actualite Ouest-Africaine). The six regions of the African Union 2017 [Available from: <u>http://www.west-africa-brief.org/content/en/six-regions-african-union</u>, Accessed on June, 2019.

3. World Bank. World Bank Country and Lending Groups (Available at: <u>https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups</u>. Accessed in June 2017) 2017 [

4. Abdool Karim Q, Kharsany AB, Leask K, Ntombela F, Humphries H, Frohlich JA, et al. Prevalence of HIV, HSV-2 and pregnancy among high school students in rural KwaZulu-Natal, South Africa: a biobehavioural cross-sectional survey. Sexually transmitted infections. 2014;90(8):620-6.

5. Akinyi B, Odhiambo C, Otieno F, Inzaule S, Oswago S, Kerubo E, et al. Prevalence, incidence and correlates of HSV-2 infection in an HIV incidence adolescent and adult cohort study in western Kenya. PLoS One. 2017;12(6):e0178907.

6. Biraro S, Kamali A, White R, Karabarinde A, Nsiimire Ssendagala J, Grosskurth H, et al. Effect of HSV-2 on population-level trends in HIV incidence in Uganda between 1990 and 2007. Tropical medicine & international health : TM & IH. 2013;18(10):1257-66.

7. De Baetselier I, Menten J, Cuylaerts V, Ahmed K, Deese J, Van Damme L, et al. Prevalence and incidence estimation of HSV-2 by two IgG ELISA methods among South African women at high risk of HIV. PLoS One. 2015;10(3):e0120207.

8. del Mar Pujades Rodriguez M, Obasi A, Mosha F, Todd J, Brown D, Changalucha J, et al. Herpes simplex virus type 2 infection increases HIV incidence: a prospective study in rural Tanzania. Aids. 2002;16(3):451-62.

9. Hallfors DD, Cho H, Hartman S, Mbai I, Ouma CA, Halpern CT. Process Evaluation of a Clinical Trial to Test School Support as HIV Prevention Among Orphaned Adolescents in Western Kenya. Prevention science : the official journal of the Society for Prevention Research. 2017;18(8):955-63.

10. Heffron R, Chao A, Mwinga A, Sinyangwe S, Sinyama A, Ginwalla R, et al. High prevalent and incident HIV-1 and herpes simplex virus 2 infection among male migrant and non-migrant sugar farm workers in Zambia. Sexually transmitted infections. 2011;87(4):283-8.

11. Jewkes R, Nduna M, Levin J, Jama N, Dunkle K, Puren A, et al. Impact of stepping stones on incidence of HIV and HSV-2 and sexual behaviour in rural South Africa: cluster randomised controlled trial. BMJ (Clinical research ed). 2008;337:a506.

12. Kamali A, Nunn AJ, Mulder DW, Van Dyck E, Dobbins JG, Whitworth JA. Seroprevalence and incidence of genital ulcer infections in a rural Ugandan population. Sexually transmitted infections. 1999;75(2):98-102.

13. Kamali A, Quigley M, Nakiyingi J, Kinsman J, Kengeya-Kayondo J, Gopal R, et al. Syndromic management of sexually-transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: a community randomised trial. Lancet (London, England). 2003;361(9358):645-52.

14. Kebede Y, Dorigo-Zetsma W, Mengistu Y, Mekonnen Y, Schaap A, Wolday D, et al. Transmission of herpes simplex virus Type 2 among factory workers in Ethiopia. The Journal of infectious diseases. 2004;190(2):365-72.

15. McFarland W, Gwanzura L, Bassett MT, Machekano R, Latif AS, Ley C, et al. Prevalence and incidence of herpes simplex virus type 2 infection among male Zimbabwean factory workers. The Journal of infectious diseases. 1999;180(5):1459-65.

16. Mensch BS, Grant MJ, Soler-Hampejsek E, Kelly CA, Chalasani S, Hewett PC. Does schooling protect sexual health? The association between three measures of education and STIs among adolescents in Malawi. Population studies. 2020;74(2):241-61.

17. Munjoma MW, Kurewa EN, Mapingure MP, Mashavave GV, Chirenje MZ, Rusakaniko S, et al. The prevalence, incidence and risk factors of herpes simplex virus type 2 infection among pregnant Zimbabwean women followed up nine months after childbirth. BMC women's health. 2010;10:2.

18. Nakubulwa S, Kaye DK, Bwanga F, Tumwesigye NM, Nakku-Joloba E, Mirembe FM. Incidence and risk factors for herpes simplex virus type 2 seroconversion among pregnant women in Uganda: A prospective study. Journal of infection in developing countries. 2016;10(10):1108-15.

19. Pettifor A, MacPhail C, Hughes JP, Selin A, Wang J, Gomez-Olive FX, et al. The effect of a conditional cash transfer on HIV incidence in young women in rural South Africa (HPTN 068): a phase 3, randomised controlled trial. The Lancet Global health. 2016;4(12):e978-e88.

20. Radebe F, Jemmott J, Klopper A, Jemmott L, O'Leary A, Ngwane Z, et al. Incidence and prevalence of sexually transmitted infections among school students in the eastern cape, South Africa. Sexually Transmitted Infections. 2011;87(SUPPL. 1):A30-A1.

21. Rosenberg M, Pettifor A, Duta M, Demeyere N, Wagner RG, Selin A, et al. Executive function associated with sexual risk in young South African women: Findings from the HPTN 068 cohort. PLoS One. 2018;13(4):e0195217.

22. Sobngwi-Tambekou J, Taljaard D, Lissouba P, Zarca K, Puren A, Lagarde E, et al. Effect of HSV-2 serostatus on acquisition of HIV by young men: results of a longitudinal study in Orange Farm, South Africa. The Journal of infectious diseases. 2009;199(7):958-64.

23. Stoner MCD, Edwards JK, Miller WC, Aiello AE, Halpern CT, Julien A, et al. Does partner selection mediate the relationship between school attendance and HIV/Herpes simplex virus-2 among adolescent girls and young women in South Africa: An analysis of HIV prevention trials network 068 data. Journal of Acquired Immune Deficiency Syndromes. 2018;79(1):20-7.

24. Tobian AA, Charvat B, Ssempijja V, Kigozi G, Serwadda D, Makumbi F, et al. Factors associated with the prevalence and incidence of herpes simplex virus type 2 infection among men in Rakai, Uganda. The Journal of infectious diseases. 2009;199(7):945-9.

25. Tobian AA, Kigozi G, Redd AD, Serwadda D, Kong X, Oliver A, et al. Male circumcision and herpes simplex virus type 2 infection in female partners: a randomized trial in Rakai, Uganda. The Journal of infectious diseases. 2012;205(3):486-90.

26. van de Wijgert JH, Morrison CS, Brown J, Kwok C, Van Der Pol B, Chipato T, et al. Disentangling contributions of reproductive tract infections to HIV acquisition in African Women. Sexually transmitted diseases. 2009;36(6):357-64.

27. Wagner HU, Van Dyck E, Roggen E, Nunn AJ, Kamali A, Schmid DS, et al. Seroprevalence and incidence of sexually transmitted diseases in a rural Ugandan population. International journal of STD & AIDS. 1994;5(5):332-7.

28. Kapiga SH, Sam NE, Shao JF, Masenga EJ, Renjifo B, Kiwelu IE, et al. Herpes simplex virus type 2 infection among bar and hotel workers in northern Tanzania: prevalence and risk factors. Sexually transmitted diseases. 2003;30(3):187-92.

29. Meque I, Dube K, Feldblum PJ, Clements AC, Zango A, Cumbe F, et al. Prevalence, incidence and determinants of herpes simplex virus type 2 infection among HIV-seronegative women at high-risk of HIV infection: a prospective study in Beira, Mozambique. PLoS One. 2014;9(2):e89705.

30. Ondondo RO, Ng'ang'a ZW, Mpoke S, Kiptoo M, Bukusi E. Incidence and prevalence of herpes simplex virus type-2 infections among fishermen in Kisumu, Kenya. International Journal of Infectious Diseases. 2014;21(SUPPL. 1):422.

31. Riedner G, Hoffmann O, Rusizoka M, Mmbando D, Maboko L, Grosskurth H, et al. Decline in sexually transmitted infection prevalence and HIV incidence in female barworkers attending prevention and care services in Mbeya Region, Tanzania. Aids. 2006;20(4):609-15.

32. Tassiopoulos KK, Seage G, 3rd, Sam N, Kiwelu I, Shao J, Ao TT, et al. Predictors of herpes simplex virus type 2 prevalence and incidence among bar and hotel workers in Moshi, Tanzania. The Journal of infectious diseases. 2007;195(4):493-501.

33. Braunstein SL, Ingabire CM, Kestelyn E, Uwizera AU, Mwamarangwe L, Ntirushwa J, et al. High human immunodeficiency virus incidence in a cohort of Rwandan female sex workers. Sexually transmitted diseases. 2011b;38(5):385-94.

34. Chohan V, Baeten JM, Benki S, Graham SM, Lavreys L, Mandaliya K, et al. A prospective study of risk factors for herpes simplex virus type 2 acquisition among high-risk HIV-1 seronegative women in Kenya. Sexually transmitted infections. 2009;85(7):489-92.

35. Kaul R, Nagelkerke NJ, Kimani J, Ngugi E, Bwayo JJ, Macdonald KS, et al. Prevalent herpes simplex virus type 2 infection is associated with altered vaginal flora and an increased susceptibility to multiple sexually transmitted infections. The Journal of infectious diseases. 2007;196(11):1692-7.

36. Masese L, Baeten JM, Richardson BA, Bukusi E, John-Stewart G, Jaoko W, et al. Incident herpes simplex virus type 2 infection increases the risk of subsequent episodes of bacterial vaginosis. The Journal of infectious diseases. 2014;209(7):1023-7.

37. Ramjee G, Williams B, Gouws E, Van Dyck E, De Deken B, Karim SA. The impact of incident and prevalent herpes simplex virus-2 infection on the incidence of HIV-1 infection among commercial sex workers in South Africa. Journal of acquired immune deficiency syndromes (1999). 2005;39(3):333-9.

38. Traore IT, Hema MN, Meda N, Konate I, Some F, Bazie W, et al. Effect of a tailored intervention package on HIV-1 acquisition among young female sex workers in ouagadougou, Burkina Faso. Sexually Transmitted Infections. 2013;89(SUPPL. 1).

39. de Bruyn G, Shiboski S, van der Straten A, Blanchard K, Chipato T, Ramjee G, et al. The effect of the vaginal diaphragm and lubricant gel on acquisition of HSV-2. Sexually transmitted infections. 2011;87(4):301-5.

40. McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet (London, England). 2010;376(9749):1329-37.

41. Mehta SD, Moses S, Parker CB, Agot K, Maclean I, Bailey RC. Circumcision status and incident herpes simplex virus type 2 infection, genital ulcer disease, and HIV infection. Aids. 2012;26(9):1141-9.

42. Mehta SD, Moses S, Agot K, Maclean I, Odoyo-June E, Li H, et al. Medical male circumcision and herpes simplex virus 2 acquisition: posttrial surveillance in Kisumu, Kenya. The Journal of infectious diseases. 2013;208(11):1869-76.

43. Mlisana K, Naicker N, Werner L, Roberts L, Van Loggerenberg F, Baxter C, et al. Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa. Journal of Infectious Diseases. 2012;206(1):6-14.

44. Perti T, Nyati M, Gray G, De Bruyn G, Selke S, Magaret A, et al. Frequent genital HSV-2 shedding among women during labor in Soweto, South Africa. Infectious diseases in obstetrics and gynecology. 2014;2014:258291.

45. Celum C, Morrow RA, Donnell D, Hong T, Hendrix CW, Thomas KK, et al. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial. Annals of internal medicine. 2014;161(1):11-9.

46. Cowan FM, Humphrey JH, Ntozini R, Mutasa K, Morrow R, Iliff P. Maternal Herpes simplex virus type 2 infection, syphilis and risk of intra-partum transmission of HIV-1: results of a case control study. Aids. 2008a;22(2):193-201.

47. Muiru AN, Guthrie BL, Bosire R, Merkel M, Liu AY, Choi RY, et al. Incident HSV-2 infections are common among HIV-1-discordant couples. The Journal of infectious diseases. 2013;208(7):1093-101.

48. Okuku HS, Sanders EJ, Nyiro J, Ngetsa C, Ohuma E, McClelland RS, et al. Factors associated with herpes simplex virus type 2 incidence in a cohort of human immunodeficiency virus type 1-seronegative Kenyan men and women reporting high-risk sexual behavior. Sexually transmitted diseases. 2011;38(9):837-44.

49. Amornkul PN, Vandenhoudt H, Nasokho P, Odhiambo F, Mwaengo D, Hightower A, et al. HIV prevalence and associated risk factors among individuals aged 13-34 years in Rural Western Kenya. PLoS One. 2009;4(7):e6470.

50. Anjulo AA, Abebe T, Hailemichael F, Mihret A. Seroprevalence and risk factors of herpes simplex virus-2 among pregnant women attending antenatal care at health facilities in Wolaita zone, Ethiopia. Virology journal. 2016;13:43.

51. Behling J, Chan AK, Zeh C, Nekesa C, Heinzerling L. Evaluating HIV Prevention Programs: Herpes Simplex Virus Type 2 Antibodies as Biomarker for Sexual Risk Behavior in Young Adults in Resource-Poor Countries. PLoS One. 2015;10(5):e0128370.

52. Braunstein SL, Ingabire CM, Geubbels E, Vyankandondera J, Umulisa MM, Gahiro E, et al. High burden of prevalent and recently acquired HIV among female sex workers and female HIV voluntary testing center clients in Kigali, Rwanda. PLoS One. 2011a;6(9):e24321.

53. De Walque D, Dow WH, Nathan R, Abdul R, Abilahi F, Gong E, et al. Incentivising safe sex: A randomised trial of conditional cash transfers for HIV and sexually transmitted infection prevention in rural Tanzania. BMJ Open. 2012;2(1):000747.

54. Dhont N, van de Wijgert J, Luchters S, Muvunyi C, Vyankandondera J, Temmerman M. Sexual violence, HSV-2 and HIV are important predictors for infertility in Rwanda. Human reproduction (Oxford, England). 2010;25(10):2507-15.

55. Doyle AM, Ross DA, Maganja K, Baisley K, Masesa C, Andreasen A, et al. Long-term biological and behavioural impact of an adolescent sexual health intervention in Tanzania: follow-up survey of the community-based MEMA kwa Vijana Trial. PLoS medicine. 2010;7(6):e1000287.

56. Duflo E, Dupas P, Kremer M. Education, HIV, and Early Fertility: Experimental Evidence from Kenya. The American economic review. 2015;105(9):2757-97.

57. Ghebrekidan H, Ruden U, Cox S, Wahren B, Grandien M. Prevalence of herpes simplex virus types 1 and 2, cytomegalovirus, and varicella-zoster virus infections in Eritrea. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 1999;12(1):53-64.

58. Ghebremichael M, Paintsil E. High risk behaviors and sexually transmitted infections among men in Tanzania. AIDS and behavior. 2011;15(5):1026-32.

59. Ghebremichael M, Habtzgi D, Paintsil E. Deciphering the epidemic synergy of herpes simplex virus type 2 (HSV-2) on human immunodeficiency virus type 1 (HIV-1) infection among women in sub-Saharan Africa. BMC research notes. 2012;5:451.

60. Gorander S, Mbwana J, Lyamuya E, Lagergard T, Liljeqvist JA. Mature glycoprotein g presents high performance in diagnosing herpes simplex virus type 2 infection in sera of different tanzanian cohorts. Clinical and vaccine immunology : CVI. 2006;13(6):633-9.

61. Guwatudde D, Wabwire-Mangen F, Eller LA, Eller M, McCutchan F, Kibuuka H, et al. Relatively low HIV infection rates in rural Uganda, but with high potential for a rise: a cohort study in Kayunga District, Uganda. PLoS One. 2009;4(1):e4145.

62. Hallfors DD, Cho H, Mbai, II, Millimo BW, Atieno C, Okumu D, et al. Disclosure of HSV-2 serological test results in the context of an adolescent HIV prevention trial in Kenya. Sexually transmitted infections. 2015;91(6):395-400.

63. Hokororo A, Kihunrwa A, Hoekstra P, Kalluvya SE, Changalucha JM, Fitzgerald DW, et al. High prevalence of sexually transmitted infections in pregnant adolescent girls in Tanzania: a multi-community cross-sectional study. Sexually transmitted infections. 2015;91(7):473-8.

64. Holt BY, Effler P, Brady W, Friday J, Belay E, Parker K, et al. Planning STI/HIV prevention among refugees and mobile populations: situation assessment of Sudanese refugees. Disasters. 2003;27(1):1-15.
65. Jespers V, Crucitti T, Menten J, Verhelst R, Mwaura M, Mandaliya K, et al. Prevalence and correlates of bacterial vaginosis in different sub-populations of women in sub-Saharan Africa: a cross-sectional study. PloS one. 2014;9(10):e109670.

66. Kamali A, Kinsman J, Nalweyiso N, Mitchell K, Kanyesigye E, Kengeya-Kayondo JF, et al. A community randomized controlled trial to investigate impact of improved STD management and behavioural interventions on HIV incidence in rural Masaka, Uganda: trial design, methods and baseline findings. Tropical medicine & international health : TM & IH. 2002;7(12):1053-63.

67. Kapiga SH, Ewings FM, Ao T, Chilongani J, Mongi A, Baisley K, et al. The epidemiology of HIV and HSV-2 infections among women participating in microbicide and vaccine feasibility studies in Northern Tanzania. PLoS One. 2013;8(7):e68825.

68. Kasubi MJ, Nilsen A, Marsden HS, Bergstrom T, Langeland N, Haarr L. Prevalence of antibodies against herpes simplex virus types 1 and 2 in children and young people in an urban region in Tanzania. Journal of clinical microbiology. 2006;44(8):2801-7.

69. Kuteesa MO, Weiss HA, Cook S, Seeley J, Ssentongo JN, Kizindo R, et al. Epidemiology of alcohol misuse and illicit drug use among young people aged 15-24 years in fishing communities in Uganda. International Journal of Environmental Research and Public Health. 2020;17 (7) (no pagination)(2401).

70. Mehta SD, Nordgren RK, Agingu W, Otieno F, Odongo W, Odhiambo F, et al. Sexual Quality of Life and Association With HIV and Sexually Transmitted Infections Among a Cohort of Heterosexual Couples in Kenya. Journal of Sexual Medicine. 2018;15(10):1446-55.

71. MOH Uganda, ORC Macro. Uganda HIV/AIDS sero-behavioural survey: 2004-2005. Calverton, Maryland, USA: Ministry of Health and ORC Macro.; 2006.

72. Msuya SE, Mbizvo E, Stray-Pedersen B, Sundby J, Sam NE, Hussain A. Reproductive tract infections and the risk of HIV among women in Moshi, Tanzania. Acta obstetricia et gynecologica Scandinavica. 2002;81(9):886-93.

73. Msuya SE, Mbizvo EM, Stray-Pedersen B, Uriyo J, Sam NE, Rusakaniko S, et al. Decline in HIV prevalence among women of childbearing age in Moshi urban, Tanzania. International journal of STD & AIDS. 2007;18(10):680-7.

74. Msuya SE, Uriyo J, Hussain A, Mbizvo EM, Jeansson S, Sam NE, et al. Prevalence of sexually transmitted infections among pregnant women with known HIV status in northern Tanzania. Reproductive Health. 2009;6(1):4.

75. Nakku-Joloba E, Kambugu F, Wasubire J, Kimeze J, Salata R, Albert JM, et al. Sero-prevalence of herpes simplex type 2 virus (HSV-2) and HIV infection in Kampala, Uganda. African health sciences. 2014;14(4):782-9.

76. Nakubulwa S, Kaye DK, Bwanga F, Tumwesigye NM, Mirembe FM. Genital infections and risk of premature rupture of membranes in Mulago Hospital, Uganda: a case control study. BMC research notes. 2015;8:573.

77. NASCOP (National AIDS/STI Control Program). 2007 Kenya AIDS Indicator Survey: Final Report. Nairobe, Kenya; September 2009.

78. Nilsen A, Mwakagile D, Marsden H, Langeland N, Matre R, Haarr L. Prevalence of, and risk factors for, HSV-2 antibodies in sexually transmitted disease patients, healthy pregnant females, blood donors and medical students in Tanzania and Norway. Epidemiology and infection. 2005;133(5):915-25.

79. Norris AH, Kitali AJ, Worby E. Alcohol and transactional sex: how risky is the mix? Social science & medicine (1982). 2009;69(8):1167-76.

80. Nyiro JU, Sanders EJ, Ngetsa C, Wale S, Awuondo K, Bukusi E, et al. Seroprevalence, predictors and estimated incidence of maternal and neonatal Herpes Simplex Virus type 2 infection in semi-urban women in Kilifi, Kenya. BMC infectious diseases. 2011;11:155.

81. Oliver VO, Otieno G, Gvetadze R, Desai MA, Makanga M, Akelo V, et al. High prevalence of sexually transmitted infections among women screened for a contraceptive intravaginal ring study, Kisumu, Kenya, 2014. International Journal of STD and AIDS. 2018;29(14):1390-9.

82. Otieno FO, Ndivo R, Oswago S, Pals S, Chen R, Thomas T, et al. Correlates of prevalent sexually transmitted infections among participants screened for an HIV incidence cohort study in Kisumu, Kenya. International journal of STD & AIDS. 2015;26(4):225-37.

83. Reynolds SJ, Makumbi F, Newell K, Kiwanuka N, Ssebbowa P, Mondo G, et al. Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial. The Lancet Infectious diseases. 2012;12(6):441-8.

84. Sivapalasingam S, McClelland RS, Ravel J, Ahmed A, Cleland CM, Gajer P, et al. An effective intervention to reduce intravaginal practices among HIV-1 uninfected Kenyan women. AIDS Research and Human Retroviruses. 2014;30(11):1046-54.

85. Tedla Y, Shibre T, Ali O, Tadele G, Woldeamanuel Y, Asrat D, et al. Serum antibodies to Toxoplasma gondii and Herpesvidae family viruses in individuals with schizophrenia and bipolar disorder: a case-control study. Ethiopian medical journal. 2011;49(3):211-20.

86. Todd J, Grosskurth H, Changalucha J, Obasi A, Mosha F, Balira R, et al. Risk factors influencing HIV infection incidence in a rural African population: a nested case-control study. The Journal of infectious diseases. 2006;193(3):458-66.

87. Weiss HA, Buve A, Robinson NJ, Van Dyck E, Kahindo M, Anagonou S, et al. The epidemiology of HSV-2 infection and its association with HIV infection in four urban African populations. AIDS (London, England). 2001;15 Suppl 4:S97-108.

88. Winston SE, Chirchir AK, Muthoni LN, Ayuku D, Koech J, Nyandiko W, et al. Prevalence of sexually transmitted infections including HIV in street-connected adolescents in western Kenya. Sexually transmitted infections. 2015;91(5):353-9.

89. Yahya-Malima KI, Evjen-Olsen B, Matee MI, Fylkesnes K, Haarr L. HIV-1, HSV-2 and syphilis among pregnant women in a rural area of Tanzania: prevalence and risk factors. BMC infectious diseases. 2008;8:75.
90. Yegorov S, Galiwango RM, Good SV, Mpendo J, Tannich E, Boggild AK, et al. Schistosoma mansoni infection and socio-behavioural predictors of HIV risk: a cross-sectional study in women from Uganda. BMC infectious diseases. 2018;18(1):586.

91. Ng'ayo OM, Bukusi E, R AM, Rowhani-Rahbar A, B AO, Friedrich D, et al. Sexual and demographic determinants for herpes simplex virus type 2 among fishermen along Lake Victoria, Kenya. Sexually transmitted infections. 2008;84(2):140-2.

92. Rakwar J, Jackson D, Maclean I, Obongo T, Bwayo J, Smith H, et al. Antibody to Haemophilus ducreyi among trucking company workers in Kenya. Sexually transmitted diseases. 1997;24(5):267-71.

93. Riedner G, Todd J, Rusizoka M, Mmbando D, Maboko L, Lyamuya E, et al. Possible reasons for an increase in the proportion of genital ulcers due to herpes simplex virus from a cohort of female bar workers in Tanzania. Sexually transmitted infections. 2007;83(2):91-6.

94. Vallely A, Kasindi S, Hambleton IR, Knight L, Chirwa T, Balira R, et al. Microbicides development program, Tanzania-baseline characteristics of an occupational cohort and reattendance at 3 months. Sexually transmitted diseases. 2007;34(9):638-43.

95. Watson-Jones D, Weiss HA, Rusizoka M, Baisley K, Mugeye K, Changalucha J, et al. Risk factors for herpes simplex virus type 2 and HIV among women at high risk in northwestern Tanzania: preparing for an HSV-2 intervention trial. Journal of acquired immune deficiency syndromes (1999). 2007;46(5):631-42.

96. Baeten JM, Benki S, Chohan V, Lavreys L, McClelland RS, Mandaliya K, et al. Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. Aids. 2007;21(13):1771-7.

97. Baltzer H, Chege D, Rebbapragada A, Wachihi C, Shin LY, Kimani J, et al. Relative HIV resistance in kenyan sex workers is not due to an altered prevalence or mucosal immune impact of herpes simplex virus type 2 infection. Current HIV research. 2009;7(5):504-7.

98. Masese L, Baeten JM, Richardson BA, Bukusi E, John-Stewart G, Graham SM, et al. Changes in the contribution of genital tract infections to HIV acquisition among Kenyan high-risk women from 1993 to 2012. Aids. 2015;29(9):1077-85.

99. Priddy FH, Wakasiaka S, Hoang TD, Smith DJ, Farah B, del Rio C, et al. Anal sex, vaginal practices, and HIV incidence in female sex workers in urban Kenya: implications for the development of intravaginal HIV prevention methods. AIDS Res Hum Retroviruses. 2011;27(10):1067-72.

100. Vandenhoudt HM, Langat L, Menten J, Odongo F, Oswago S, Luttah G, et al. Prevalence of HIV and other sexually transmitted infections among female sex workers in Kisumu, Western Kenya, 1997 and 2008. PLoS One. 2013;8(1):e54953.

101. Vandepitte J, Bukenya J, Weiss HA, Nakubulwa S, Francis SC, Hughes P, et al. HIV and other sexually transmitted infections in a cohort of women involved in high-risk sexual behavior in Kampala, Uganda. Sexually transmitted diseases. 2011;38(4):316-23.

102. Mehta SD, Moses S, Agot K, Agingu W, Parker C, Ndinya-Achola JO, et al. Herpes simplex virus type 2 infection among young uncircumcised men in Kisumu, Kenya. Sexually transmitted infections. 2008;84(1):42-8.

103. Nakubulwa S, Mirembe FM, Kaye DK, Kaddu-Mulindwa D. Association between HSV-2 and HIV serostatus in pregnant women of known HIV serostatus attending Mulago hospital antenatal clinic, Kampala, Uganda. Journal of infection in developing countries. 2009;3(10):803-6.

104. Serwadda D, Gray RH, Sewankambo NK, Wabwire-Mangen F, Chen MZ, Quinn TC, et al. Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested case-control study in Rakai, Uganda. The Journal of infectious diseases. 2003;188(10):1492-7.

105. Baeten JM, McClelland RS, Corey L, Overbaugh J, Lavreys L, Richardson BA, et al. Vitamin A supplementation and genital shedding of herpes simplex virus among HIV-1-infected women: a randomized clinical trial. The Journal of infectious diseases. 2004;189(8):1466-71.

106. Madebe R, Kiwelu I, Ndaro A, Francis F, Baraka V, Theilgaard Z, et al. Herpes Simplex virus type 2 seroprevalence and risk factors among adolescents and youth with HIV-1 in Northern, Tanzania. Journal of infection in developing countries. 2020;14(4):398-403.

107. McClelland RS, Wang CC, Overbaugh J, Richardson BA, Corey L, Ashley RL, et al. Association between cervical shedding of herpes simplex virus and HIV-1. Aids. 2002;16(18):2425-30.

108. Roxby AC, Drake AL, John-Stewart G, Brown ER, Matemo D, Otieno PA, et al. Herpes simplex virus type 2, genital ulcers and HIV-1 disease progression in postpartum women. PLoS One. 2011;6(5):e19947.
109. Langeland N, Haarr L, Mhalu F. Prevalence of HSV-2 antibodies among STD clinic patients in Tanzania. International journal of STD & AIDS. 1998;9(2):104-7.

110. Mostad SB, Kreiss JK, Ryncarz AJ, Mandaliya K, Chohan B, Ndinya-Achola J, et al. Cervical shedding of herpes simplex virus in human immunodeficiency virus-infected women: effects of hormonal contraception, pregnancy, and vitamin A deficiency. The Journal of infectious diseases. 2000;181(1):58-63.

111. Mwansasu A, Mwakagile D, Haarr L, Langeland N. Detection of HSV-2 in genital ulcers from STD patients in Dar es Salaam, Tanzania. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2002;24(3):183-92.

112. Suntoke TR, Hardick A, Tobian AA, Mpoza B, Laeyendecker O, Serwadda D, et al. Evaluation of multiplex real-time PCR for detection of Haemophilus ducreyi, Treponema pallidum, herpes simplex virus type 1 and 2 in the diagnosis of genital ulcer disease in the Rakai District, Uganda. Sexually transmitted infections. 2009;85(2):97-101.

113. Kassa D, Gebremichael G, Tilahun T, Ayalkebet A, Abrha Y, Mesfin G, et al. Prevalence of sexually transmitted infections (HIV, hepatitis B virus, herpes simplex virus type 2, and syphilis) in pregnant women in Ethiopia: Trends over 10 years (2005-2014). International Journal of Infectious Diseases. 2019;79:50-7.

114. Abbai NS, Govender S, Nyirenda M. Herpes simplex virus-2 infections in pregnant women from Durban, South Africa: prevalence, risk factors and co-infection with HIV-1. Southern African Journal of Infectious Diseases. 2018.

115. Achilles SL, Mhlanga F, Dezzutti CS, Matubu AT, Stoner KA, Beamer M, et al. Differences in genital tract immune cell populations and innate cervicovaginal fluid anti-HIV activity among women from Zimbabwe and the United States. AIDS Research and Human Retroviruses. 2016;32(Supplement 1):78.

116. Austrian K, Hewett PC, Soler-Hampejsek E, Bozzani F, Behrman JR, Digitale J. Adolescent Girls Empowerment Programme: research and evaluation mid-term technical report. 2016.

117. Baird SJ, Garfein RS, McIntosh CT, Ozler B. Effect of a cash transfer programme for schooling on prevalence of HIV and herpes simplex type 2 in Malawi: a cluster randomised trial. Lancet (London, England). 2012;379(9823):1320-9.

Birdthistle IJ, Floyd S, Machingura A, Mudziwapasi N, Gregson S, Glynn JR. From affected to infected? Orphanhood and HIV risk among female adolescents in urban Zimbabwe. Aids. 2008;22(6):759-66.
Bradley J, Floyd S, Piwowar-Manning E, Laeyendecker O, Young A, Bell-Mandla N, et al. Sexually transmitted bedfellows: Exquisite association between HIV and herpes simplex virus type 2 in 21 communities in Southern Africa in the HIV prevention trials network 071 (PopART) Study. Journal of Infectious Diseases. 2018;218(3):443-52.

120. Chatterjee K, Dandara C, Gyllensten U, van der Merwe L, Galal U, Hoffman M, et al. A Fas gene polymorphism influences herpes simplex virus type 2 infection in South African women. Journal of medical virology. 2010;82(12):2082-6.

121. Cowan FM, Pascoe SJS, Langhaug LF, Dirawo J, Chidiya S, Jaffar S, et al. The Regai Dzive Shiri Project: A cluster randomised controlled trial to determine the effectiveness of a multi-component communitybased HIV prevention intervention for rural youth in Zimbabwe - Study design and baseline results. Tropical Medicine and International Health. 2008b;13(10):1235-44.

122. Crucitti T, Jespers V, Mulenga C, Khondowe S, Vandepitte J, Buve A. Non-sexual transmission of Trichomonas vaginalis in adolescent girls attending school in Ndola, Zambia. PLoS One. 2011;6(1):e16310.
123. Delany-Moretlwe S, Jentsch U, Weiss H, Moyes J, Ashley-Morrow R, Stevens W, et al. Comparison of focus HerpesSelect and Kalon HSV-2 gG2 ELISA serological assays to detect herpes simplex virus type 2 antibodies in a South African population. Sexually transmitted infections. 2010;86(1):46-50.

124. Fearon E, Wiggins RD, Pettifor AE, MacPhail C, Kahn K, Selin A, et al. Associations between friendship characteristics and HIV and HSV-2 status amongst young South African women in HPTN-068. Journal of the International AIDS Society. 2017;20(4).

125. Ferrand RA, Munaiwa L, Matsekete J, Bandason T, Nathoo K, Ndhlovu CE, et al. Undiagnosed HIV infection among adolescents seeking primary health care in Zimbabwe. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2010a;51(7):844-51.

126. Ferrand RA, Bandason T, Musvaire P, Larke N, Nathoo K, Mujuru H, et al. Causes of acute hospitalization in adolescence: burden and spectrum of HIV-related morbidity in a country with an early-onset and severe HIV epidemic: a prospective survey. PLoS medicine. 2010b;7(2):e1000178.

127. Francis SC, Mthiyane TN, Baisley K, McHunu SL, Ferguson JB, Smit T, et al. Prevalence of sexually transmitted infections among young people in South Africa: A nested survey in a health and demographic surveillance site. PLoS medicine. 2018;15(2):e1002512.

128. Glynn JR, Crampin AC, Ngwira BM, Ndhlovu R, Mwanyongo O, Fine PE. Herpes simplex virus type 2 trends in relation to the HIV epidemic in northern Malawi. Sexually transmitted infections. 2008;84(5):356-60. 129. Glynn JR, Kayuni N, Gondwe L, Price AJ, Crampin AC. Earlier menarche is associated with a higher prevalence of Herpes simplex type-2 (HSV-2) in young women in rural Malawi. eLife. 2014;3:e01604.

130. Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. The Lancet Infectious diseases. 2011;11(7):507-15.

131. Gregson S, Mason PR, Garnett GP, Zhuwau T, Nyamukapa CA, Anderson RM, et al. A rural HIV epidemic in Zimbabwe? Findings from a population-based survey. International journal of STD & AIDS. 2001;12(3):189-96.

132. Gwanzura L, Chigonda TG, Mvere D, De Villiers DM, Siziya S, Mason PR. The prevalence of Herpes simplex virus type-2 infection in blood donors in Harare, Zimbabwe. The Central African journal of medicine. 2002;48(3-4):38-42.

133. Hazel A, Foxman B, Low BS. Herpes simplex virus type 2 among mobile pastoralists in northwestern Namibia. Annals of human biology. 2015;42(6):543-51.

134. Kapina M, Reid C, Roman K, Cyrus-Cameron E, Kwiecien A, Weiss S, et al. HIV incidence rates and risk factors for urban women in Zambia: Preparing for a microbicide clinical trial. Sexually Transmitted Diseases. 2009;36(3):129-33.

135. Kenyon C, Colebunders R, Buve A, Hens N. Partner-concurrency associated with herpes simplex virus 2 infection in young South Africans. International journal of STD & AIDS. 2013;24(10):804-12.

136. Kharsany ABM, McKinnon LR, Lewis L, Cawood C, Khanyile D, Maseko DV, et al. Population prevalence of sexually transmitted infections in a high HIV burden district in KwaZulu-Natal, South Africa: Implications for HIV epidemic control. International Journal of Infectious Diseases. 2020;98:130-7.

137. Kjetland EF, Gwanzura L, Ndhlovu PD, Mduluza T, Gomo E, Mason PR, et al. Herpes simplex virus type 2 prevalence of epidemic proportions in rural Zimbabwean women: association with other sexually transmitted infections. Archives of gynecology and obstetrics. 2005;272(1):67-73.

138. Kurewa NE, Mapingure MP, Munjoma MW, Chirenje MZ, Rusakaniko S, Stray-Pedersen B. The burden and risk factors of Sexually Transmitted Infections and Reproductive Tract Infections among pregnant women in Zimbabwe. BMC infectious diseases. 2010;10:127.

139. Luseno WK, Hallfors DD, Cho H, Iritani BJ, Adze J, Rusakaniko S, et al. Use of HIV and HSV-2 biomarkers in sub-saharan adolescent prevention research: a comparison of two approaches. The journal of primary prevention. 2014;35(3):181-91.

140. Mbizvo EM, Msuya Sia E, Stray-Pedersen B, Chirenje MZ, Munjoma M, Hussain A. Association of herpes simplex virus type 2 with the human immunodeficiency virus among urban women in Zimbabwe. International journal of STD & AIDS. 2002;13(5):343-8.

141. Menezes LJ, Pokharel U, Sudenga SL, Botha MH, Zeier M, Abrahamsen ME, et al. Patterns of prevalent HPV and STI co-infections and associated factors among HIV-negative young Western Cape, South African women: the EVRI trial. Sexually transmitted infections. 2018;94(1):55-61.

142. NIMH Collaborative HIV/STD Prevention Trial Group. Sexually transmitted disease and HIV prevalence and risk factors in concentrated and generalized HIV epidemic settings. AIDS. 2007;21 Suppl 2:S81-90.

143. Pascoe SJ, Langhaug LF, Mavhu W, Hargreaves J, Jaffar S, Hayes R, et al. Poverty, food insufficiency and HIV infection and sexual behaviour among young rural Zimbabwean women. PLoS One. 2015;10(1):e0115290.

144. Price J, Pettifor A, Selin A, Wagner RG, MacPhail C, Agyei Y, et al. The association between perceived household educational support and HIV risk in young women in a rural South African community (HPTN 068): A cross sectional study. PloS one. 2019;14(1):e0210632.

145. Wand H, Ramjee G. The relationship between age of coital debut and HIV seroprevalence among women in Durban, South Africa: A cohort study. BMJ Open. 2012;2(1):000285.

146. Cowan FM, Hargrove JW, Langhaug LF, Jaffar S, Mhuriyengwe L, Swarthout TD, et al. The appropriateness of core group interventions using presumptive periodic treatment among rural Zimbabwean women who exchange sex for gifts or money. Journal of acquired immune deficiency syndromes (1999). 2005;38(2):202-7.

147. Abdool Karim SS, Abdool Karim Q, Kharsany AB, Baxter C, Grobler AC, Werner L, et al. Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection. The New England journal of medicine. 2015;373(6):530-9.

148. Balkus JE, Brown ER, Hillier SL, Coletti A, Ramjee G, Mgodi N, et al. Oral and injectable contraceptive use and HIV acquisition risk among women in four African countries: A secondary analysis of data from a microbicide trial. Contraception. 2016;93(1):25-31.

149. Barnabas SL, Dabee S, Passmore JS, Jaspan HB, Lewis DA, Jaumdally SZ, et al. Converging epidemics of sexually transmitted infections and bacterial vaginosis in southern African female adolescents at risk of HIV. International journal of STD & AIDS. 2018;29(6):531-9.

150. Benjamin RJ, Busch MP, Fang CT, Notari EP, Puren A, Schoub BD, et al. Human immunodeficiency virus-1 infection correlates strongly with herpes simplex virus-2 (genital herpes) seropositivity in South African and United States blood donations. Transfusion. 2008;48(2):295-303.

151. Gust DA, Soud F, Hardnett FP, Malotte CK, Rose C, Kebaabetswe P, et al. Evaluation of sexual risk behavior among study participants in the TDF2 PrEP study among heterosexual adults in Botswana. Journal of Acquired Immune Deficiency Syndromes. 2016;73(5):556-63.

152. Mavedzenge SN, Weiss HA, Montgomery ET, Blanchard K, de Bruyn G, Ramjee G, et al. Determinants of differential HIV incidence among women in three southern African locations. Journal of acquired immune deficiency syndromes (1999). 2011;58(1):89-99.

153. Wand H, Ramjee G. Evaluating HIV prevention efforts using semiparametric regression models: Results from a large cohort of women participating in an HIV prevention trial from KwaZulu-Natal, South Africa. Journal of the International AIDS Society. 2013;16:18589.

154. Sutcliffe S, Taha TE, Kumwenda NI, Taylor E, Liomba GN. HIV-1 prevalence and herpes simplex virus 2, hepatitis C virus, and hepatitis B virus infections among male workers at a sugar estate in Malawi. Journal of acquired immune deficiency syndromes (1999). 2002;31(1):90-7.

155. Lewis DA, Chirwa TF, Msimang VM, Radebe FM, Kamb ML, Firnhaber CS. Urethritis/cervicitis pathogen prevalence and associated risk factors among asymptomatic HIV-infected patients in South Africa. Sexually transmitted diseases. 2012;39(7):531-6.

156. Lowe S, Mudzviti T, Mandiriri A, Shamu T, Mudhokwani P, Chimbetete C, et al. Sexually transmitted infections, the silent partner in HIV-infected women in Zimbabwe. Southern African Journal of HIV Medicine. 2019;20 (1) (no pagination)(a849).

157. Kufa T, Radebe F, Maseko V, Puren A, Kularatne R. Medical Male Circumcision and Associations Among Sexually Transmitted Infections Service Attendees. AIDS and behavior. 2020;24(5):1422-31.

158. Rabenau HF, Lennemann T, Kircher C, Gurtler L, Staszewski S, Preiser W, et al. Prevalence- and gender-specific immune response to opportunistic infections in HIV-infected patients in Lesotho. Sexually transmitted diseases. 2010;37(7):454-9.

159. Varo R, Buck WC, Kazembe PN, Phiri S, Andrianarimanana D, Weigel R. Seroprevalence of CMV, HSV-2 and HBV among HIV-Infected Malawian Children: A Cross-sectional Survey. Journal of tropical pediatrics. 2016;62(3):220-6.

160. Chen CY, Ballard RC, Beck-Sague CM, Dangor Y, Radebe F, Schmid S, et al. Human immunodeficiency virus infection and genital ulcer disease in South Africa: the herpetic connection. Sexually transmitted diseases. 2000;27(1):21-9.

161. Esber A, Rao N, Norris A, Carr Reese P, Kandodo J, Nampandeni P, et al. Intravaginal Practices and Prevalence of Sexual and Reproductive Tract Infections Among Women in Rural Malawi. Sexually transmitted diseases. 2016;43(12):750-5.

162. Hoyo C, Hoffman I, Moser BK, Hobbs MM, Kazembe P, Krysiak RG, et al. Improving the accuracy of syndromic diagnosis of genital ulcer disease in Malawi. Sexually transmitted diseases. 2005;32(4):231-7.
163. Kularatne RS, Muller EE, Maseko DV, Kufa-Chakezha T, Lewis DA. Trends in the relative prevalence of genital ulcer disease pathogens and association with HIV infection in Johannesburg, South Africa, 2007-2015. PLoS One. 2018;13(4):e0194125.

164. Lewis DA, Pillay C, Mohlamonyane O, Vezi A, Mbabela S, Mzaidume Y, et al. The burden of asymptomatic sexually transmitted infections among men in Carletonville, South Africa: implications for syndromic management. Sexually transmitted infections. 2008;84(5):371-6.

165. Lewis DA, Marsh K, Radebe F, Maseko V, Hughes G. Trends and associations of Trichomonas vaginalis infection in men and women with genital discharge syndromes in Johannesburg, South Africa. Sexually transmitted infections. 2013;89(6):523-7.

166. Mhlongo S, Magooa P, Muller EE, Nel N, Radebe F, Wasserman E, et al. Etiology and STI/HIV coinfections among patients with urethral and vaginal discharge syndromes in South Africa. Sexually transmitted diseases. 2010;37(9):566-70.

167. Morse SA, Trees DL, Htun Y, Radebe F, Orle KA, Dangor Y, et al. Comparison of clinical diagnosis and standard laboratory and molecular methods for the diagnosis of genital ulcer disease in Lesotho: association with human immunodeficiency virus infection. The Journal of infectious diseases. 1997;175(3):583-9.

168. O'Farrell N, Morison L, Moodley P, Pillay K, Vanmali T, Quigley M, et al. High-risk sexual behaviour in men attending a sexually transmitted infection clinic in Durban, South Africa. Sexually transmitted infections. 2007;83(7):530-3.

169. Paz-Bailey G, Sternberg M, Puren AJ, Markowitz LE, Ballard R, Delany S, et al. Improvement in healing and reduction in HIV shedding with episodic acyclovir therapy as part of syndromic management among men: a randomized, controlled trial. The Journal of infectious diseases. 2009;200(7):1039-49.
170. Phiri S, Zadrozny S, Weiss HA, Martinson F, Nyirenda N, Chen CY, et al. Etiology of genital ulcer disease and association with HIV infection in Malawi. Sexually transmitted diseases. 2013;40(12):923-8.

171. Zimba TF, Apalata T, Sturm WA, Moodley P. Aetiology of sexually transmitted infections in Maputo, Mozambique. Journal of infection in developing countries. 2011;5(1):41-7.

172. Chattopadhyay K, Williamson AL, Hazra A, Dandara C. The combined risks of reduced or increased function variants in cell death pathway genes differentially influence cervical cancer risk and herpes simplex virus type 2 infection among black Africans and the Mixed Ancestry population of South Africa. BMC cancer. 2015;15:680.

173. Anaedobe CG, Ajani TA. Co-infection of herpes simplex virus type 2 and HIV infections among pregnant women in Ibadan, Nigeria. Journal of Global Infectious Diseases. 2019;11(1):19-24.

174. Ashley-Morrow R, Nollkamper J, Robinson NJ, Bishop N, Smith J. Performance of focus ELISA tests for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies among women in ten diverse geographical locations. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2004;10(6):530-6.

175. Behanzin L, Diabate S, Minani I, Lowndes CM, Boily MC, Labbe AC, et al. Decline in HIV Prevalence among Young Men in the General Population of Cotonou, Benin, 1998-2008. PLoS ONE. 2012;7(8):e43818.
176. Cisse BC, Zaba F, Meite S, Mlan A, Inwoley K, Kouassi M'Bengue A, et al. Seroprevalence of herpes simplex virus 2 infection among pregnant women in urban health training Yopougon-Attie (Cote D'ivoire). Academic Journals. 2015;6(3):17-21.

177. Eltom MA, Mbulaiteye SM, Dada AJ, Whitby D, Biggar RJ. Transmission of human herpesvirus 8 by sexual activity among adults in Lagos, Nigeria. Aids. 2002;16(18):2473-8.

178. Kane CT, Diawara S, Ndiaye HD, Diallo PA, Wade AS, Diallo AG, et al. Concentrated and linked epidemics of both HSV-2 and HIV-1/HIV-2 infections in Senegal: public health impacts of the spread of HIV. International journal of STD & AIDS. 2009;20(11):793-6.

179. Katz I, De Luca F, Dzudzor B, Sarpong BK, Osei-Appiah B, Azoulay D, et al. Seroprevalences of autoantibodies and anti-infectious antibodies among Ghana's healthy population. Scientific reports. 2020;10(1):2814.

180. Kirakoya-Samadoulougou F, Nagot N, Defer MC, Yaro S, Fao P, Ilboudo F, et al. Epidemiology of herpes simplex virus type 2 infection in rural and Urban Burkina Faso. Sexually Transmitted Diseases. 2011;38(2):117-23.

181. Lagarde E, Congo Z, Meda N, Baya B, Yaro S, Sangli G, et al. Epidemiology of HIV infection in urban Burkina Faso. International Journal of STD and AIDS. 2004;15(6):395-402.

182. Mawak JD, Dashe N, Atseye AB, Agabi YA, Zakeri H. Seroprevalence and co-infection of herpes simplex virus type 2 and human immunodeficiency virus in Nigeria. Shiraz E Medical Journal. 2012;13(1):33-9.

183. Patnaik P, Herrero R, Morrow RA, Munoz N, Bosch FX, Bayo S, et al. Type-specific seroprevalence of herpes simplex virus type 2 and associated risk factors in middle-aged women from 6 countries: the IARC multicentric study. Sexually transmitted diseases. 2007;34(12):1019-24.

184. Shaw M, van der Sande M, West B, Paine K, Ceesay S, Bailey R, et al. Prevalence of herpes simplex type 2 and syphilis serology among young adults in a rural Gambian community. Sexually transmitted infections. 2001;77(5):358-65.

185. Thomas JO, Herrero R, Omigbodun AA, Ojemakinde K, Ajayi IO, Fawole A, et al. Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. British journal of cancer. 2004;90(3):638-45.

186. Walraven G, Scherf C, West B, Ekpo G, Paine K, Coleman R, et al. The burden of reproductive-organ disease in rural women in The Gambia, West Africa. Lancet (London, England). 2001;357(9263):1161-7.

187. Aho J, Koushik A, Coutlee F, Diakite SL, Rashed S. Prevalence of HIV, human papillomavirus type 16 and herpes simplex virus type 2 among female sex workers in Guinea and associated factors. International Journal of STD and AIDS. 2014;25(4):280-8.

188. Dada AJ, Ajayi AO, Diamondstone L, Quinn TC, Blattner WA, Biggar RJ. A serosurvey of Haemophilus ducreyi, syphilis, and herpes simplex virus type 2 and their association with human immunodeficiency virus among female sex workers in Lagos, Nigeria. Sexually transmitted diseases. 1998;25(5):237-42.

189. Low AJ, Clayton T, Konate I, Nagot N, Ouedraogo A, Huet C, et al. Genital warts and infection with human immunodeficiency virus in high-risk women in Burkina Faso: a longitudinal study. BMC infectious diseases. 2011;11(1):20.

190. Nagot N, Ouedraogo A, Ouangre A, Cartoux M, Defer MC, Meda N, et al. Is sexually transmitted infection management among sex workers still able to mitigate the spread of HIV infection in West Africa? Journal of Acquired Immune Deficiency Syndromes. 2005;39(4):454-8.

191. Traore IT, Meda N, Hema NM, Ouedraogo D, Some F, Some R, et al. HIV prevention and care services for female sex workers: Efficacy of a targeted community-based intervention in Burkina Faso. Journal of the International AIDS Society. 2015;18(1):20088.

192. Wade AS, Kane CT, Diallo PA, Diop AK, Gueye K, Mboup S, et al. HIV infection and sexually transmitted infections among men who have sex with men in Senegal. Aids. 2005;19(18):2133-40.

193. Camara M, Seydi M, Dieye TN, Sow PS, Mboup S, Kestens L, et al. Association between herpes simplex virus type 2 and HIV-1 in a population of married couples from Dakar, Senegal. International journal of STD & AIDS. 2012;23(11):810-4.

194. Odebisi-Omokanye M, Udeze A, Akanbi K, Jimoh N, Imam M. Serosurvey of Herpes Simplex Virus type-2 infection among HIV Infected Individuals Accessing a Secondary Health Care Facility in Kwara State, North Central Nigeria. Nig J Pure & Appl Sci. 2017;30(2).

195. Yunusa T, Haruna S, Garba H. Seroprevalence of Herpes Simplex virus among human immunodeficiency virus-positive patients in resource-limited setting. Journal of Global Infectious Diseases. 2019;11(3):107-11.

196. Aryee EA, Bailey RL, Natividad-Sancho A, Kaye S, Holland MJ. Detection, quantification and genotyping of Herpes Simplex Virus in cervicovaginal secretions by real-time PCR: a cross sectional survey. Virology journal. 2005;2(1):61.

197. Charpentier C, Koyalta D, Ndinaromtan M, Tchobkreo B, Jenabian MA, Day N, et al. Distribution of HIV-1 and HSV-2 epidemics in Chad revealing HSV-2 hot-spot in regions of high-risk HIV spread. Journal of infection in developing countries. 2011;5(1):64-7.

198. Eis-Hubinger AM, Nyankiye E, Bitoungui DM, Ndjomou J. Prevalence of herpes simplex virus type 2 antibody in Cameroon. Sexually Transmitted Diseases. 2002;29(11):637-42.

199. Ozouaki F, Ndjoyi-Mbiguino A, Legoff J, Onas IN, Kendjo E, Si-Mohamed A, et al. Genital shedding of herpes simplex virus type 2 in childbearing-aged and pregnant women living in Gabon. International journal of STD & AIDS. 2006;17(2):124-7.

200. Volpi A, Sarmati L, Suligoi B, Montano M, Rezza G, Andreoni M. Correlates of human herpes virus-8 and herpes simplex virus type 2 infections in Northern Cameroon. Journal of Medical Virology. 2004;74(3):467-72.

201. Longo JDD, Simaleko MM, Diemer HSC, Gresenguet G, Brucker G, Belec L. Risk factors for HIV infection among female sex workers in Bangui, Central African Republic. PLoS ONE. 2017;12(11):e0187654.
202. Nzila N, Laga M, Thiam MA, Mayimona K, Edidi B, Van Dyck E, et al. HIV and other sexually transmitted diseases among female prostitutes in Kinshasa. AIDS. 1991;5(6):715-21.

203. LeGoff J, Gresenguet G, Gody C, Longo JDD, Khonde N, Weiss HA, et al. Performance of the BioPlex 2200 multiplexing immunoassay platform for the detection of herpes simplex virus type 2 specific antibodies in African settings. Clinical and Vaccine Immunology. 2011;18(7):1191-3.

204. Mbopi-Keou FX, Gresenguet G, Mayaud P, Weiss HA, Gopal R, Matta M, et al. Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in african women: Opportunities for intervention. Journal of Infectious Diseases. 2000;182(4):1090-6.

205. Vandepitte JM, Malele F, Kivuvu DM, Edidi S, Muwonga J, Lepira F, et al. HIV and other sexually transmitted infections among female sex workers in Kinshasa, Democratic Republic of Congo, in 2002. Sexually transmitted diseases. 2007;34(4):203-8.

206. Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. Lancet (London, England). 2019;394(10195):303-13.

207. Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine. 2015;372(6):509-18.

208. Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infectious Diseases. 2012;12(1):19-26.

209. LeGoff J, Weiss HA, Gresenguet G, Nzambi K, Frost E, Hayes RJ, et al. Cervicovaginal HIV-1 and herpes simplex virus type 2 shedding during genital ulcer disease episodes. Aids. 2007;21(12):1569-78.

210. Ahmed HJ, Mbwana J, Gunnarsson E, Ahlman K, Guerino C, Svensson LA, et al. Etiology of genital ulcer disease and association with human immunodeficiency virus infection in two tanzanian cities. Sexually transmitted diseases. 2003;30(2):114-9.

211. Gray RH, Serwadda D, Tobian AA, Chen MZ, Makumbi F, Suntoke T, et al. Effects of genital ulcer disease and herpes simplex virus type 2 on the efficacy of male circumcision for HIV prevention: Analyses from the Rakai trials. PLoS medicine. 2009;6(11):e1000187.

212. Kamya MR, Nsubuga P, Grant RM, Hellman N. The high prevalence of genital herpes among patients with genital ulcer disease in Uganda. Sexually transmitted diseases. 1995;22(6):351-4.

213. Makasa M, Buve A, Sandoy IF. Etiologic pattern of genital ulcers in Lusaka, Zambia: has chancroid been eliminated? Sexually transmitted diseases. 2012;39(10):787-91.

214. Mayaud P, Nagot N, Konate I, Ouedraogo A, Weiss HA, Foulongne V, et al. Effect of HIV-1 and antiretroviral therapy on herpes simplex virus type 2: A prospective study in African women. Sexually Transmitted Infections. 2008;84(5):332-7.

215. Mungati M, Machiha A, Mugurungi O, Tshimanga M, Kilmarx PH, Nyakura J, et al. The Etiology of Genital Ulcer Disease and Coinfections With Chlamydia trachomatis and Neisseria gonorrhoeae in Zimbabwe: Results From the Zimbabwe STI Etiology Study. Sexually transmitted diseases. 2018;45(1):61-8.

216. Nilsen A, Kasubi MJ, Mohn SC, Mwakagile D, Langeland N, Haarr L. Herpes simplex virus infection and genital ulcer disease among patients with sexually transmitted infections in Dar es Salaam, Tanzania. Acta dermato-venereologica. 2007;87(4):355-9.

217. Oni AA, Adu FD, Ekweozor CC, Bakare RA. Herpetic urethritis in male patients in Ibadan. West African journal of medicine. 1997;16(1):27-9.

218. Paz-Bailey G, Rahman M, Chen C, Ballard R, Moffat HJ, Kenyon T, et al. Changes in the etiology of sexually transmitted diseases in botswana between 1993 and 2002: Implications for the clinical management of genital ulcer disease. Clinical Infectious Diseases. 2005;41(9):1304-12.

219. Pickering JM, Whitworth JA, Hughes P, Kasse M, Morgan D, Mayanja B, et al. Aetiology of sexually transmitted infections and response to syndromic treatment in southwest Uganda. Sexually transmitted infections. 2005;81(6):488-93.

220. Tanton C, Weiss HA, Rusizoka M, Legoff J, Changalucha J, Baisley K, et al. Long-term impact of acyclovir suppressive therapy on genital and plasma HIV RNA in Tanzanian women: a randomized controlled trial. The Journal of infectious diseases. 2010;201(9):1285-97.

221. Lai W, Chen CY, Morse SA, Htun Y, Fehler HG, Liu H, et al. Increasing relative prevalence of HSV-2 infection among men with genital ulcers from a mining community in South Africa. Sexually transmitted infections. 2003;79(3):202-7.